
<html lang="en"     class="pb-page"  data-request-id="05e27ea8-4d3d-449e-869c-bc7fd0ec7551"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.1c00136;requestedJournal:journal:jmcmar;issue:issue:10.1021/jmcmar.2021.64.issue-11;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of STAT3 and Histone Deacetylase (HDAC) Dual-Pathway Inhibitors for the Treatment of Solid Cancer" /></meta><meta name="dc.Creator" content="Yuhao  Ren" /></meta><meta name="dc.Creator" content="Shanshan  Li" /></meta><meta name="dc.Creator" content="Ren  Zhu" /></meta><meta name="dc.Creator" content="Chengying  Wan" /></meta><meta name="dc.Creator" content="Dongmei  Song" /></meta><meta name="dc.Creator" content="Jiawen  Zhu" /></meta><meta name="dc.Creator" content="Guiping  Cai" /></meta><meta name="dc.Creator" content="Sihui  Long" /></meta><meta name="dc.Creator" content="Lingyi  Kong" /></meta><meta name="dc.Creator" content="Wenying  Yu" /></meta><meta name="dc.Description" content="Nowadays, simultaneous inhibition of multiple targets through drug combination is an important anticancer strategy owing to the complex mechanism behind tumorigenesis. Recent studies have demonstra..." /></meta><meta name="Description" content="Nowadays, simultaneous inhibition of multiple targets through drug combination is an important anticancer strategy owing to the complex mechanism behind tumorigenesis. Recent studies have demonstra..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 27, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00136" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00136" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00136" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00136" /></link>
        
    
    

<title>Discovery of STAT3 and Histone Deacetylase (HDAC) Dual-Pathway Inhibitors for the Treatment of Solid Cancer | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00136" /></meta><meta property="og:title" content="Discovery of STAT3 and Histone Deacetylase (HDAC) Dual-Pathway Inhibitors for the Treatment of Solid Cancer" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0021.jpeg" /></meta><meta property="og:description" content="Nowadays, simultaneous inhibition of multiple targets through drug combination is an important anticancer strategy owing to the complex mechanism behind tumorigenesis. Recent studies have demonstrated that the inhibition of histone deacetylases (HDACs) will lead to compensated activation of a notorious cancer-related drug target, signal transducer and activator of transcription 3 (STAT3), in breast cancer through a cascade, which probably limits the anti-proliferation effect of HDAC inhibitors in solid tumors. By incorporating the pharmacophore of the HDAC inhibitor SAHA (vorinostat) into the STAT3 inhibitor pterostilbene, a series of potent pterostilbene hydroxamic acid derivatives with dual-target inhibition activity were synthesized. An excellent hydroxamate derivate, compound 14, inhibited STAT3 (KD = 33 nM) and HDAC (IC50 = 23.15 nM) with robust potency in vitro. Compound 14 also showed potent anti-proliferation ability in vivo and in vitro. Our study provides the first STAT3 and HDAC dual-target inhibitor for further exploration." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00136"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00136">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-13/achre4.2021.54.issue-13/20210706/achre4.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-26/aamick.2021.13.issue-26/20210707/aamick.2021.13.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-13/accacs.2021.11.issue-13/20210702/accacs.2021.11.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-13/acncdm.2021.12.issue-13/20210707/acncdm.2021.12.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/acsodf/largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-27/ascecg.2021.9.issue-27/20210712/ascecg.2021.9.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/ancham/largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-27/bichaw.2021.60.issue-27/20210713/bichaw.2021.60.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/cmatex/largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-13/enfuem.2021.35.issue-13/20210701/enfuem.2021.35.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-13/esthag.2021.55.issue-13/20210706/esthag.2021.55.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-26/iecred.2021.60.issue-26/20210707/iecred.2021.60.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-13/inocaj.2021.60.issue-13/20210705/inocaj.2021.60.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-26/jafcau.2021.69.issue-26/20210707/jafcau.2021.69.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/jceda8/largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/jctcce/largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/jmcmar.2021.64.issue-13/20210708/jmcmar.2021.64.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-13/joceah.2021.86.issue-13/20210702/joceah.2021.86.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-26/jpcafh.2021.125.issue-26/20210708/jpcafh.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-26/jpcbfk.2021.125.issue-26/20210708/jpcbfk.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-26/jpccck.2021.125.issue-26/20210708/jpccck.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-26/jpclcd.2021.12.issue-26/20210708/jpclcd.2021.12.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-26/jacsat.2021.143.issue-26/20210707/jacsat.2021.143.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/langd5/largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/mamobx/largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-13/orlef7.2021.23.issue-13/20210702/orlef7.2021.23.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-13/orgnd7.2021.40.issue-13/20210712/orgnd7.2021.40.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00136&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00136&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00136&amp;href=/doi/10.1021/acs.jmedchem.1c00136" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 11</span><span class="cit-fg-pageRange">, 7468-7482</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/11" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.1c00110" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.1c00160" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of STAT3 and Histone Deacetylase (HDAC) Dual-Pathway Inhibitors for the Treatment of Solid Cancer</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Yuhao Ren</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yuhao Ren</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yuhao++Ren">Yuhao Ren</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shanshan Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shanshan Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shanshan++Li">Shanshan Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ren Zhu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ren Zhu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory for Green Chemical Process of Ministry of Education, Hubei Key Laboratory of Novel Reactor and Green Chemical Technology, Hubei Engineering Research Center for Advanced Fine Chemicals, School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology, 206 1st Rd Optics Valley, East Lake New Technology Development District, Wuhan, Hubei 430205, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ren++Zhu">Ren Zhu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chengying Wan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chengying Wan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chengying++Wan">Chengying Wan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dongmei Song</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dongmei Song</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dongmei++Song">Dongmei Song</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jiawen Zhu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jiawen Zhu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jiawen++Zhu">Jiawen Zhu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Guiping Cai</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Guiping Cai</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Guiping++Cai">Guiping Cai</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sihui Long</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sihui Long</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory for Green Chemical Process of Ministry of Education, Hubei Key Laboratory of Novel Reactor and Green Chemical Technology, Hubei Engineering Research Center for Advanced Fine Chemicals, School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology, 206 1st Rd Optics Valley, East Lake New Technology Development District, Wuhan, Hubei 430205, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sihui++Long">Sihui Long</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-4424-6374" title="Orcid link">https://orcid.org/0000-0002-4424-6374</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lingyi Kong</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lingyi Kong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, People’s Republic of China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#3c5f4c496350455753525b7c0d0e0a125f5351"><span class="__cf_email__" data-cfemail="1b786b6e4477627074757c5b2a292d35787476">[email protected]</span></a>. Phone/Fax: +86-25-83271405.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lingyi++Kong">Lingyi Kong</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-9712-2618" title="Orcid link">https://orcid.org/0000-0001-9712-2618</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Wenying Yu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wenying Yu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, People’s Republic of China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#6e1719172e0d1e1b400b0a1b400d00"><span class="__cf_email__" data-cfemail="85fcf2fcc5e6f5f0abe0e1f0abe6eb">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wenying++Yu">Wenying Yu</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00136&amp;href=/doi/10.1021%2Facs.jmedchem.1c00136" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 11</span><span class="cit-pageRange">, 7468–7482</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 27, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>24 January 2021</li><li><span class="item_label"><b>Published</b> online</span>27 May 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 June 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00136" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00136</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D7468%26pageCount%3D15%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYuhao%2BRen%252C%2BShanshan%2BLi%252C%2BRen%2BZhu%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D11%26contentID%3Dacs.jmedchem.1c00136%26title%3DDiscovery%2Bof%2BSTAT3%2Band%2BHistone%2BDeacetylase%2B%2528HDAC%2529%2BDual-Pathway%2BInhibitors%2Bfor%2Bthe%2BTreatment%2Bof%2BSolid%2BCancer%26numPages%3D15%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D7482%26publicationDate%3DJune%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00136"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">998</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00136" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of STAT3 and Histone Deacetylase (HDAC) Dual-Pathway Inhibitors for the Treatment of Solid Cancer&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Yuhao&quot;,&quot;last_name&quot;:&quot;Ren&quot;},{&quot;first_name&quot;:&quot;Shanshan&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Ren&quot;,&quot;last_name&quot;:&quot;Zhu&quot;},{&quot;first_name&quot;:&quot;Chengying&quot;,&quot;last_name&quot;:&quot;Wan&quot;},{&quot;first_name&quot;:&quot;Dongmei&quot;,&quot;last_name&quot;:&quot;Song&quot;},{&quot;first_name&quot;:&quot;Jiawen&quot;,&quot;last_name&quot;:&quot;Zhu&quot;},{&quot;first_name&quot;:&quot;Guiping&quot;,&quot;last_name&quot;:&quot;Cai&quot;},{&quot;first_name&quot;:&quot;Sihui&quot;,&quot;last_name&quot;:&quot;Long&quot;},{&quot;first_name&quot;:&quot;Lingyi&quot;,&quot;last_name&quot;:&quot;Kong&quot;},{&quot;first_name&quot;:&quot;Wenying&quot;,&quot;last_name&quot;:&quot;Yu&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;27&quot;,&quot;issue&quot;:&quot;11&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;7468-7482&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00136&quot;},&quot;abstract&quot;:&quot;Nowadays, simultaneous inhibition of multiple targets through drug combination is an important anticancer strategy owing to the complex mechanism behind tumorigenesis. Recent studies have demonstrated that the inhibition of histone deacetylases (HDACs) will lead to compensated activation of a notorious cancer-related drug target, signal transducer and activator of transcription 3 (STAT3), in breast cancer through a cascade, which probably limits the anti-proliferation effect of HDAC inhibitors in solid tumors. By incorporating the pharmacophore of the HDAC inhibitor SAHA (vorinostat) into the STAT3 inhibitor pterostilbene, a series of potent pterostilbene hydroxamic acid derivatives with dual-target inhibition activity were synthesized. An excellent hydroxamate derivate, compound 14, inhibited STAT3 (KD = 33 nM) and HDAC (IC50 = 23.15 nM) with robust potency in vitro. Compound 14 also showed potent anti-proliferation ability in vivo and in vitro. Our study provides the first STAT3 and HDAC dual-target inhibit&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00136&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00136" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00136&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00136" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00136&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00136" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00136&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00136&amp;href=/doi/10.1021/acs.jmedchem.1c00136" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00136" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00136" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00136%26sid%3Dliteratum%253Aachs%26pmid%3D34043359%26genre%3Darticle%26aulast%3DRen%26date%3D2021%26atitle%3DDiscovery%2Bof%2BSTAT3%2Band%2BHistone%2BDeacetylase%2B%2528HDAC%2529%2BDual-Pathway%2BInhibitors%2Bfor%2Bthe%2BTreatment%2Bof%2BSolid%2BCancer%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D11%26spage%3D7468%26epage%3D7482%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/11" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/jmcmar.2021.64.issue-11/20210610/jmcmar.2021.64.issue-11.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/medium/jm1c00136_0021.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00136&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Nowadays, simultaneous inhibition of multiple targets through drug combination is an important anticancer strategy owing to the complex mechanism behind tumorigenesis. Recent studies have demonstrated that the inhibition of histone deacetylases (HDACs) will lead to compensated activation of a notorious cancer-related drug target, signal transducer and activator of transcription 3 (STAT3), in breast cancer through a cascade, which probably limits the anti-proliferation effect of HDAC inhibitors in solid tumors. By incorporating the pharmacophore of the HDAC inhibitor SAHA (vorinostat) into the STAT3 inhibitor pterostilbene, a series of potent pterostilbene hydroxamic acid derivatives with dual-target inhibition activity were synthesized. An excellent hydroxamate derivate, compound <b>14</b>, inhibited STAT3 (<i>K</i><sub>D</sub> = 33 nM) and HDAC (IC<sub>50</sub> = 23.15 nM) with robust potency <i>in vitro</i>. Compound <b>14</b> also showed potent anti-proliferation ability <i>in vivo</i> and <i>in vitro</i>. Our study provides the first STAT3 and HDAC dual-target inhibitor for further exploration.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47464" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47464" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Cancer is a multifaceted disease which requires multiple therapeutic interventions.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Traditional approaches represented by chemotherapy remain the primary choice to treat cancer.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> However, most chemotherapeutic agents merely act on one target, which may lead to drug resistance after a period of treatment and ultimately cause failure.<a onclick="showRef(event, 'ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5">(3−5)</a> An increasing number of therapies inhibiting two specific targets have achieved success in clinical research. Thus, a drug which regulates two or more relevant targets might result in a synergic therapeutic effect in cancer treatment.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6,7)</a></div><div class="NLM_p">Histone deacetylases (HDACs) are a class of epigenetic enzymes closely related to tumorigenesis.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a> Together with histone acetyltransferases, HDACs regulate the acetylation balance of histones and other proteins through lysine acetylation and deacetylation.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> HDACs play an important regulatory role in many vital cellular processes including cell growth, cell differentiation, and apoptosis. Moreover, the expression and/or function of HDACs is often perturbed in cancer.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Dozens of HDAC inhibitors (HDACi) have shown significant anti-tumor effects in various types of cancer cells <i>in vitro</i>, including colon cancer, breast cancer, and liver cancer.<a onclick="showRef(event, 'ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14">(12−14)</a> The release of oncogenic transcriptional repressors caused by HDAC inhibition can lead to cell cycle arrest and apoptosis.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Hundreds of HDACi have been developed in the past few decades, and several have been approved by the FDA (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>),<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16,17)</a> such as vorinostat (or named as SAHA) for cutaneous T-cell lymphoma, panobinostat for multiple myeloma, and belinostat for relapsed or refractory peripheral T-cell lymphoma.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Unfortunately, HDACi lack visible efficacy against human solid tumors,<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19,20)</a> limiting their application in more tumor indications. Previously, efforts were made in combining the HDACi pharmacophore with other protein inhibitors in order to enhance the efficacy in solid tumors. HDACi have also been shown to synergize with other agents, including receptor tyrosine kinase (RTK) inhibitors, to suppress proliferation and induce apoptosis in multiple cancer cells <i>in vitro</i>.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/medium/jm1c00136_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative HDACi.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00136&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The indications of the approved HDACi are concentrated on hematological malignancies such as lymphoma and myeloma. As for the reason why HDACi fail in solid tumors, there is still no consensus. Recent research studies have demonstrated that the inhibition of HDACs will lead to compensated activation of signal transducer and activator of transcription 3 (STAT3), a notorious cancer-related drug target, in breast cancer through a cascade, which probably limits the anti-proliferation effect of HDACi in solid tumors.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Zeng et al. demonstrated that HDACi indirectly activated the leukemia inhibitory factor receptor (LIFR) by promoting the activation of BRD4. Afterward, LIFR activated the downstream JAK1-STAT3 pathway, which ultimately restrained the antitumor effect of HDACi in breast cancer cells. Using inhibitors or siRNA to inhibit BRD4 or JAK enhanced the sensitivity of breast cancer, especially the triple negative breast cancer, to HDACi.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> The JAK–HDAC dual-target inhibitors designed by Yao et al. showed broad cellular anti-proliferative potency, including hematological cell lines and breast cancer.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Pan et al. synthesized several BRD4–HDAC inhibitors that suppressed colorectal carcinoma <i>in vitro</i> and <i>in vivo</i>.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> These research studies indicated a signal cascade, namely, the HDAC-BRD4-LIFR-JAK-STAT3 signal cascade, which starts with HDAC inhibition and ends up with STAT3 activation (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). The cascade gives a possible explanation about why HDACi are ineffective on solid tumors. STAT3 activation by HDAC inhibition attenuates the intrinsic anticancer ability of HDACi. Inhibiting the factors in this cascade could sensitize breast cancer and colorectal cancer to HDACi. Inspired by their studies, a series of STAT3–HDAC dual-target inhibitors were designed. Compared to BRD4–HDAC and JAK1–HDAC inhibition, STAT3–HDAC inhibition might be an effective alternative combination. Herein, we designed the first series of STAT3–HDAC dual-target inhibitors.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/medium/jm1c00136_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. HDAC-BRD4-LIFR-JAK-STAT3 signal cascade.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00136&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">STAT3, a cytosolic member of the STAT family, plays dual roles as a signal transducer and a transcription factor.<a onclick="showRef(event, 'ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref25 ref26 ref27">(25−27)</a> Studies have indicated that persistently activated STAT3 is indispensable for various cancers including breast cancer and colorectal cancer, which makes it an ideal drug target.<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28,29)</a> Briefly, the binding of growth factors, cytokines, or other stimuli to their respective membrane receptors could activate corresponding RTKs.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Tyrosine kinases such as JAK and Src subsequently phosphorylate specific tyrosine residues in the receptor’s intracellular domain, creating binding sites for cytosolic STAT3. After recruitment, phosphorylation of STAT3 at the Tyr705 site is carried out by JAK as well. Phosphorylation of Tyr705 is necessary for STAT3 dimerization and the subsequent transactivation of target genes.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Two phosphorylated STAT3 proteins form a homodimer through reciprocal interaction of one pTyr705 and another SH2 domain. Dimerized STAT3 translocates into the nucleus, subsequently binds to the specific region of the DNA promoter, and promotes target gene expression, including <i>Bcl-2</i>, <i>Mcl-1</i>, and <i>Cyclin D1</i>.<a onclick="showRef(event, 'ref22 ref28 ref31'); return false;" href="javascript:void(0);" class="ref ref22 ref28 ref31">(22,28,31)</a> There are several known STAT3 inhibitors; however, none of them have been approved yet. Our group has developed a series of STAT3 inhibitors, including small molecules derived from computer-aided rational design and derivatives of natural compounds.<a onclick="showRef(event, 'ref32 ref33 ref34 ref35 ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref32 ref33 ref34 ref35 ref36 ref37">(32−37)</a></div><div class="NLM_p">A compound selectively inhibiting both STAT3 protein and HDAC enzymes with high ligand efficiency might cure the resistant solid tumors. Pterostilbene (PTE), a STAT3 inhibitor, was chosen as the parent molecule.<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38,39)</a> PTE, a natural dimethylated analogue of resveratrol extracted from blueberries, is verified to be safe and effective, which is safe in doses up to 250 mg/day, according to human clinical trials.<a onclick="showRef(event, 'ref40 ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref40 ref41 ref42">(40−42)</a> Herein, hydroxamic acid was efficiently incorporated into PTE by various linkers (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Compound <b>14</b> was the most potent inhibitor in MDA-MB-231 (IC<sub>50</sub> = 0.78 μM) and HCT116 (IC<sub>50</sub> = 1.07 μM). <b>14</b> could directly bind to STAT3 with a robust affinity (<i>K</i><sub>D</sub> = 33 nM). It also inhibited HDACs with an IC<sub>50</sub> of 23.15 nM <i>in vitro</i>. Compound <b>14</b> inhibited the phosphorylation of STAT3 and downregulated STAT3 downstream gene expression. It induced MDA-MB-231 cell apoptosis through the caspase signal pathway. The safety and antitumor efficacy of <b>14</b> were demonstrated both <i>in vitro</i> and <i>in vivo</i>. Herein, the first STAT3–HDAC dual inhibitor was discovered with potent anticancer activity.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/medium/jm1c00136_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structures of PTE, SAHA, and merged molecules. Compound <b>14</b> had high ligand efficiency.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00136&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61488" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61488" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">2.1.  Chemistry</h3><div class="NLM_p">Synthetic routes of compounds <b>11–21</b> are listed in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a>-<named-content content-type="anchor" rid="sch2" type="simple"></named-content><named-content content-type="anchor" rid="sch3" type="simple"></named-content><a class="ref internalNav" href="#sch4" aria-label="4">4</a>. Preparation of analogues with various chain lengths (<b>11–15</b>) is shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Alkylation of the 4′-OH group of PTE with different ethyl bromoalkanoates yielded ester products <b>2–6</b> by Williamson ether synthesis. Conversion of esters <b>2–6</b> to hydroxamic acids using hydroxylamine yielded final compounds <b>11–15</b>. To extend structural diversity, compounds <b>16–21</b> possessing non-aliphatic hydrocarbon linkers were also synthesized.</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/medium/jm1c00136_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0016.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>11–18</b>: (a) Ethyl Bromoalkanoate, Potassium Carbonate, DMF, 60 °C, Overnight; (b) Bromobenzoate, Potassium Carbonate, DMF, 60 °C, Overnight; and (c) Hydroxylamine Solution (50% NH<sub>2</sub>OH), Potassium Hydroxide, THF–MeOH, Ice Bath to Room Temperature (rt), 12 h</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00136&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/medium/jm1c00136_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0017.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compound <b>19</b>: (a) Triethyl Phosphite, Reflux, 40 min; (b) DMF, NaOCH<sub>3</sub>, Ice Bath to rt, 12 h; (c) Ethyl Acetate, Stannous Chloride Dihydrate, Reflux, 5 h; (d) Methyl 4-Formylcinnamate, NaB(OAc)<sub>3</sub>H, Acetic Acid, CH<sub>2</sub>Cl<sub>2</sub>, rt, Overnight; and (e) Hydroxylamine Solution (50% NH<sub>2</sub>OH), Potassium Hydroxide, THF–MeOH, Ice Bath to rt, 12 h</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00136&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/medium/jm1c00136_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0018.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compound <b>20</b>: (a) 1,2-Dibromoethane, K<sub>2</sub>CO<sub>3</sub>, 80 °C, 6 h; (b) Ethyl 2-(piperazin-1-yl)acetate, KI, K<sub>2</sub>CO<sub>3</sub>, Reflux, 8 h; and (c) Hydroxylamine Solution (50% NH<sub>2</sub>OH), Potassium Hydroxide, THF–MeOH, Ice Bath to rt, 12 h</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00136&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/medium/jm1c00136_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0019.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthetic Route of Compound <b>21</b>: (a) MeOH–H<sub>2</sub>O (1:1, v/v), Sodium Ascorbate, CuSO<sub>4</sub>, 5 h; (b) CH<sub>3</sub>CN, K<sub>2</sub>CO<sub>3</sub>, Reflux, 8 h; and (c) Hydroxylamine Solution (50% NH<sub>2</sub>OH), Potassium Hydroxide, THF–MeOH, Ice Bath to rt, 12 h</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00136&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The preparation of the analogue with aniline substitution (<b>19</b>) is shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. First of all, <b>1a</b> was converted to phosphonic precursor diethyl (4-nitrobenzyl)phosphonate (<b>2a</b>) through the Arbuzov reaction.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Then, <b>2a</b> reacted with 3,5-dimethoxybenzaldehyde (<b>3a</b>) to give product <b>4a</b> by Horner–Emmons–Wadsworth olefination.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Under a nitrogen atmosphere, <b>4a</b> reacted with stannous chloride dihydrate to generate the reduced product (<i>E</i>)-4-(3,5-dimethoxystyryl) aniline (<b>5a</b>).<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Under an acetic acid condition, <b>5a</b> and methyl 4-formylcinnamate reacted to form a Schiff base, which was reduced to <b>6a</b> in the presence of NaB(OAc)<sub>3</sub>H. Then, the ester product (<b>6a</b>) was prepared from reductive amination of methyl 4-formylcinnamate with <b>5a</b> using acetic-acid-activated NaB(OAc)<sub>3</sub>H. Finally, conversion of ester (<b>6a</b>) to hydroxamic acid using hydroxylamine yielded the final compound <b>19</b>.</div><div class="NLM_p">We designed two derivatives of compound <b>18</b>, in which non-benzene groups displaced the <i>N</i>-hydroxybenzamide group to examine whether other rings could confer a better anticancer activity. The synthetic routes of <b>20</b> and <b>21</b> are shown in <a class="ref internalNav" href="#sch3" aria-label="Schemes 3">Schemes 3</a> and <a class="ref internalNav" href="#sch4" aria-label="4">4</a>. <b>1b</b> was synthesized through the reaction of <b>1</b> and excessive 1, 2-dibromoethane. Then, <b>1b</b> reacted with ethyl 2-(piperazin-1-yl)acetate, generating <b>2b</b>. Finally, <b>20</b> was generated in an alkaline hydroxylamine solution.</div><div class="NLM_p last">Ethyl 2-azidoacetate reacted with 4-bromobut-1-yne through copper-catalyzed azide–alkyne cycloaddition to generate <b>1c</b>. <b>1</b> and <b>1c</b> reacted under the alkaline condition to form <b>2c</b>. <b>21</b> was obtained by the same method as that of <b>20</b>.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">2.2.  Evaluation of <i>In Vitro</i> Antitumor Activity</h3><div class="NLM_p">The <i>in vitro</i> antitumor activity of compounds <b>11–21</b> was evaluated on two cancer cell lines (HCT116 and MDA-MB-231). A 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-<i>H</i>-tetrazolium bromide (MTT) assay was utilized. SAHA and PTE were used as positive controls. The antitumor activity data (IC<sub>50</sub>) of the compounds are shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. Compound <b>14</b> (IC<sub>50</sub> = 0.78 ± 0.34 μM for MDA-MB-231 and IC<sub>50</sub> = 1.07 ± 0.39 μM for HCT116) was not only the most potent one among all these designed compounds but also better than the two positive control drugs. In addition, the antitumor activity of compounds <b>11–21</b> was significantly higher than that of PTE. It is worth noting that compared with HCT116, most of the designed compounds had a stronger inhibitory effect on MDA-MB-231, which is consistent with the conclusion of Zeng et al.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. IC<sub>50</sub> (μM) of <b>11–21</b> against MDA-MB-231 and HCT116 Cells</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/medium/jm1c00136_0020.gif" alt="" id="GRAPHIC-d7e779-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compounds</th><th class="colsep0 rowsep0" align="center" char="±">MDA-MB-231</th><th class="colsep0 rowsep0" align="center" char="±">HCT116</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="char" char="±">3.89 ± 0.64</td><td class="colsep0 rowsep0" align="char" char="±">5.20 ± 0.72</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="char" char="±">4.21 ± 0.57</td><td class="colsep0 rowsep0" align="char" char="±">3.35 ± 0.54</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="char" char="±">3.56 ± 0.21</td><td class="colsep0 rowsep0" align="char" char="±">4.10 ± 0.14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="char" char="±">0.78 ± 0.34</td><td class="colsep0 rowsep0" align="char" char="±">1.07 ± 0.39</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="char" char="±">5.05 ± 0.13</td><td class="colsep0 rowsep0" align="char" char="±">12.61 ± 0.11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="char" char="±">7.18 ± 0.18</td><td class="colsep0 rowsep0" align="char" char="±">13.89 ± 1.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="char" char="±">9.22 ± 0.42</td><td class="colsep0 rowsep0" align="char" char="±">13.74 ± 0.72</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="char" char="±">6.88 ± 0.83</td><td class="colsep0 rowsep0" align="char" char="±">10.39 ± 0.65</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="char" char="±">5.95 ± 0.35</td><td class="colsep0 rowsep0" align="char" char="±">11.20 ± 1.38</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="char" char="±">7.42 ± 0.48</td><td class="colsep0 rowsep0" align="char" char="±">8.87 ± 0.52</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="char" char="±">6.52 ± 0.33</td><td class="colsep0 rowsep0" align="char" char="±">7.44 ± 0.31</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PTE<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">31.17 ± 0.64</td><td class="colsep0 rowsep0" align="char" char="±">34.08 ± 1.25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SAHA<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">1.77 ± 1.17</td><td class="colsep0 rowsep0" align="char" char="±">2.59 ± 0.56</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub>, Data are expressed as means ± SD of three independent experiments.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Positive control.</p></div></div></div><div class="NLM_p last">Results showed that the linker-length-dependent antitumor activity peaked with compound <b>14</b>, an analogue with six methylene linkers separating the benzene ring from the zinc-binding hydroxamic acid group. Compounds <b>11–13</b>, analogues having shorter methylene linkers than <b>14</b>, showed decreased anti-proliferative activity with the decreased linker length. Compound <b>15</b>, an analogue with a longer methylene linker than <b>14</b>, also showed reduced anti-proliferative activity. Besides, substituting the phenyl linker for the alkyl linker decreased the anti-proliferative activity, regardless of the ortho-, meta-, or para-benzene ring substituent (compounds <b>16–18</b>). When a cinnamyl fragment (compound <b>19</b>) was introduced, which is similar to the structure of panobinostat (HDACi approved by the FDA), the antitumor efficacy of <b>19</b> was better than that of the compounds with a benzene ring linker (<b>16–18</b>) although lower than that of <b>14</b> likewise. Simple replacement of the benzene ring by nitrogen-containing heterocycles (<b>20</b> and <b>21</b>) did not improve the activity. In general, all the compounds displayed higher sensitivity than positive control PTE in cancer cells.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11">2.3.  Compound <b>14</b> Inhibited HDAC Activity</h3><div class="NLM_p">HDAC inhibitory ability of compounds is one of the most critical parameters to HDACi. HDAC inhibitory ability of compound <b>14</b> was first evaluated on a nuclear extract level. Using the HDAC activity fluorometric assay kit, eight concentrations (0, 6.25, 12.5, 25, 50, 100, 250, and 500 nM) were used to derive the IC<sub>50</sub> value of compound <b>14</b> for 24 h in an MDA-MB-231 cell. As shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A, the IC<sub>50</sub> value of compound <b>14</b> was 23.15 ± 0.15 nM, which exhibited excellent sensitivity to HDACs.</div><figure id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/medium/jm1c00136_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Compound <b>14</b> inhibited HDAC activity. (A) HDAC activities [IC<sub>50</sub> (nM)] of compound <b>14</b>. Data represented as mean ± SD from three independent experiments. (B) Levels of acetylated α-tubulin, acetylated histone H3, and GAPDH (the loading control) after 24 h incubation with compound <b>14</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00136&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Hybrid molecules, which were designed as multifunctional anticancer agents, were expected to retain HDACi activities. Since HDACs regulate the acetylation status of histone and non-histone proteins in the cell, the acetylation levels of histone H3 (a well-known nuclear substrate of HDACs) and α-tubulin (a well-known cytoplasmic substrate of HDACs) were frequently used as markers of cellular HDAC activity, respectively. MDA-MB-231 cells were incubated with compound <b>14</b> (0.5–5 μM) for 24 h, and the levels of acetylation of histone H3 and α-tubulin were detected by the Western blot. As shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B, compound <b>14</b> markedly increased Ac-α-tubulin and Ac-histone H3 levels in a concentration-dependent manner.</div><div class="NLM_p">Profiling the inhibition ability of compound <b>14</b> on subtypes of HDACs was subsequently carried out. Four subtypes from the four respective HDAC subfamilies were tested: HDAC1 (I), HDAC4 (IIA), HDAC6 (IIA), and HDAC11 (IV). The result in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> showed that <b>14</b> could selectively inhibit HDAC6 (104 nM) and HDAC1 (683 nM) but not HDAC4 or HDAC11.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Inhibition Activity of Compound <b>14</b> against HDAC Subtypes</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center">IC<sub>50</sub> (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">HDAC1</th><th class="colsep0 rowsep0" align="center">HDAC4</th><th class="colsep0 rowsep0" align="center">HDAC6</th><th class="colsep0 rowsep0" align="center">HDAC11</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">683</td><td class="colsep0 rowsep0" align="left">12%<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">104</td><td class="colsep0 rowsep0" align="left">37%<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> performed using the 10-dose IC<sub>50</sub> mode with 3-fold serial dilution beginning from 10 μM.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">% inhibition at 10 μM.</p></div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13">2.4.  Effect of Compound <b>14</b> on Phosphorylation of STAT3</h3><div class="NLM_p">Designed as a dual-target inhibitor, compound <b>14</b> was expected to inhibit STAT3 phosphorylation. Western blot analysis was utilized to determine the levels of phosphorylated STAT3 (p-STAT3). Western blot assays of Ac-α-tubulin, Ac-histone H3, and STAT3 were done in the same experiment. MDA-MB-231 cells were incubated with different concentrations (0.5–5 μM) of compound <b>14</b> for 24 h, and then, the levels of total STAT3 and phosphorylated STAT3 at the tyrosine 705 residue were detected. The result (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) showed that as the concentration of compound <b>14</b> increased, the level of phosphorylated STAT3 continued to decrease, while the level of total STAT3 remained unchanged, which indicated that compound <b>14</b> did not reduce the level of phosphorylated STAT3 by affecting the total level of STAT3.</div><figure id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/medium/jm1c00136_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>14</b> reduced STAT3 tyrosine phosphorylation in MDA-MB-231 cells. The expression of p-STAT3 was downregulated, while the expression of total STAT3 was unchanged.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00136&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14">2.5.  Compound <b>14</b> Affected the Expression of STAT3-Regulated Oncogenes</h3><div class="NLM_p">Persistently activated STAT3 promotes the expression of oncoproteins, including cell-cycle-related oncoprotein cyclin D1 and anti-apoptotic oncoprotein Bcl-2. The levels of cyclin D1 and Bcl-2 were also determined by the Western blot. The results in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A showed that compound <b>14</b> significantly inhibited the expression of STAT3 downstream proteins cyclin D1 and Bcl-2.</div><figure id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/medium/jm1c00136_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Compound <b>14</b> affected the expression of STAT3-regulated oncogenes. (A) Compound <b>14</b> reduced the levels of STAT3 downstream proteins. (B) Compound <b>14</b> reduced the levels of STAT3 downstream mRNA. The data were obtained by real-time quantitative RT-PCR, normalized based on the levels of GAPDH, and are expressed as the mean ± SD from three independent experiments. ** <i>p</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00136&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Activated STAT3 translocates into the nucleus and then initiates the expression of downstream genes. The mRNA levels of <i>cyclin D1</i> and <i>Bcl-2</i> were assessed by real-time RT-PCR. The results (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B) were consistent with the Western blot results. Compound <b>14</b> inhibited the transcription of STAT3 downstream genes <i>cyclin D1</i> and <i>Bcl-2</i>. These results indicated that compound <b>14</b> reduced the transcription of downstream genes of STAT3, thereby reducing the expression of downstream proteins.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15">2.6.  Kinetic Affinity of Compound <b>14</b> against STAT3</h3><div class="NLM_p">To confirm that compound <b>14</b> is a direct STAT3 inhibitor, SPR (surface plasmon resonance) analysis was carried out, and the method was the same as that in our previous work.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Briefly, recombinant STAT3 with a GST tag was immobilized on CM5 chips, and then, the solution containing compound <b>14</b> flowed over the chip surface. The signal was collected, kinetic affinity was calculated by the software, and data were matched up with the requirements of the predictive model (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). The affinity (<i>K</i><sub>D</sub>) was 33 nM. The result indicated that compound <b>14</b> had a strong affinity to STAT3 protein.</div><figure id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/medium/jm1c00136_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Kinetic analysis of compound <b>14</b> against STAT3. An SPR assay was conducted on Biacore T200 utilizing a CM5 chip. Kinetic curve fitting and <i>K</i><sub>D</sub> calculation were done by Biacore S200 Evaluation Software.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00136&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Kinetic Result of Compound <b>14</b> against Recombinant STAT3<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"><i>k</i><sub>a</sub> (1/M s)</th><th class="colsep0 rowsep0" align="center"><i>k</i><sub>d</sub> (1/s)</th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>D</sub> (nM)</th><th class="colsep0 rowsep0" align="center">χ<sup>2</sup> (RU<sup>2</sup>)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">451,200</td><td class="colsep0 rowsep0" align="left">0.01516</td><td class="colsep0 rowsep0" align="left">33.61</td><td class="colsep0 rowsep0" align="left">0.729</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Values were calculated by Biacore S200 Evaluation Software.</p></div></div></div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17">2.7.  Influence of Compound <b>14</b> on STAT3 Upstream Kinases</h3><div class="NLM_p">It is possible that compound <b>14</b> affected the phosphorylation status of upstream kinases such as JAK or Src and, consequently, hampered the phosphorylation of STAT3. Levels of JAK1, p-JAK1, Src, and p-Src after treatment with compound <b>14</b> were assessed by the Western blot. According to Zeng et al.,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> the level of p-JAK1 was increased after the treatment with HDACi, and the results in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a> are consistent with this; p-JAK1 was increased not decreased after treatment with <b>14</b> in 10 μM, while compound <b>14</b> had little effect on p-Src.</div><figure id="fig8" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/medium/jm1c00136_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Influence of compound <b>14</b> on JAK and Src. (A) The level of p-JAK1 slightly increased at 10 μM. (B) Levels of p-Src and total Src were not significantly changed.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00136&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18">2.8.  Effect of Compound <b>14</b> on Cell Apoptosis</h3><div class="NLM_p">Apoptosis in cancer cells could be caused by the inhibition of HDACs and/or STAT3. Three methods were utilized to assess the effect of compound <b>14</b> on the apoptosis of MDA-MB-231 cells. First of all, Hoechst 33342 was utilized to stain MDA-MB-231 cells that were pretreated with different concentrations of compound <b>14</b>, and then, the cells were observed under a fluorescence microscope. As shown in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>, chromatin condensation and chromatinorrhexis were observed in the treated cells. Second, the annexin V-FITC/PI double staining method was used to quantitatively detect the effect of compound <b>14</b> on cell apoptosis. Quantitative analysis was performed using flow cytometry. The result in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>A indicates that compound <b>14</b> induced MDA-MB-231 cell apoptosis in a dose-dependent manner, and the apoptotic cells reached 59.3% at a dose of 10 μM. Third, caspase family proteins are well-known apoptosis-related proteins, and their levels were determined by the Western blot. The levels of cleaved PARP and cleaved Caspase3/7 in MDA-MB-231 cells were increased after the treatment with <b>14</b>, while the total Caspase3/7 and PARP levels were basically unaffected (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>B).</div><figure id="fig9" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/medium/jm1c00136_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Compound <b>14</b> induced tumor cell apoptosis <i>in vitro</i>. After being treated with compound <b>14</b> (0.5–5 μM), cells were fixed and stained with Hoechst 33342 and observed under a fluorescence microscope.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00136&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig10" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/medium/jm1c00136_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. (A) Compound <b>14</b> induced tumor cell apoptosis <i>in vitro</i>. After incubation with compound <b>14</b> (0–10 μM), cells were analyzed using flow cytometry. (B) Levels of Caspase3/7, PARP, cleaved Caspase3/7, and cleaved PARP after incubation with compound <b>14</b> (0.5–5 μM) for 24 h. GAPDH was used as a control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00136&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19">2.9.  Effect of Compound <b>14</b> on Colony Formation</h3><div class="NLM_p">The cell colony formation experiment is one of the effective methods to assess the anti-proliferation ability of compounds. Therefore, a colony formation assay was performed to test whether compound <b>14</b> treatment could inhibit proliferation. MDA-MB-231 cells were first incubated with <b>14</b> for 24 h, and then, the medium was replaced with the drug-free medium, and the cells continued to be cultured for 15 days. As shown in <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>, the colony forming ability of MDA-MB-231 cells was significantly inhibited after compound <b>14</b> treatment, and the result was consistent with the MTT assays.</div><figure id="fig11" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/medium/jm1c00136_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Colony formation assay. MDA-MB-231 cells were incubated with compound <b>14</b> with different doses. Afterward, the medium was replaced by the drug-free medium, and the cells continued to be cultured for 15 days.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00136&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20">2.10.  Compound <b>14</b> Inhibited Migration Activity of MDA-MB-231 Cells</h3><div class="NLM_p">Migration is a key step in cancer progression, and the evidence has shown that over-activated STAT3 is one of the key driving factors of this process. Hence, the anti-migration activity of compound <b>14</b> was tested. Cells seeded in a proper density were scratched in the middle of each group. Subsequently, cells were cultured in a medium with compound <b>14</b> or 0.1% dimethyl sulfoxide (DMSO) for 24 h. As shown in <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>, migration was totally inhibited by compound <b>14</b> at 5 μM.</div><figure id="fig12" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/medium/jm1c00136_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0013.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Wound Healing Assay. MDA-MB-231 cells were cultured in a 6-well plate (3 × 10<sup>5</sup>/well), scratched in the middle of each well with a 10 μL plastic pipette tip to create a mechanical wound. Then, the culture medium was changed to a fresh medium with different concentrations of compound <b>14</b>. Images were taken at 0 and 24 h after scraping by a phase-contrast microscope.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00136&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21">2.11.  Molecular Docking</h3><div class="NLM_p">A large percentage of STAT3 inhibitors, including PTE, reduce STAT3 phosphorylation by occupying the SH2 domain. Given that compound <b>14</b> could notably reduce STAT3 phosphorylation, the merged molecule might bind to SH2 domain, and its binding mode should be similar to parent compound PTE. Molecular docking assay was subsequently performed to predict the binding model of compound <b>14</b> with the STAT3 SH2 domain (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1BG1">1BG1</a>). The hydroxamic acid chain forming three hydrogen bonds with Arg609 (1.864 and 2.742 Å) and Ser613 (2.096 Å) occupied the native hot spot pTyr705 site, and the PTE fragment forming one hydrogen bond with Arg595 (1.797 Å) took up the side pocket (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>). Moreover, a suitable conformation of compound <b>14</b> contributed a lot to the tight binding. The predicted binding energy was −6.6 kcal/mol. All data and figures indicated that compound <b>14</b> is a direct inhibitor of the STAT3 SH2 domain.</div><figure id="fig13" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/medium/jm1c00136_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0014.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Molecular docking. Docking model between compound <b>14</b> and the SH2 domain of STAT3 protein (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1BG1">1BG1</a>) was produced by Autodock 4.2. (A) Carbon atoms of the inhibitor are light brown, oxygen atoms are red, and nitrogen atoms are blue. (B) Hydrogen bonds are marked as blue lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00136&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22">2.12.  Safety Evaluation of Compound <b>14</b><i>In Vitro</i> and <i>In Vivo</i></h3><div class="NLM_p">Compound <b>14</b> exhibited excellent anticancer ability on cells. Further safety evaluation was subsequently launched. Parent compounds PTE and SAHA were both clinically used compounds, and their safety was confirmed.<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44,45)</a> Normal breast cells MCF-10A and liver cells L02 were selected and then tested by MTT assays. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>, compound <b>14</b> was safe enough on the tested cell lines (IC<sub>50</sub> > 32 vs 0.78 μM on MDA-MB-231). An acute toxicity test was then carried out on ICR mice. Maximal tolerable dose (MTD) data are listed in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>. Mice were still alive when they were orally administered with a high dose (400 mg/kg) of compound <b>14</b>. The preliminary acute toxicity test proved the safety of compound <b>14</b>.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Safety Assessment of Compound <b>14</b><i>In Vitro</i></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">% inhibition of proliferation at 32 μM<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">MCF-10A</th><th class="colsep0 rowsep0" align="center">L02</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">38</td><td class="colsep0 rowsep0" align="left">32</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SAHA</td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" align="left">26</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PTE<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Results were obtained by three replications.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Instead of inhibition, PTE promoted the growth of the two selected normal cells. ND means that no inhibition of proliferation was observed.</p></div></div></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Safety Assessment of Compound <b>14</b><i>In Vivo</i><a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">MTD (mg/kg)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SAHA</td><td class="colsep0 rowsep0" align="left">>400</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">compound <b>14</b></td><td class="colsep0 rowsep0" align="left">>400</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PTE</td><td class="colsep0 rowsep0" align="left">>400</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Mice were orally dosed with a gradient concentration of drugs. Death was recorded after administration.</p></div></div></div></div><div id="sec2_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25">2.13.  Pharmacokinetics of Compound <b>14</b> in SD Rats</h3><div class="NLM_p last">The pharmacokinetics of compound <b>14</b> was investigated in SD rats following a single intravenous injection (iv, 2 mg/kg) or oral administration (po, 20 mg/kg). After intravenous injection of compound <b>14</b> (2 mg/kg), the mean volume of distribution at the steady state (<i>V</i><sub>ss</sub>) was 1.65 L/kg. The mean blood clearance was 63.89 mL/min/kg. The mean half-life was 0.47 h. After oral administration of compound <b>14</b> (20 mg/kg), the mean oral bioavailability was 5.81%, estimated based on AUC<sub>0–<i>t</i></sub>. The mean half-life was 0.88 h (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00136/suppl_file/jm1c00136_si_001.pdb" class="ext-link">Figure S1</a>).</div></div><div id="sec2_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26">2.14.  Antitumor Activity in a Mouse Model</h3><div class="NLM_p">Compound <b>14</b> had shown excellent antitumor activity in <i>in vitro</i> experiments, so a mouse 4T1 allograft tumor model was established to evaluate the <i>in vivo</i> antitumor activity of compound <b>14</b>. 4T1 cells are also triple-negative breast cancer cells, which express over-activated STAT3 likewise. There were five groups of mice according to the dosage and type of drugs (six mice per group): compound <b>14</b> (15 mg/kg or 30 mg/kg), SAHA (30 mg/kg), PTE (30 mg/kg), or saline. Mice were dosed intraperitoneally for 21 days. As shown in <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>, compound <b>14</b> significantly reduced the tumor volume and weight. In the 15 mg/kg group of compound <b>14</b> administration, the volume reduction reached 54% and the weight reduction reached 53% compared to the control group. In the 30 mg/kg group of compound <b>14</b> administration, the volume reduction reached 64%, and the weight reduction reached 62%. In addition, compound <b>14</b> did not cause apparent body weight change. The result indicated that compound <b>14</b> was a promising anticancer compound with excellent safety performance.<named-content content-type="anchor" rid="fig13" type="simple"></named-content><named-content content-type="anchor" rid="fig14" type="simple"></named-content></div><figure id="fig14" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/medium/jm1c00136_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0015.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. <i>In vivo</i> antitumor assay. Compound <b>14</b> suppressed the growth of the transplanted tumor. (A) Tumor weight was measured by an electronic balance. (B) Growing curves of mice’s tumor volume. (C) Curves of body weights. (D) Mice’s tumor tissue. * <i>p</i> < 0.05, ** <i>p</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00136&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i27">3.  Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64588" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64588" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">A series of novel PTE derivatives were designed, synthesized by merging the hydroxamic acid fragment into the STAT3 inhibitor, and evaluated as dual-target STAT3 and HDAC inhibitors. Among these compounds, compound <b>14</b> had the best antitumor activity (IC<sub>50</sub> = 0.78 μM on MDA-MB-231 cells). The affinity assay and HDAC inhibitory test confirmed that compound <b>14</b> is an effective inhibitor of STAT3 (<i>K</i><sub>D</sub> = 33 nM) and HDACs (IC<sub>50</sub> = 23.15 nM). Selectivity of <b>14</b> against representative HDAC isoforms was evaluated, and <b>14</b> could selectively inhibit HDAC6 (104 nM) and HDAC1 (683 nM) but not HDAC4 or HDAC11. The Western blot assay suggested that compound <b>14</b> reduced the level of activated STAT3 without affecting upstream kinases and total STAT3. The expression of STAT3 downstream target genes and target proteins was also suppressed by compound <b>14</b>. Results of Western blot analysis also indicated that compound <b>14</b> could increase the level of Ac-α-tubulin and Ac-histone H3 and cleaved caspase in a concentration-dependent manner. The staining experiment utilizing Hoechest 33342 and annexin V-FITC/PI proved that <b>14</b> induced the apoptosis of MDA-MB-231 cells. Docking studies illustrated the possible conformation of compound <b>14</b> binding to the STAT3-SH2 domain. Furthermore, compound <b>14</b> displayed excellent <i>in vivo</i> antitumor efficacy and safety performance. In summary, targeting both STAT3 and HDAC could result in a synergic therapeutic effect in tumorigenesis.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i28">4.  Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66578" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66578" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29">4.1.  Chemistry</h3><div class="NLM_p">All common reagents and solvents were obtained from commercial suppliers and used without further purification. The reaction progress was monitored using analytical thin-layer chromatography on pre-coated silica gel GF254 plates (Qingdao Haiyang Chemical Plant, Qingdao, China), and the spots were detected under UV light (254 nm). Column chromatography was performed using silica gel (90–150 μm; Qingdao Marine Chemical Inc.) The amount of silica gel used in column chromatography was 50–100 times the weight charged on the column. The melting point was measured on an XT-4 micromelting point instrument and uncorrected. All the <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were measured on a Bruker ACF-500 spectrometer or a Bruker 600 spectrometer at 25 °C and referenced to tetramethylsilane. Chemical shifts are reported in ppm (δ) using the residual solvent line as an internal standard. Splitting patterns were designed as s, singlet; br s, broad single; d, doublet; t, triplet; and m, multiplet. The purity of all compounds used for biological evaluation was confirmed to be higher than 95% through analytical high-performance liquid chromatography (HPLC) performed with an Agilent 1100 HPLC System. Mass spectra were obtained on an MS Agilent 1100 Series LC/MSD Trap mass spectrometer (ESI-MS) and a Mariner ESI-TOF spectrometer (HRESI-MS), respectively.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30">4.1.1.  General Procedure for the Synthesis of <b>2–9</b> (a,b)</h4><div class="NLM_p last">A mixture of PTE (<b>1</b>, 1.0 mmol), appropriate ethyl bromoalkanoate or bromobenzoate (1.1 mmol), and potassium carbonate (2.5 mmol) in dimethylformamide (DMF) was stirred at 60 °C overnight. The reaction was quenched by pouring in ice water. After stirring for 10–20 min, the solid precipitated was collected by filtration, washed with water and petroleum ether, and recrystallized from ethanol. Intermediates <b>2–9</b> were obtained after being dried in vacuum.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31">4.1.2.  General Procedure for the Synthesis of <b>11–18</b> from Their Corresponding Esters (c)</h4><div class="NLM_p">The appropriate esters (<b>2–9</b>, 1.0 mmol) and potassium hydroxide (1.7 mmol) in tetrahydrofuran (THF)–MeOH (1:1) were added to the hydroxylamine solution (10 mmol) at 0 °C. The reaction mixture was warmed to room temperature and stirred at 25 °C for 12–24 h until the reaction was complete (the reaction progress was monitored by thin-layer chromatography). The reaction mixture was neutralized with acetic acid. The formed precipitate was collected by filtration, washed with water, and dried to give title compounds <b>11–18</b>. If the precipitate did not form after neutralization, the solvent was removed to yield a crude mixture, which was purified by silica gel chromatography to give the title compounds.</div><div id="sec4_1_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32">4.1.2.1.  (<i>E</i>)-4-(4-(3,5-Dimethoxystyryl)phenoxy)-<i>N</i>-hydroxybutanamide (<b>11</b>)</h5><div class="NLM_p last">Yield 87%, white solid, mp 145–146 °C; IR (KBr): ν 846, 1052, 1069, 1150, 1162, 1251, 1598, 1644, 3237, 3441 cm<sup>–1</sup>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.41 (s, 1H), 8.70 (s, 1H), 7.52 (d, <i>J</i> = 8.6 Hz, 2H), 7.20 (d, <i>J</i> = 16.4 Hz, 1H), 7.01 (d, <i>J</i> = 16.4 Hz, 1H), 6.93 (d, <i>J</i> = 8.6 Hz, 2H), 6.74 (d, <i>J</i> = 1.9 Hz, 2H), 6.38 (t, <i>J</i> = 1.9 Hz, 1H), 3.98 (t, <i>J</i> = 6.3 Hz, 2H), 3.77 (s, 6H), 2.13 (t, <i>J</i> = 7.4 Hz, 2H), 1.98 (m, 2H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>): δ 169.07, 161.09, 158.78, 139.89, 129.99, 129.02, 128.30, 126.60, 115.16, 104.62, 99.92, 67.30, 55.64, 29.18, 25.27; HRMS (ESI) <i>m</i>/<i>z</i>: 380.1470 [M + Na]<sup>+</sup> (calcd for 380.1468, C<sub>20</sub>H<sub>23</sub>NNaO<sub>5</sub>).</div></div><div id="sec4_1_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33">4.1.2.2.  (<i>E</i>)-5-(4-(3,5-Dimethoxystyryl)phenoxy)-<i>N</i>-hydroxypentanamide (<b>12</b>)</h5><div class="NLM_p last">Yield 91%, white solid, mp 118–119 °C; IR (KBr): ν 840, 1058, 1158, 1259, 1384, 1457, 1634, 2922, 3445 cm<sup>–1</sup>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.37 (s, 1H), 8.68 (s, 1H), 7.52 (d, <i>J</i> = 8.6 Hz, 2H), 7.20 (d, <i>J</i> = 16.4 Hz, 1H), 7.01 (d, <i>J</i> = 16.4 Hz, 1H), 6.93 (d, <i>J</i> = 8.6 Hz, 2H), 6.74 (d, <i>J</i> = 2.0 Hz, 2H), 6.38 (t, <i>J</i> = 1.9 Hz, 1H), 3.98 (t, <i>J</i> = 6.0 Hz, 2H), 3.77 (s, 6H), 2.02 (t, <i>J</i> = 7.0 Hz, 2H), 1.71 (m, 4H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>): δ 169.36, 161.09, 158.87, 139.90, 129.90, 129.04, 128.29, 126.54, 115.13, 104.61, 99.92, 67.55, 55.64, 32.36, 28.64, 22.25; HRMS (ESI) <i>m</i>/<i>z</i>: 394.1627 [M + Na]<sup>+</sup> (calcd for 394.1625, C<sub>21</sub>H<sub>25</sub>NNaO<sub>5</sub>).</div></div><div id="sec4_1_2_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34">4.1.2.3.  (<i>E</i>)-6-(4-(3,5-Dimethoxystyryl)phenoxy)-<i>N</i>-hydroxyhexanamide (<b>13</b>)</h5><div class="NLM_p last">Yield 84%, white solid, mp 133–134 °C; IR (KBr): ν 828, 961, 1054, 1068, 1423, 1462, 1513, 1593, 1638, 3270, 3377 cm<sup>–1</sup>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.36 (s, 1H), 8.67 (s, 1H), 7.52 (d, <i>J</i> = 8.7 Hz, 2H), 7.21 (d, <i>J</i> = 16.4 Hz, 1H), 7.02 (d, <i>J</i> = 16.4 Hz, 1H), 6.94 (d, <i>J</i> = 8.7 Hz, 2H), 6.75 (d, <i>J</i> = 2.1 Hz, 2H), 6.39 (t, <i>J</i> = 2.1 Hz, 1H), 3.98 (t, <i>J</i> = 6.4 Hz, 2H), 3.78 (s, 6H), 1.99 (t, <i>J</i> = 7.3 Hz, 2H), 1.76 (m, 2H), 1.57 (m, 2H), 1.40 (dt, <i>J</i> = 15.0, 7.6 Hz, 2H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>): δ 169.48, 161.10, 158.92, 139.92, 129.88, 129.06, 128.31, 126.54, 115.12, 104.63, 99.92, 67.84, 55.64, 32.69, 28.90, 25.64, 25.38; HRMS (ESI) <i>m</i>/<i>z</i>: 408.1783 [M + Na]<sup>+</sup> (calcd for 408.1781, C<sub>22</sub>H<sub>27</sub>NNaO<sub>5</sub>).</div></div><div id="sec4_1_2_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35">4.1.2.4.  (<i>E</i>)-7-(4-(3,5-Dimethoxystyryl)phenoxy)-<i>N</i>-hydroxyheptanamide (<b>14</b>)</h5><div class="NLM_p last">Yield 89%, white solid, mp 121–122 °C; IR (KBr): ν 823, 839, 961, 1055, 1065, 1152, 1162, 1462, 1152, 1597, 1630, 1669, 2938, 3226, 3310, 3419 cm<sup>–1</sup>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.32 (s, 1H), 8.64 (s, 1H), 7.51 (d, <i>J</i> = 8.6 Hz, 2H), 7.20 (d, <i>J</i> = 16.4 Hz, 1H), 7.01 (d, <i>J</i> = 16.4 Hz, 1H), 6.93 (d, <i>J</i> = 8.6 Hz, 2H), 6.73 (d, <i>J</i> = 2.0 Hz, 2H), 6.38 (t, <i>J</i> = 1.9 Hz, 1H), 3.97 (t, <i>J</i> = 6.4 Hz, 2H), 3.77 (s, 6H), 1.95 (t, <i>J</i> = 7.3 Hz, 2H), 1.70 (m, 2H), 1.51 (m, 2H), 1.40 (m, 2H), 1.30 (m, 2H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>): δ 169.27, 160.80, 158.64, 139.62, 129.57, 128.76, 128.01, 126.23, 114.83, 104.32, 99.62, 67.58, 55.35, 32.38, 28.74, 28.51, 25.42, 25.25; HRMS (ESI) <i>m</i>/<i>z</i>: 422.1940 [M + Na]<sup>+</sup> (calcd for 422.1938, C<sub>23</sub>H<sub>29</sub>NNaO<sub>5</sub>).</div></div><div id="sec4_1_2_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36">4.1.2.5.  (<i>E</i>)-8-(4-(3,5-Dimethoxystyryl)phenoxy)-<i>N</i>-hydroxyoctanamide (<b>15</b>)</h5><div class="NLM_p last">Yield 87%, white solid, mp 116–117 °C; IR (KBr): ν 828, 962, 1150, 1208, 1252, 1422, 1430, 1511, 1594, 1638, 2928, 3274, 3378 cm<sup>–1</sup>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.33 (s, 1H), 8.66 (s, 1H), 7.51 (d, <i>J</i> = 8.7 Hz, 2H), 7.20 (d, <i>J</i> = 16.4 Hz, 1H), 7.01 (d, <i>J</i> = 16.4 Hz, 1H), 6.93 (d, <i>J</i> = 8.7 Hz, 2H), 6.74 (d, <i>J</i> = 2.2 Hz, 2H), 6.38 (t, <i>J</i> = 2.2 Hz, 1H), 3.97 (t, <i>J</i> = 6.5 Hz, 2H), 3.77 (s, 6H), 1.94 (t, <i>J</i> = 7.3 Hz, 2H), 1.73 (m, 2H), 1.53 (m, 2H), 1.39 (m, 2H), 1.36 (m, 2H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>): δ 169.58, 161.10, 158.95, 139.92, 129.86, 129.06, 128.30, 126.52, 115.12, 104.62, 99.91, 79.66, 79.44, 79.22, 67.91, 55.64, 32.71, 29.11, 29.00, 28.95, 25.89, 25.54; HRMS (ESI) <i>m</i>/<i>z</i>: 436.2097 [M + Na]<sup>+</sup> (calcd for 436.2094, C<sub>24</sub>H<sub>31</sub>NNaO<sub>5</sub>).</div></div><div id="sec4_1_2_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37">4.1.2.6.  (<i>E</i>)-2-((4-(3,5-Dimethoxystyryl)phenoxy)methyl)-<i>N</i>-hydroxybenzamide (<b>16</b>)</h5><div class="NLM_p last">Yield 81%, white solid, mp 122–128 °C; IR (KBr): ν 824, 1059, 1050, 1174, 1247, 1457, 1510, 1596, 1625, 3243, 3441 cm<sup>–1</sup>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.04 (s, 1H), 9.14 (s, 1H), 7.61 (d, <i>J</i> = 7.7 Hz, 1H), 7.55 (d, <i>J</i> = 8.7 Hz, 2H), 7.51 (t, <i>J</i> = 8.2 Hz, 1H), 7.43 (m, 1H), 7.41 (d, <i>J</i> = 7.5 Hz, 1H), 7.23 (d, <i>J</i> = 16.4 Hz, 1H), 7.05 (d, <i>J</i> = 16.4 Hz, 1H), 7.01 (d, <i>J</i> = 8.7 Hz, 2H), 6.76 (d, <i>J</i> = 2.2 Hz, 2H), 6.41 (t, <i>J</i> = 2.2 Hz, 1H), 5.29 (s, 2H), 3.79 (s, 6H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 165.87, 161.14, 158.55, 139.88, 130.49, 130.38, 128.98, 128.85, 128.32, 128.19, 128.13, 126.85, 115.52, 104.71, 110.04, 67.30, 55.68; HRMS (ESI) <i>m</i>/<i>z</i>: 428.1469 [M + Na]<sup>+</sup> (calcd for 428.1468, C<sub>24</sub>H<sub>23</sub>NNaO<sub>5</sub>).</div></div><div id="sec4_1_2_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38">4.1.2.7.  (<i>E</i>)-3-((4-(3,5-Dimethoxystyryl)phenoxy)methyl)-<i>N</i>-hydroxybenzamide (<b>17</b>)</h5><div class="NLM_p last">Yield 85%, white solid, mp 149–151 °C; IR (KBr): ν 803, 830, 1155, 1150, 1203, 1250, 1457, 1510, 1594, 3216, 3443 cm<sup>–1</sup>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.83 (br s, 1H),7.83 (s, 1H), 7.69 (d, <i>J</i> = 7.5 Hz, 1H), 7.52 (d, <i>J</i> = 8.4 Hz, 2H), 7.45 (d, <i>J</i> = 7.3 Hz, 1H), 7.36 (t, <i>J</i> = 7.6 Hz, 1H), 7.20 (d, <i>J</i> = 16.4 Hz, 1H), 7.07 (d, <i>J</i> = 16.4 Hz, 1H), 7.03 (d, <i>J</i> = 8.7 Hz, 2H), 6.73 (s, 2H), 6.41 (t, <i>J</i> = 2.2 Hz, 1H), 5.13 (s, 2H), 3.76 (s, 5H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 161.14, 158.61, 139.92, 137.23, 130.31, 129.20, 129.02, 128.50, 128.33, 126.83, 126.26, 115.59, 104.71, 100.04, 69.71, 55.68; HRMS (ESI) <i>m</i>/<i>z</i> 428.1471 [M + Na]<sup>+</sup> (calcd for 428.1468, C<sub>24</sub>H<sub>23</sub>NNaO<sub>5</sub>).</div></div><div id="sec4_1_2_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39">4.1.2.8.  (<i>E</i>)-4-((4-(3,5-Dimethoxystyryl)phenoxy)methyl)-<i>N</i>-hydroxybenzamide (<b>18</b>)</h5><div class="NLM_p last">Yield 88%, white solid, mp 185–188 °C; IR (KBr): ν 825, 1152, 1204, 1457, 1510, 1596, 3240, 3242 cm<sup>–1</sup>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.76 (br s, 1H), 7.76 (d, <i>J</i> = 8.1 Hz, 2H), 7.53 (d, <i>J</i> = 8.7 Hz, 2H), 7.43 (d, <i>J</i> = 8.1 Hz, 2H), 7.21 (d, <i>J</i> = 16.4 Hz, 1H), 7.03 (m, 3H), 6.74 (d, <i>J</i> = 2.2 Hz, 2H), 6.38 (t, <i>J</i> = 2.1 Hz, 1H), 5.14 (s, 2H), 3.77 (s, 6H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 161.14, 158.58, 139.92, 130.33, 129.01, 128.33, 127.59, 126.93, 126.84, 115.59, 104.71, 100.04, 69.51, 55.68; HRMS (ESI) <i>m</i>/<i>z</i>: 428.1469 [M + Na]<sup>+</sup> (calcd for 428.1468, C<sub>24</sub>H<sub>23</sub>NNaO<sub>5</sub>).</div></div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40">4.1.3.  Procedure for the Synthesis of <b>19</b></h4><div class="NLM_p">A mixture of 4-nitrobenzyl bromide (<b>1a</b>, 1 mmol) and triethyl phosphite (30 mmol) was heated at reflux in an oil bath for 40 min to give intermediate <b>2a</b>. Intermediate <b>2a</b> and sodium methoxide (6 mmol) were dissolved in 15 mL of dry DMF, and the solution was stirred at 0 °C for 30 min. Then, 3,5-dimethoxybenzaldehyde (<b>3a</b>, 1.2 mmol) dissolved in 10 mL of DMF was added dropwise at 0 °C. The mixture was stirred at room temperature overnight to give intermediate <b>4a</b>. Compound <b>4a</b> (1 mmol) dissolved in ethyl acetate was added with tin(II) chloride dihydrate (5 mmol), and the mixture was refluxed for 5 h to give intermediate <b>5a</b>. Then, a mixture of <b>5a</b> (1.0 mmol), methyl 4-formylcinnamate (1.2 mmol), and acetic acid (1.2 mmol) mixed in CH<sub>2</sub>Cl<sub>2</sub> was stirred at room temperature for 1 h. NaB(OAc)<sub>3</sub>H (2 mmol) was added to the resulting mixture, and then, the mixture was stirred to give the ester product <b>5a</b>. Finally, <b>5a</b> (1.0 mmol) and potassium hydroxide (1.7 mmol) in THF–MeOH (1:1) were added to the hydroxylamine solution (10 mmol) at 0 °C. The reaction mixture was warmed to room temperature and stirred at 25 °C overnight. The reaction mixture was neutralized with acetic acid. The formed precipitate was collected by filtration, washed with water, and dried to give the title compound <b>19</b>.</div><div id="sec4_1_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41">4.1.3.1.  (<i>E</i>)-3-(4-((4-(3,5-Dimethoxystyryl)phenylamino)methyl)phenyl)-<i>N</i>-hydroxyacrylamide (<b>19</b>)</h5><div class="NLM_p last">Yield 82%, pale yellow solid, mp 174–176 °C; IR (KBr): ν 823, 1058, 1151, 1204, 1421, 1519, 1593, 1625, 1658, 3385, 3424 cm<sup>–1</sup>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.75 (br s, 1H), 9.06 (br s, 1H), 7.51 (d, <i>J</i> = 8.1 Hz, 2H), 7.42 (d, <i>J</i> = 15.9 Hz, 1H), 7.38 (d, <i>J</i> = 8.1 Hz, 2H), 7.29 (d, <i>J</i> = 8.6 Hz, 2H), 7.06 (d, <i>J</i> = 16.3 Hz, 1H), 6.82 (d, <i>J</i> = 16.3 Hz, 1H), 6.66 (d, <i>J</i> = 2.2 Hz, 2H), 6.57 (d, <i>J</i> = 8.6 Hz, 2H), 6.43 (d, <i>J</i> = 15.8 Hz, 1H), 6.33 (t, <i>J</i> = 2.1 Hz, 1H), 4.32 (d, <i>J</i> = 5.8 Hz, 2H), 3.75 (s, 6H); <sup>13</sup>C NMR (150 MHz): δ 161.05, 148.94, 142.24, 140.42, 133.81, 129.89, 128.12, 127.98, 125.26, 123.55, 118.89, 112.82, 104.9, 99.36, 79.66, 55.59, 46.47; HRMS (ESI) <i>m</i>/<i>z</i>: 453.1786 [M + Na]<sup>+</sup> (calcd for 453.1785, C<sub>26</sub>H<sub>26</sub>N<sub>2</sub>NaO<sub>4</sub>).</div></div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42">4.1.4.  Procedure for the Synthesis of <b>20</b></h4><div class="NLM_p"><b>1</b> (1.2 mmol) and 1,2-dibromoethane (11.7 mmol) were dissolved in 15 mL of DMF, and potassium carbonate (1.4 mmol) was added subsequently. The reaction was carried out under 80 °C for 6 h, and then, <b>1b</b> was separated through silica gel column chromatography. <b>1b</b> (688.2 μmol), ethyl 2-(piperazin-1-yl)acetate (757.1 μmol), KI (82.6 μmol), and K<sub>2</sub>CO<sub>3</sub> (1.0 mmol) were dispersed in 15 mL of acetonitrile. After 8 h reflux, the mixture was filtered, and the solvent was evaporated; then, <b>2b</b> was separated by silica gel column chromatography. Finally, <b>2b</b> (200 mg, 440 μmol) and potassium hydroxide (1.0 mmol) in THF–MeOH (1:1) were added to the hydroxylamine solution (10 mmol) at 0 °C. The reaction mixture was warmed to room temperature naturally and stirred overnight. Then, the reaction mixture was neutralized with acetic acid, the solvent was evaporated, and the remaining mixture was allowed to undergo chromatographic separation to yield <b>20</b> as a white solid.</div><div id="sec4_1_4_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43">4.1.4.1.  (<i>E</i>)-2-(4-(2-(4-(3,5-Dimethoxystyryl)phenoxy)ethyl)piperazin-1-yl)-<i>N</i>-hydroxyacetamide (<b>20</b>)</h5><div class="NLM_p last">Yield 66%, white solid, mp 166–168 °C; <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.39 (s, 1H), 8.77 (s, 1H), 7.52 (d, <i>J</i> = 8.4 Hz, 2H), 7.21 (d, <i>J</i> = 16.4 Hz, 1H), 7.03 (d, <i>J</i> = 16.4 Hz, 1H), 6.96 (d, <i>J</i> = 8.4 Hz, 2H), 6.74 (d, <i>J</i> = 2.2 Hz, 2H), 6.39 (s, 1H), 4.10 (t, <i>J</i> = 5.8 Hz, 2H), 3.78 (s, 6H), 2.87 (s, 2H), 2.72 (t, <i>J</i> = 5.8 Hz, 2H), 2.57–2.39 (m, 8H); <sup>13</sup>C NMR (151 MHz): δ 166.16, 161.10, 158.70, 139.89, 130.04, 129.01, 128.30, 126.64, 115.22, 104.64, 99.94, 65.90, 59.53, 56.98, 55.65, 53.31, 53.16; HRMS (ESI) <i>m</i>/<i>z</i>: 442.2336 [M + H]<sup>+</sup> (calcd for 442.2336, C<sub>24</sub>H<sub>32</sub>N<sub>3</sub>O<sub>5</sub>).</div></div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44">4.1.5.  Procedure for the Synthesis of <b>21</b></h4><div class="NLM_p">Ethyl 2-azidoacetate (500 mg, 3.9 mmol) and 4-bromobut-1-yne (515.0 mg, 3.9 mmol) were added in a MeOH–H<sub>2</sub>O (1:1, v/v) solution containing sodium ascorbate (115.1 mg, 580.9 μmol) and CuSO<sub>4</sub> (92.7 mg, 580.9 μmol) with stirring. After 5 h, the reaction was quenched, and the mixture was extracted with ethyl acetate three times. The organic layer was combined and dried with anhydrous MgSO<sub>4</sub> for 24 h. Then, the mixture was filtered, and the solution was condensed to obtain a light-red liquid as <b>1c</b>. <b>1c</b> (300 mg, 1.1 mmol), <b>1</b> (332.9 mg, 1.3 mmol), and K<sub>2</sub>CO<sub>3</sub> (215 mg, 1.56 mmol) were dissolved in CH<sub>3</sub>CN, and the mixture was kept under reflux for 8 h. The solvent was then removed by rotary evaporation, and the residue was separated by a silica column to give <b>2c</b>. <b>2c</b> reacted with NH<sub>2</sub>OH in the same way as that of <b>2b</b> to generate as a white powder <b>21</b>.</div><div id="sec4_1_5_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45">4.1.5.1.  (<i>E</i>)-2-(4-(2-(4-(3,5-Dimethoxystyryl)phenoxy)ethyl)-1<i>H</i>-1,2,3-triazol-1-yl)-<i>N</i>-hydroxyacetamide (<b>21</b>)</h5><div class="NLM_p last">Yield 62%, white solid, mp 179–182 °C; <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.99 (s, 1H), 9.16 (s, 1H), 7.96 (s, 1H), 7.59–7.48 (m, 2H), 7.22 (d, <i>J</i> = 16.4 Hz, 1H), 7.03 (d, <i>J</i> = 16.4 Hz, 1H), 7.00–6.96 (m, 2H), 6.75 (d, <i>J</i> = 2.2 Hz, 2H), 6.39 (t, <i>J</i> = 2.2 Hz, 1H), 4.96 (s, 2H), 4.26 (t, <i>J</i> = 6.6 Hz, 2H), 3.78 (s, 6H), 3.12 (t, <i>J</i> = 6.6 Hz, 2H); <sup>13</sup>C NMR (126 MHz): δ 162.87, 161.11, 158.62, 143.80, 139.89, 130.18, 129.01, 128.31, 126.72, 124.55, 115.27, 104.67, 99.98, 67.09, 55.66, 50.13, 25.98; HRMS (ESI) <i>m</i>/<i>z</i>: 447.1641 [M + Na]<sup>+</sup> (calcd for 447.1639, C<sub>22</sub>H<sub>24</sub>N<sub>4</sub>NaO<sub>5</sub>).</div></div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46">4.2.  HDAC Inhibition Assays</h3><div class="NLM_p last">The activities of HDACs were assessed using the HDAC activity fluorometric assay kit. Briefly, cell nuclear extracts derived from MDA-MB-231 were used as a source of HDACs. The cell extract was obtained according to the manual of the assay kit. Different concentrations of drugs were added into the cell nuclear extracts in the presence of a colorimetric artificial substrate. The developer was added at the end of the assay, and enzyme activity was measured by the fluorescence plate reader (Ex/Em = 350–380/440–460 nm).</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47">4.3.  HDAC Subtype Inhibition Assays</h3><div class="NLM_p last">Enzyme inhibition assays were conducted by the Reaction Biology Corporation, Malvern, PA, using the HDAC fluorescent activity assay. The substrate for the HDAC1 and 6 test was fluorogenic peptides from p53 residues 379–382 [RHKK(Ac)AMC], and the substrate for the HDAC4 and 11 test was the fluorogenic HDAC ClassIIA substrate (trifluoroacetyl lysine). Then, we performed the inhibition assays by using recombinant HDACs and their respective fluorescent substrates (purchased from Abcam) to examine the result. Compounds were dissolved in DMSO and tested in the 10-dose IC<sub>50</sub> mode with 3-fold serial dilution. IC<sub>50</sub> values were calculated using the GraphPad Prism 4 program based on a sigmoidal dose–response equation.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48">4.4.  Cell Lines and Cell Culture</h3><div class="NLM_p last">Human colonic carcinoma HCT116 cells, human breast cancer MDA-MB-231 cells, human liver cells L02, human breast cells MCF-10A, and mouse breast cancer 4T1 cells were purchased from the Cell Bank of Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai, China). HCT116, MDA-MB-231, L02, and MCF-10A were cultured in Dulbecco’s modified Eagle medium, supplemented with 10% (v/v) fetal bovine serum, 50 μg/mL penicillin, and 50 μg/mL streptomycin. 4T1 cells were cultured in the modified RPMI medium, supplemented with 10% (vol/vol) fetal bovine serum, 50 μg/mL penicillin, and 50 μg/mL streptomycin. All cell lines were incubated at 37 °C in a humidified atmosphere containing 5% CO<sub>2</sub>.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49">4.5.  MTT Assays</h3><div class="NLM_p last">Cell viability was measured by MTT assays. Cells (HCT116, MDA-MB-231, L02, and MCF-10A) were seeded in 96-well culture plates (4–6 × 10<sup>3</sup> cells/well). After overnight incubation, cells were treated with different concentrations of test compounds for 48 h. MTT (5 mg/mL) was dissolved in phosphate-buffered saline (PBS) and filter-sterilized, and then, 20 μL of the prepared MTT solution was added to each well, and the cells were incubated for another 4 h until a purple precipitate was visible. The formed formazan crystals were dissolved in DMSO (150 μL/well) by continuous shaking for 10 min. The absorbance was measured on an enzyme-linked immunosorbent assay reader (Spectra Max Plus384, Molecular Devices, Sunnyvale, CA) at a test wavelength of 570 nm and a reference wavelength of 630 nm. The assays were performed at least three times in a parallel manner; for each compound, six concentrations were evaluated, and each was done in three replicate wells.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50">4.6.  Western Blot Assays</h3><div class="NLM_p last">Protein levels were determined by the standard Western blot. MDA-MB-231 cells were incubated with different concentrations of compound <b>14</b> or 0.1% DMSO for 24 h. Cells harvested with trypsin were treated with 1× RIPA lysis buffer [50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.25% deoxycholic acid, 1% NP-40, 1 mM ethylenediaminetetraacetate (EDTA), and protease inhibitors PMSF] (Amresco, Solon, USA) to extract the total proteins. Then, an aliquot of proteins from the total cell lysates (4–40 μg/lane) was separated by sodium dodecyl sulfate (8, 10, or 12%) polyacrylamide gel electrophoresis (BioRad Laboratories, Hercules, CA), wet-transferred to a PVDF membrane (BioRad Laboratories, Hercules, CA), blotted with primary antibodies (purchased from Cell signaling Technology) specific for STAT3, p-STAT3, Ac-histone H3, Ac-α-tublin, Bcl-2, cyclin D1, caspase3, caspase7, PARP, cleaved caspase3, cleaved caspase7, cleaved PARP, JAK1, Src, p-JAK1, p-Src, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as the internal standard overnight, and then probed with secondary isotype-specific antibodies for another 1 h at 37 °C. Bound immuno-complexes were detected using a ChemiDOC XRS + system (BioRad Laboratories, Hercules, CA).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51">4.7.  Quantitative Real-Time RT-PCR</h3><div class="NLM_p last">Levels of mRNA expression were analyzed with the RT-PCR assays, with total RNA isolated from MDA-MB-231 cells by using an EASYspin Plus tissue/cell RNA extraction kit (Aidlab Biotechnologies Co. Ltd). RNA was quantified by measuring absorption at 260 nm, and 1 μg of RNA was reverse transcribed to cDNA by using the Transcriptor First Strand cDNA Synthesis Kit (Roche Diagnostics, Basel, Switzerland). Thermal cycling conditions included 95 °C initial denaturation for 5 min, followed by 40 cycles of denaturation (10 s at 95 °C), annealing (15 s at 60 °C), and extension (15 s at 72 °C with a single fluorescence measurement), a melt curve program (60–95 °C with a 0.11 °C/s heat increase and continuous fluorescence measurement), and a cooling step to 40 °C. The Δ cycle threshold method was used for the calculation of relative differences in mRNA abundance with LightCycler 480 (Roche Molecular Biochemicals, Mannheim, Germany). Data were normalized to the expression of GAPDH. The results are expressed as fold changes.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52">4.8.  Cell Apoptosis Analysis Using a Hoechst 33342 Staining Assay</h3><div class="NLM_p last">Apoptosis was determined by Hoechst 33342 staining. MDA-MB-231 cells were seeded in a 6-well plate with 3 × 10<sup>5</sup> cells per well for 24 h. Then, the cells were incubated with different concentrations of compound <b>14</b> or 0.1% DMSO for another 24 h. Then, the cells were harvested and stained with Hoechst 33342 for 10 min. The cells were washed with PBS twice and then observed under a fluorescent microscope (LEICA DMI3000 B, Germany).</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53">4.9.  Cell Apoptosis Analysis Using Annexin V-FITC/PI Double Staining</h3><div class="NLM_p last">MDA-MB-231 cells seeded in a 6-well plate (3 × 10<sup>5</sup> per well) were incubated with different concentrations of compound <b>14</b> or 0.1% DMSO for 24 h. Then, the cells were digested with 0.25% trypsin (without EDTA) and were washed twice with PBS. The cells were then collected and resuspended in 500 μL of the binding buffer. 5 μL of annexin V-FITC and 10 μL of PI were added in turn to the mixture in the dark. After 15 min incubation, a flow cytometer (FACSCalibur; Becton Dickinson, USA) was used to detect apoptosis (FITC Ex/Em = 488/525 nm and PI Ex/Em = 535/615 nm).</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54">4.10.  Colony Formation Assay</h3><div class="NLM_p last">MDA-MB-231 cells were cultured at 1 × 10<sup>3</sup> cells per well in a 6-well plate with a regular growth medium for 12 h. After the cells were fixed on the wall, they were treated with different concentrations of compound <b>14</b> or 0.1% DMSO for 24 h. Then, the cells were cultured in a fresh medium for 2 weeks until the colonies were visible. A crystal violet staining solution (Beyotime, China) was used to stain the colonies for 30 min, and the result was recorded by a smartphone.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55">4.11.  <i>In Vivo</i> Anticancer Studies</h3><div class="NLM_p last">Female BALB/c mice (6 weeks after birth) of specified pathogens-free grade were purchased from the Nanjing Qinglongshan Animal Breeding Base. 3 × 10<sup>6</sup> mouse breast cancer 4T1 cells in 200 μL of PBS were seeded in the right flank area by subcutaneous injection. Mice were randomly divided into five groups (six mice per group) when the average radius of tumors increased to 3 mm. Afterward, mice were intraperitoneally administered with compound <b>14</b> (15 or 30 mg/kg), SAHA (30 mg/kg), PTE (30 mg/kg), or saline daily for 21 days. The tumor size was measured every 3 days using a vernier caliper, and the tumor volume was calculated by the formula: <i>V</i> = 0.52 × <i>a</i><sup>2</sup> × <i>b</i> (<i>a</i> is the length of the tumor and <i>b</i> is the width of the tumor). Compound <b>14</b> was dissolved in a mixture comprised of 10% β-cyclodextrin, 10% castor oil ethoxylated, and 80% saline to generate 1.5 or 3 mg/mL solution. After 21 days, all mice were sacrificed, and tumors were segregated, weighed, and stored at −80 °C for later use. The tumor inhibitory ratio TI (%) was calculated as TI (%) = (1 – <i>W</i><sub>T</sub>/<i>W</i><sub>V</sub>) × 100%, where <i>W</i><sub>T</sub> and <i>W</i><sub>V</sub> are the average tumor weights of the treated and vehicle groups, respectively.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56">4.12.  Molecular Docking</h3><div class="NLM_p last">Molecular docking study was carried out to dock our designed small molecule to predict its binding mode and approximate binding free energy to the STAT3 SH2 domain with computational docking program AutoDock4.2. Compound <b>14</b> was docked using the Lamarckian genetic algorithm. Gasteiger charges were assigned to the ligands by AutoDock Tools. Schrodinger software was used to prepare the macromolecule and ligand. AutoGrid maps were further precomputed for all atom types in the ligand set. After completing 10 million energy evaluations, the root-mean-square deviation threshold was set as 1.5 Å, and all the conformations of the ligands in the binding pocket of the macromolecule were clustered. The lowest energy clusters were identified, and the binding energy was evaluated.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57">4.13.  Kinetic Affinity Assay</h3><div class="NLM_p last">The kinetic affinity assay was performed at 25 °C using BIAcore T200 (GE Healthcare). In the binding assay, <b>14</b> was diluted 2-fold into a series with a running buffer [10 mM <i>N</i>-(2-hydroxyethyl)piperazine-<i>N</i>′-ethanesulfonic acid, pH 7.4, 150 mM NaCl, 3 mM EDTA, and 0.005% Tween-20] supplemented with 5% DMSO. The running buffer was used for blank injections, and referencing errors in samples were corrected using the solvent correction. The pH scouting for recombinant STAT3 immobilization was performed in 10 mM acetate buffer at pH 4.0, 4.5, 5.0, and 5.5. The most appropriate condition is pH 5.0, which is consistent with Chen et al.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Approximately 20,000 response units (RU) of recombinant STAT3 were covalently immobilized onto a CM5 sensor chip by a standard amine-coupling procedure at pH 5.0. Compound <b>14</b> was injected into the STAT3-immobilized flow cell with a flow rate of 30 μL/min for 120 s and allowed to dissociate for 120 s. The steady-state <i>K</i><sub>D</sub> value was calculated using BIAcore T200 evaluation software.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58">4.14.  Acute Toxicity Test</h3><div class="NLM_p last">Compound <b>14</b>, SAHA, and PTE were suspended in saline to generate a series of putrid fluids (50, 100, 200, and 400 mg/kg). Adult ICR mice were split into 12 groups, each of which comprised three mice. Mice were orally administrated with different concentrations of drugs once, and their health condition after administration was recorded for 7 days.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59">4.15.  Pharmacokinetics</h3><div class="NLM_p last">This experiment was carried out by Medicilon Preclinical Research (Shanghai) LLC. The pharmacokinetcs of <b>14</b> was characterized in SD rats following single intravenous and oral doses of 2 and 20 mg/kg, respectively. First of all, the required quantity of compound <b>14</b> was dissolved in 5% DMSO + 10% Solutol + 85% saline to get the required formulation for iv (2 mg/kg) and po (20 mg/kg). After dosing, the blood was taken <i>via</i> the jugular vein at appropriate time points (iv: post-dose at 0.083, 0.25, 0.5, 1, 2, 4, 8, and 24 h; po: post-dose at 0.25, 0.5, 1, 2, 4, 6, 8, and 24 h.), 0.20 mL/time point. Samples were placed in tubes containing K<sub>2</sub>-EDTA and stored on ice until centrifuged. The blood samples were centrifuged at 6800<i>g</i> for 6 min at 2–8 °C within 1 h after being collected and stored frozen at approximately −80 °C. An aliquot of 20 μL of the plasma sample was protein-precipitated with 400 μL of ACN containing 100 ng/mL IS. The mixture was vortexed for 1 min and centrifuged at 18,000<i>g</i> for 7 min. 200 μL of the supernatant was transferred to 96-well plates. An aliquot of 2 μL of the supernatant was injected for LC–MS/MS analysis.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60">4.16.  Statistical Analysis</h3><div class="NLM_p last">Results are expressed as the mean ± SD for the indicated number of separate experiments. Means were assessed for significant differences using <i>t</i>-test, and <i>P</i>-values < 0.05 were considered significant.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i61"><a href="/doi/suppl/10.1021/acs.jmedchem.1c00136" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46830" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46830" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.1c00136?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00136</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Atomic coordinates of the STAT3/compound <b>14</b> complex (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00136/suppl_file/jm1c00136_si_001.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00136/suppl_file/jm1c00136_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Representative <sup>1</sup>H NMR, <sup>13</sup>C NMR, HPLC, IR, and HRMS (ESI) spectra of compounds; Pharmacokinetics of <b>14</b> in SD rats (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00136/suppl_file/jm1c00136_si_003.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00136/suppl_file/jm1c00136_si_001.pdb">jm1c00136_si_001.pdb (2.5 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00136/suppl_file/jm1c00136_si_002.csv">jm1c00136_si_002.csv (0.83 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00136/suppl_file/jm1c00136_si_003.pdf">jm1c00136_si_003.pdf (2.43 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.1c00136" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38414" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38414" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lingyi Kong</span> - <span class="hlFld-Affiliation affiliation">Jiangsu
Key Laboratory of Bioactive Natural Product Research and State Key
Laboratory of Natural Medicines, China Pharmaceutical
University, 24 Tong Jia Xiang, Nanjing 210009, People’s Republic of China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-9712-2618" title="Orcid link">https://orcid.org/0000-0001-9712-2618</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#e4879491bb889d8f8b8a83a4d5d6d2ca878b89"><span class="__cf_email__" data-cfemail="a1c2d1d4fecdd8cacecfc6e19093978fc2cecc">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenying Yu</span> - <span class="hlFld-Affiliation affiliation">Jiangsu
Key Laboratory of Bioactive Natural Product Research and State Key
Laboratory of Natural Medicines, China Pharmaceutical
University, 24 Tong Jia Xiang, Nanjing 210009, People’s Republic of China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#7a030d033a190a0f541f1e0f541914"><span class="__cf_email__" data-cfemail="b9c0cec0f9dac9cc97dcddcc97dad7">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuhao Ren</span> - <span class="hlFld-Affiliation affiliation">Jiangsu
Key Laboratory of Bioactive Natural Product Research and State Key
Laboratory of Natural Medicines, China Pharmaceutical
University, 24 Tong Jia Xiang, Nanjing 210009, People’s Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shanshan Li</span> - <span class="hlFld-Affiliation affiliation">Jiangsu
Key Laboratory of Bioactive Natural Product Research and State Key
Laboratory of Natural Medicines, China Pharmaceutical
University, 24 Tong Jia Xiang, Nanjing 210009, People’s Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ren Zhu</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory for Green Chemical Process of Ministry of Education, Hubei
Key Laboratory of Novel Reactor and Green Chemical Technology, Hubei
Engineering Research Center for Advanced Fine Chemicals, School of
Chemical Engineering and Pharmacy, Wuhan
Institute of Technology, 206 1st Rd Optics Valley, East Lake New Technology
Development District, Wuhan, Hubei 430205, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chengying Wan</span> - <span class="hlFld-Affiliation affiliation">Jiangsu
Key Laboratory of Bioactive Natural Product Research and State Key
Laboratory of Natural Medicines, China Pharmaceutical
University, 24 Tong Jia Xiang, Nanjing 210009, People’s Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dongmei Song</span> - <span class="hlFld-Affiliation affiliation">Jiangsu
Key Laboratory of Bioactive Natural Product Research and State Key
Laboratory of Natural Medicines, China Pharmaceutical
University, 24 Tong Jia Xiang, Nanjing 210009, People’s Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jiawen Zhu</span> - <span class="hlFld-Affiliation affiliation">Jiangsu
Key Laboratory of Bioactive Natural Product Research and State Key
Laboratory of Natural Medicines, China Pharmaceutical
University, 24 Tong Jia Xiang, Nanjing 210009, People’s Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guiping Cai</span> - <span class="hlFld-Affiliation affiliation">Jiangsu
Key Laboratory of Bioactive Natural Product Research and State Key
Laboratory of Natural Medicines, China Pharmaceutical
University, 24 Tong Jia Xiang, Nanjing 210009, People’s Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sihui Long</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory for Green Chemical Process of Ministry of Education, Hubei
Key Laboratory of Novel Reactor and Green Chemical Technology, Hubei
Engineering Research Center for Advanced Fine Chemicals, School of
Chemical Engineering and Pharmacy, Wuhan
Institute of Technology, 206 1st Rd Optics Valley, East Lake New Technology
Development District, Wuhan, Hubei 430205, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-4424-6374" title="Orcid link">https://orcid.org/0000-0002-4424-6374</a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Y.R. and S.L. contributed equally to this article. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i63">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46636" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46636" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We gratefully acknowledge the financial support from the National Natural Science Foundation of China (grant nos. 81973180 and 81673298), the National Major Scientific and Technological Special Project for “Significant New Drugs Development” (2019ZX09301142), the Natural Science Foundation of the Jiangsu Higher Education Institutions of China for Excellent Young Scholars (grant no. BK20180077), and the Program for Changjiang Scholars and Innovative Research Team in University (IRT_15R63), a project funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">HDAC</td><td class="NLM_def"><p class="first last">histone deacetylase</p></td></tr><tr><td class="NLM_term">HDACi</td><td class="NLM_def"><p class="first last">histone deacetylase inhibitor</p></td></tr><tr><td class="NLM_term">PTE</td><td class="NLM_def"><p class="first last">pterostilbene</p></td></tr><tr><td class="NLM_term">SPR</td><td class="NLM_def"><p class="first last">surface plasmon resonance</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">rt</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">MTT</td><td class="NLM_def"><p class="first last">3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-<i>H</i>-tetrazolium bromide</p></td></tr><tr><td class="NLM_term">STAT</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription</p></td></tr><tr><td class="NLM_term">PI</td><td class="NLM_def"><p class="first last">propidium iodide</p></td></tr><tr><td class="NLM_term">GAPDH</td><td class="NLM_def"><p class="first last">glyceraldehyde-3-phosphate dehydrogenase</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i65">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34011" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34011" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 46 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, S.</span></span> <span> </span><span class="NLM_article-title">World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, Who Press, 2015</span>. <i>Adv. Nutr.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">418</span>– <span class="NLM_lpage">419</span>, <span class="refDoi"> DOI: 10.3945/an.116.012211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.3945%2Fan.116.012211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=26980827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A280%3ADC%252BC28fgslGhug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=418-419&author=S.+McGuire&title=World+Cancer+Report+2014.+Geneva%2C+Switzerland%3A+World+Health+Organization%2C+International+Agency+for+Research+on+Cancer%2C+Who+Press%2C+2015&doi=10.3945%2Fan.116.012211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015</span></div><div class="casAuthors">McGuire Shelley</div><div class="citationInfo"><span class="NLM_cas:title">Advances in nutrition (Bethesda, Md.)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">418-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTrQN7I_r2GkZ0d-O_J5C0AfW6udTcc2eZ0gK1kiwY3eLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28fgslGhug%253D%253D&md5=fb111acc7e8cd67cdb11adaef7a981cd</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3945%2Fan.116.012211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3945%252Fan.116.012211%26sid%3Dliteratum%253Aachs%26aulast%3DMcGuire%26aufirst%3DS.%26atitle%3DWorld%2520Cancer%2520Report%25202014.%2520Geneva%252C%2520Switzerland%253A%2520World%2520Health%2520Organization%252C%2520International%2520Agency%2520for%2520Research%2520on%2520Cancer%252C%2520Who%2520Press%252C%25202015%26jtitle%3DAdv.%2520Nutr.%26date%3D2016%26volume%3D7%26spage%3D418%26epage%3D419%26doi%3D10.3945%2Fan.116.012211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al-Lazikani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerji, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span> <span> </span><span class="NLM_article-title">Combinatorial Drug Therapy for Cancer in the Post-Genomic Era</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">679</span>– <span class="NLM_lpage">692</span>, <span class="refDoi"> DOI: 10.1038/nbt.2284</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1038%2Fnbt.2284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=22781697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvFGmtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=679-692&author=B.+Al-Lazikaniauthor=U.+Banerjiauthor=P.+Workman&title=Combinatorial+Drug+Therapy+for+Cancer+in+the+Post-Genomic+Era&doi=10.1038%2Fnbt.2284"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Combinatorial drug therapy for cancer in the post-genomic era</span></div><div class="casAuthors">Al-Lazikani, Bissan; Banerji, Udai; Workman, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">679-692</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Over the past decade, whole genome sequencing and other 'omics' technologies have defined pathogenic driver mutations to which tumor cells are addicted.  Such addictions, synthetic lethalities and other tumor vulnerabilities have yielded novel targets for a new generation of cancer drugs to treat discrete, genetically defined patient subgroups.  This personalized cancer medicine strategy could eventually replace the conventional one-size-fits-all cytotoxic chemotherapy approach.  However, the extraordinary intratumor genetic heterogeneity in cancers revealed by deep sequencing explains why de novo and acquired resistance arise with molecularly targeted drugs and cytotoxic chemotherapy, limiting their utility.  One soln. to the enduring challenge of polygenic cancer drug resistance is rational combinatorial targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon5IOOPfsgR7Vg90H21EOLACvtfcHk0lgId4ZOxK7-xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvFGmtLg%253D&md5=a61b1b222a7146a92366f57cb0e708ca</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2284%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Lazikani%26aufirst%3DB.%26aulast%3DBanerji%26aufirst%3DU.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DCombinatorial%2520Drug%2520Therapy%2520for%2520Cancer%2520in%2520the%2520Post-Genomic%2520Era%26jtitle%3DNat.%2520Biotechnol.%26date%3D2012%26volume%3D30%26spage%3D679%26epage%3D692%26doi%3D10.1038%2Fnbt.2284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheffler, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroeze, W. K.</span></span> <span> </span><span class="NLM_article-title">Magic Shotguns Versus Magic Bullets: Selectively Non-Selective Drugs for Mood Disorders and Schizophrenia</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">353</span>– <span class="NLM_lpage">359</span>, <span class="refDoi"> DOI: 10.1038/nrd1346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1038%2Fnrd1346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=15060530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Gkt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=353-359&author=B.+L.+Rothauthor=D.+J.+Shefflerauthor=W.+K.+Kroeze&title=Magic+Shotguns+Versus+Magic+Bullets%3A+Selectively+Non-Selective+Drugs+for+Mood+Disorders+and+Schizophrenia&doi=10.1038%2Fnrd1346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia</span></div><div class="casAuthors">Roth, Bryan L.; Sheffler, Douglas J.; Kroeze, Wesley K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">353-359</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Most common central nervous system disorders - such as depression, bipolar disorder, and schizophrenia - seem to be polygenic in origin, and the most effective medications have exceedingly complex pharmacologies.  Attempts to develop more effective treatments for diseases such as schizophrenia and depression by discovering drugs selective for single mol. targets (i.e., 'magic bullets') have, not surprisingly, been largely unsuccessful.  Here the authors propose that designing selectively non-selective drugs (i.e., 'magic shotguns') that interact with several mol. targets will lead to new and more effective medications for a variety of central nervous system disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnSsuUXzmbirVg90H21EOLACvtfcHk0lgId4ZOxK7-xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Gkt78%253D&md5=77196583acccca65457fec7a67218463</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrd1346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1346%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DSheffler%26aufirst%3DD.%2BJ.%26aulast%3DKroeze%26aufirst%3DW.%2BK.%26atitle%3DMagic%2520Shotguns%2520Versus%2520Magic%2520Bullets%253A%2520Selectively%2520Non-Selective%2520Drugs%2520for%2520Mood%2520Disorders%2520and%2520Schizophrenia%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D353%26epage%3D359%26doi%3D10.1038%2Fnrd1346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knight, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">Targeting the Cancer Kinome through Polypharmacology</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">130</span>– <span class="NLM_lpage">137</span>, <span class="refDoi"> DOI: 10.1038/nrc2787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1038%2Fnrc2787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=20094047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=130-137&author=Z.+A.+Knightauthor=H.+Linauthor=K.+M.+Shokat&title=Targeting+the+Cancer+Kinome+through+Polypharmacology&doi=10.1038%2Fnrc2787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the cancer kinome through polypharmacology</span></div><div class="casAuthors">Knight, Zachary A.; Lin, Henry; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-137</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Kinase inhibitors are the largest class of new cancer drugs.  However, it is already apparent that most tumors can escape from the inhibition of any single kinase.  If it is necessary to inhibit multiple kinases, how do we choose which ones.  In this Opinion article, we discuss some of the strategies that are currently being used to identify new therapeutic combinations of kinase targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkDv2FeeH58rVg90H21EOLACvtfcHk0lgId4ZOxK7-xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D&md5=9aaa314e54b43889e147a9f11ac77072</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrc2787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2787%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DTargeting%2520the%2520Cancer%2520Kinome%2520through%2520Polypharmacology%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D130%26epage%3D137%26doi%3D10.1038%2Fnrc2787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brötz-Oesterhelt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunner, N. A.</span></span> <span> </span><span class="NLM_article-title">How Many Modes of Action Should an Antibiotic Have?</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">564</span>– <span class="NLM_lpage">573</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2008.06.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1016%2Fj.coph.2008.06.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=18621146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A280%3ADC%252BD1cjhsFygsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=564-573&author=H.+Br%C3%B6tz-Oesterheltauthor=N.+A.+Brunner&title=How+Many+Modes+of+Action+Should+an+Antibiotic+Have%3F&doi=10.1016%2Fj.coph.2008.06.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">How many modes of action should an antibiotic have?</span></div><div class="casAuthors">Brotz-Oesterhelt Heike; Brunner Nina A</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">564-73</span>
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    </div><div class="casAbstract">All antibiotics that have been successfully employed for decades as monotherapeutics in the treatment of bacterial infections rely on mechanisms of bacterial growth inhibition which are by far more complex than inhibition of a single enzyme.  Such successful antibiotics have in common that they address several targets in parallel and/or that their targets are encoded by multiple genes.  Such multiplicity of targets and of target genes has the advantage that the emergence of spontaneous target-related resistance is a comparatively slow process.  Recently registered antibiotics and novel antibiotics in development are discussed in the light of this promising concept of antibacterial polypharmacology.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQzIF5GvxYY_0HdcurJClFcfW6udTcc2eax9pfmcSSi07ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cjhsFygsA%253D%253D&md5=820b32bfce47dd05c0a37bf310a7884e</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2008.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2008.06.008%26sid%3Dliteratum%253Aachs%26aulast%3DBr%25C3%25B6tz-Oesterhelt%26aufirst%3DH.%26aulast%3DBrunner%26aufirst%3DN.%2BA.%26atitle%3DHow%2520Many%2520Modes%2520of%2520Action%2520Should%2520an%2520Antibiotic%2520Have%253F%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2008%26volume%3D8%26spage%3D564%26epage%3D573%26doi%3D10.1016%2Fj.coph.2008.06.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujulu, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J. J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Janus Kinase 2 (Jak2) and Histone Deacetlyase (Hdac) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8233</span>– <span class="NLM_lpage">8262</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00157</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00157" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlyls7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8233-8262&author=E.+G.+Yangauthor=N.+Mustafaauthor=E.+C.+Tanauthor=A.+Poulsenauthor=P.+M.+Ramanujuluauthor=W.+J.+Chngauthor=J.+J.+Y.+Yenauthor=B.+W.+Dymock&title=Design+and+Synthesis+of+Janus+Kinase+2+%28Jak2%29+and+Histone+Deacetlyase+%28Hdac%29+Bispecific+Inhibitors+Based+on+Pacritinib+and+Evidence+of+Dual+Pathway+Inhibition+in+Hematological+Cell+Lines&doi=10.1021%2Facs.jmedchem.6b00157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines</span></div><div class="casAuthors">Yang, Eugene Guorong; Mustafa, Nurulhuda; Tan, Eng Chong; Poulsen, Anders; Ramanujulu, Pondy Murugappan; Chng, Wee Joo; Yen, Jeffrey J. Y.; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8233-8262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Blockage of more than one oncoprotein or pathway is now a std. approach in modern cancer therapy.  Multiple inhibition is typically achieved with two or more drugs.  Herein the authors describe a pharmacophore merging strategy combining the JAK2/FLT3 inhibitor pacritnib with the pan-HDAC inhibitor, vorinostat, to create bispecific single mols. with both JAK and HDAC targeted inhibition.  A preferred ether hydroxamate, compd. 51 (11-(4-(N-hydroxyheptanamide)oxy)-[4,1,9]dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12-(27),16,21,23-decaene) inhibits JAK2 and HDAC6 with low nanomolar potency, is <100 nM potent against HDACs 2 and 10, sub-micromolar potent against HDACs 1, 8 and 11, and >50-fold selective for JAK2 in a panel of 97 kinases.  Broad cellular antiproliferative potency is supported by demonstration of JAK-STAT and HDAC pathway blockade in several hematol. cell lines, inhibition of colony formation in HEL cells, and anal. of apoptosis.  This study provides new tool compds. for further exploration of dual JAK-HDAC pathway inhibition achieved with a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeUHzB39AGWrVg90H21EOLACvtfcHk0ljEjD2S2hP11Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlyls7rL&md5=aa9ae07a1ac1aa21d70ee0f24621fe82</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00157%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DE.%2BG.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DTan%26aufirst%3DE.%2BC.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DRamanujulu%26aufirst%3DP.%2BM.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DYen%26aufirst%3DJ.%2BJ.%2BY.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Janus%2520Kinase%25202%2520%2528Jak2%2529%2520and%2520Histone%2520Deacetlyase%2520%2528Hdac%2529%2520Bispecific%2520Inhibitors%2520Based%2520on%2520Pacritinib%2520and%2520Evidence%2520of%2520Dual%2520Pathway%2520Inhibition%2520in%2520Hematological%2520Cell%2520Lines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8233%26epage%3D8262%26doi%3D10.1021%2Facs.jmedchem.6b00157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span> <span> </span><span class="NLM_article-title">Network Pharmacology: The Next Paradigm in Drug Discovery</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">682</span>– <span class="NLM_lpage">690</span>, <span class="refDoi"> DOI: 10.1038/nchembio.118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1038%2Fnchembio.118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=18936753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=682-690&author=A.+L.+Hopkins&title=Network+Pharmacology%3A+The+Next+Paradigm+in+Drug+Discovery&doi=10.1038%2Fnchembio.118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Network pharmacology: the next paradigm in drug discovery</span></div><div class="casAuthors">Hopkins, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">682-690</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The dominant paradigm in drug discovery is the concept of designing maximally selective ligands to act on individual drug targets.  However, many effective drugs act via modulation of multiple proteins rather than single targets.  Advances in systems biol. are revealing a phenotypic robustness and a network structure that strongly suggests that exquisitely selective compds., compared with multi-target drugs, may exhibit lower than desired clin. efficacy.  This new appreciation of the role of polypharmacol. has significant implications for tackling the two major sources of attrition in drug development, efficacy and toxicity.  Integrating network biol. and polypharmacol. holds the promise of expanding the current opportunity space for druggable targets.  However, the rational design of polypharmacol. faces considerable challenges in the need for new methods to validate target combinations and optimize multiple structure-activity relationships while maintaining drug-like properties.  Advances in these areas are creating the foundation of the next paradigm in drug discovery: network pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqHy4FqkK-h7Vg90H21EOLACvtfcHk0ljEjD2S2hP11Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7fK&md5=03b8be3ddbcab7dc65afd17df7ee8395</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.118%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DNetwork%2520Pharmacology%253A%2520The%2520Next%2520Paradigm%2520in%2520Drug%2520Discovery%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D4%26spage%3D682%26epage%3D690%26doi%3D10.1038%2Fnchembio.118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ropero, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteller, M.</span></span> <span> </span><span class="NLM_article-title">The Role of Histone Deacetylases (Hdacs) in Human Cancer</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1016/j.molonc.2007.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1016%2Fj.molonc.2007.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=19383284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOitbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2007&pages=19-25&author=S.+Roperoauthor=M.+Esteller&title=The+Role+of+Histone+Deacetylases+%28Hdacs%29+in+Human+Cancer&doi=10.1016%2Fj.molonc.2007.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The role of histone deacetylases (HDACs) in human cancer</span></div><div class="casAuthors">Ropero, Santiago; Esteller, Manel</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-25</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The balance of histone acetylation and deacetylation is an epigenetic layer with a crit. role in the regulation of gene expression.  Histone acetylation induced by histone acetyl transferases (HATs) is assocd. with gene transcription, while histone hypoacetylation induced by histone deacetylase (HDAC) activity is assocd. with gene silencing.  Altered expression and mutations of genes that encode HDACs have been linked to tumor development since they both induce the aberrant transcription of key genes regulating important cellular functions such as cell proliferation, cell-cycle regulation and apoptosis.  Thus, HDACs are among the most promising therapeutic targets for cancer treatment, and they have inspired researchers to study and develop HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvbJD8bqroSLVg90H21EOLACvtfcHk0li4JEbNMoAvDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOitbnI&md5=d925bcde258dce7d53cbb98563e1f2ae</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2007.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2007.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DRopero%26aufirst%3DS.%26aulast%3DEsteller%26aufirst%3DM.%26atitle%3DThe%2520Role%2520of%2520Histone%2520Deacetylases%2520%2528Hdacs%2529%2520in%2520Human%2520Cancer%26jtitle%3DMol.%2520Oncol.%26date%3D2007%26volume%3D1%26spage%3D19%26epage%3D25%26doi%3D10.1016%2Fj.molonc.2007.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marks, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richon, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rifkind, R. A.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">1210</span>– <span class="NLM_lpage">1216</span>, <span class="refDoi"> DOI: 10.1093/jnci/92.15.1210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1093%2Fjnci%2F92.15.1210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10922406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlvFyhsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2000&pages=1210-1216&author=P.+A.+Marksauthor=V.+M.+Richonauthor=R.+A.+Rifkind&title=Histone+Deacetylase+Inhibitors%3A+Inducers+of+Differentiation+or+Apoptosis+of+Transformed+Cells&doi=10.1093%2Fjnci%2F92.15.1210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells</span></div><div class="casAuthors">Marks, Paul A.; Richon, Victoria M.; Rifkind, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1210-1216</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review with 84 refs.  Histone deacetylase (HDAC) inhibitors have been shown to be potent inducers of growth arrest, differentiation, and/or apoptotic cell death of transformed cells in vitro and in vivo.  One class of HDAC inhibitors, hydroxamic acid-based hybrid polar compds. (HPCs), induce differentiation at micromolar or lower concns.  Studies (x-ray crystallog.) showed that the catalytic site of HDAC has a tubular structure with a zinc atom at its base and that these HDAC inhibitors, such as suberoylanilide hydroxamic acid and trichostatin A, fit into this structure with the hydroxamic moiety of the inhibitor binding to the zinc.  HDAC inhibitors cause acetylated histones to accumulate in both tumor and normal tissues, and this accumulation can be used as a marker of the biol. activity of the HDAC inhibitors.  Hydroxamic acid-based HPCs act selectively to inhibit tumor cell growth at levels that have little or no toxicity for normal cells.  These compds. also act selectively on gene expression, altering the expression of only about 2% of the genes expressed in cultured tumor cells.  In general, chromatin fractions enriched in actively transcribed genes are also enriched in highly acetylated core histones, whereas silent genes are assocd. with nucleosomes with a low level of acetylation.  However, HDACs can also acetylate proteins other than histones in nucleosomes.  The role that these other targets play in the induction of cell growth arrest, differentiation, and/or apoptotic cell death has not been detd.  Our working hypothesis is that inhibition of HDAC activity leads to the modulation of expression of a specific set of genes that, in turn, result in growth arrest, differentiation, and/or apoptotic cell death.  The hydroxamic acid-based HPCs are potentially effective agents for cancer therapy and, possibly, cancer chemoprevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoa7JHGYu0fJLVg90H21EOLACvtfcHk0li4JEbNMoAvDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlvFyhsb8%253D&md5=413775f266f555bfc6539d052b4d2b15</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F92.15.1210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F92.15.1210%26sid%3Dliteratum%253Aachs%26aulast%3DMarks%26aufirst%3DP.%2BA.%26aulast%3DRichon%26aufirst%3DV.%2BM.%26aulast%3DRifkind%26aufirst%3DR.%2BA.%26atitle%3DHistone%2520Deacetylase%2520Inhibitors%253A%2520Inducers%2520of%2520Differentiation%2520or%2520Apoptosis%2520of%2520Transformed%2520Cells%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2000%26volume%3D92%26spage%3D1210%26epage%3D1216%26doi%3D10.1093%2Fjnci%2F92.15.1210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Vreese, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galle, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Depetter, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franceus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desmet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Hecke, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benoy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Den
Bosch, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Hooghe, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Potent and Selective Hdac6 Inhibitors Bearing a Cyclohexane- or Cycloheptane-Annulated 1,5-Benzothiazepine Scaffold</span>. <i>Chem.—Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">128</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1002/chem.201604167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1002%2Fchem.201604167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=27717044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFKjtrzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=128-136&author=R.+De%0AVreeseauthor=L.+Galleauthor=Y.+Depetterauthor=J.+Franceusauthor=T.+Desmetauthor=K.+Van+Heckeauthor=V.+Benoyauthor=L.+Van+Den%0ABoschauthor=M.+D%E2%80%99Hooghe&title=Synthesis+of+Potent+and+Selective+Hdac6+Inhibitors+Bearing+a+Cyclohexane-+or+Cycloheptane-Annulated+1%2C5-Benzothiazepine+Scaffold&doi=10.1002%2Fchem.201604167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Potent and Selective HDAC6 Inhibitors Bearing a Cyclohexane- or Cycloheptane-Annulated 1,5-Benzothiazepine Scaffold</span></div><div class="casAuthors">De Vreese, Rob; Galle, Lisa; Depetter, Yves; Franceus, Jorick; Desmet, Tom; Van Hecke, Kristof; Benoy, Veronick; Van Den Bosch, Ludo; D'hooghe, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">128-136</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Synthesis and isolation of (dihydrobenzo[b][1,4]thiazepinyl)methyl-N-hydroxybenzamides I [R = H, Cl, CF3; X = S, SO, SO2; n = 1, 2], a new class of HDAC6 inhibitors, is reported.  Evaluations of their HDAC-inhibiting activity resulted in the identification of I (X = SO2; n = 1; R = H, CF3) as highly potent and selective HDAC6 inhibitors with activity in the low nanomolar range, which also showed excellent selectivity on the enzymic and cellular levels.  Furthermore, four promising inhibitors were subjected to an Ames fluctuation assay, which revealed no mutagenic effects assocd. with these structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQAN_gYUuzi7Vg90H21EOLACvtfcHk0li4JEbNMoAvDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFKjtrzF&md5=589c80b2c951fd8e59b931875b9087f0</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fchem.201604167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201604167%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BVreese%26aufirst%3DR.%26aulast%3DGalle%26aufirst%3DL.%26aulast%3DDepetter%26aufirst%3DY.%26aulast%3DFranceus%26aufirst%3DJ.%26aulast%3DDesmet%26aufirst%3DT.%26aulast%3DVan%2BHecke%26aufirst%3DK.%26aulast%3DBenoy%26aufirst%3DV.%26aulast%3DVan%2BDen%2BBosch%26aufirst%3DL.%26aulast%3DD%25E2%2580%2599Hooghe%26aufirst%3DM.%26atitle%3DSynthesis%2520of%2520Potent%2520and%2520Selective%2520Hdac6%2520Inhibitors%2520Bearing%2520a%2520Cyclohexane-%2520or%2520Cycloheptane-Annulated%25201%252C5-Benzothiazepine%2520Scaffold%26jtitle%3DChem.%25E2%2580%2594Eur.%2520J.%26date%3D2017%26volume%3D23%26spage%3D128%26epage%3D136%26doi%3D10.1002%2Fchem.201604167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Falkenberg, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylases and Their Inhibitors in Cancer, Neurological Diseases and Immune Disorders</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">673</span>– <span class="NLM_lpage">691</span>, <span class="refDoi"> DOI: 10.1038/nrd4360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1038%2Fnrd4360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=25131830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlKrtLjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=673-691&author=K.+J.+Falkenbergauthor=R.+W.+Johnstone&title=Histone+Deacetylases+and+Their+Inhibitors+in+Cancer%2C+Neurological+Diseases+and+Immune+Disorders&doi=10.1038%2Fnrd4360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders</span></div><div class="casAuthors">Falkenberg, Katrina J.; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">673-691</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Epigenetic aberrations, which are recognized as key drivers of several human diseases, are often caused by genetic defects that result in functional deregulation of epigenetic proteins, their altered expression and/or their atypical recruitment to certain gene promoters.  Importantly, epigenetic changes are reversible, and epigenetic enzymes and regulatory proteins can be targeted using small mols.  This Review discusses the role of altered expression and/or function of one class of epigenetic regulators - histone deacetylases (HDACs) - and their role in cancer, neurol. diseases and immune disorders.  We highlight the development of small-mol. HDAC inhibitors and their use in the lab., in preclin. models and in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXiWEG49LhebVg90H21EOLACvtfcHk0ljSDp1wvZyefQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlKrtLjI&md5=ccfb68fa3fd4685e2305cdf8a6a9c81a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnrd4360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4360%26sid%3Dliteratum%253Aachs%26aulast%3DFalkenberg%26aufirst%3DK.%2BJ.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DHistone%2520Deacetylases%2520and%2520Their%2520Inhibitors%2520in%2520Cancer%252C%2520Neurological%2520Diseases%2520and%2520Immune%2520Disorders%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D673%26epage%3D691%26doi%3D10.1038%2Fnrd4360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birkeland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lago, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johanson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, E.</span></span> <span> </span><span class="NLM_article-title">Induction and Superinduction of Growth Arrest and DNA Damage Gene 45 (Gadd45) Alpha and Beta Messenger Rnas by Histone Deacetylase Inhibitors Trichostatin a (Tsa) and Butyrate in Sw620 Human Colon Carcinoma Cells</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>188</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">140</span>, <span class="refDoi"> DOI: 10.1016/s0304-3835(02)00322-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1016%2FS0304-3835%2802%2900322-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=12406558" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BD38Xot1Wquro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=188&publication_year=2002&pages=127-140&author=Z.+Chenauthor=S.+Clarkauthor=M.+Birkelandauthor=C.-M.+Sungauthor=A.+Lagoauthor=R.+Liuauthor=R.+Kirkpatrickauthor=K.+Johansonauthor=J.+D.+Winklerauthor=E.+Hu&title=Induction+and+Superinduction+of+Growth+Arrest+and+DNA+Damage+Gene+45+%28Gadd45%29+Alpha+and+Beta+Messenger+Rnas+by+Histone+Deacetylase+Inhibitors+Trichostatin+a+%28Tsa%29+and+Butyrate+in+Sw620+Human+Colon+Carcinoma+Cells&doi=10.1016%2Fs0304-3835%2802%2900322-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Induction and superinduction of growth arrest and DNA damage gene 45 (GADD45) α and β messenger RNAs by histone deacetylase inhibitors trichostatin A (TSA) and butyrate in SW620 human colon carcinoma cells</span></div><div class="casAuthors">Chen, Zunxuan; Clark, Steven; Birkeland, Marian; Sung, Chiu-Mei; Lago, Amparo; Liu, Ronggang; Kirkpatrick, Robert; Johanson, Kyung; Winkler, James D.; Hu, Erding</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">188</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">127-140</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) inhibitors such as trichostatin (TSA) and butyrate have been shown to inhibit cancer cell proliferation, induce apoptosis and regulate the expression of genes involved in cell cycle.  Although the precise mechanism underlying HDAC inhibitor-induced cell growth arrest is not fully understood, induction of cell cycle related genes such as p21(cip/waf), is thought to be important.  Here we showed that in the SW620 human colon cancer cell line, TSA and butyrate induced the growth arrest and DNA damage gene 45α (GADD45α) and GADD45β.  Furthermore, GADD45β and p21(cip/waf) mRNA were induced in the absence of protein synthesis, indicating that both genes were immediate target genes for TSA.  Cyclohexamide and TSA super-induced the expression of GADD45α and β, but not p21(cip/waf).  Interestingly while mitogen-activated kinase (MEK) inhibitor PD98059 and p38 kinase inhibitor SB242235 were unable to affect GADD45 induction, two serine/threonine protein kinase inhibitors (H7 and H8) as well as curcumin completely blocked the super-induction.  Concomitant to the inhibition of GADD45 induction, H7 and H8 also blocked TSA-induced apoptosis.  Taken together, these results suggest that GADD45 induction may play important role in TSA-induced cellular effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ3d3QeDYT57Vg90H21EOLACvtfcHk0ljSDp1wvZyefQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xot1Wquro%253D&md5=4a0350a835870f0e8f81037b810be534</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FS0304-3835%2802%2900322-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0304-3835%252802%252900322-1%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DClark%26aufirst%3DS.%26aulast%3DBirkeland%26aufirst%3DM.%26aulast%3DSung%26aufirst%3DC.-M.%26aulast%3DLago%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DKirkpatrick%26aufirst%3DR.%26aulast%3DJohanson%26aufirst%3DK.%26aulast%3DWinkler%26aufirst%3DJ.%2BD.%26aulast%3DHu%26aufirst%3DE.%26atitle%3DInduction%2520and%2520Superinduction%2520of%2520Growth%2520Arrest%2520and%2520DNA%2520Damage%2520Gene%252045%2520%2528Gadd45%2529%2520Alpha%2520and%2520Beta%2520Messenger%2520Rnas%2520by%2520Histone%2520Deacetylase%2520Inhibitors%2520Trichostatin%2520a%2520%2528Tsa%2529%2520and%2520Butyrate%2520in%2520Sw620%2520Human%2520Colon%2520Carcinoma%2520Cells%26jtitle%3DCancer%2520Lett.%26date%3D2002%26volume%3D188%26spage%3D127%26epage%3D140%26doi%3D10.1016%2Fs0304-3835%2802%2900322-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sato, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitagawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayahara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ninomiya, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fushida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miwa, K.</span></span> <span> </span><span class="NLM_article-title">Fr901228, a Novel Histone Deacetylase Inhibitor, Induces Cell Cycle Arrest and Subsequent Apoptosis in Refractory Human Pancreatic Cancer Cells</span>. <i>Int. J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">679</span>– <span class="NLM_lpage">685</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=14767553" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitFantb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=679-685&author=N.+Satoauthor=T.+Ohtaauthor=H.+Kitagawaauthor=M.+Kayaharaauthor=I.+Ninomiyaauthor=S.+Fushidaauthor=T.+Fujimuraauthor=G.+Nishimuraauthor=K.+Shimizuauthor=K.+Miwa&title=Fr901228%2C+a+Novel+Histone+Deacetylase+Inhibitor%2C+Induces+Cell+Cycle+Arrest+and+Subsequent+Apoptosis+in+Refractory+Human+Pancreatic+Cancer+Cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells</span></div><div class="casAuthors">Sato, Nariatsu; Ohta, Tetsuo; Kitagawa, Hirohisa; Kayahara, Masato; Ninomiya, Itasu; Fushida, Sachio; Fujimura, Takashi; Nishimura, Gen-Ichi; Shimizu, Koichi; Miwa, Koichi</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">679-685</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1019-6439</span>.
    
            (<span class="NLM_cas:orgname">International Journal of Oncology</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) inhibitors have antiproliferative activity against human cancer cells via cell cycle arrest, differentiation, and apoptosis.  However, no report has focused on the apoptotic potential of HDAC inhibitors in refractory human pancreatic cancer.  This study was designed to examine the apoptotic potential of FR901228, a novel HDAC inhibitor, in five human pancreatic cancer cell lines: Capan-1, BxPC-3, HPAF, Panc-1, and MIAPaCa-2.  FR901228 markedly inhibited the proliferation of all five cell lines (IC50: 1-500 nM), with the greatest effect in MIAPaCa-2 cells.  Treatment of each cell line with FR901228 (10-100 nM) caused cell cycle arrest at the G1 or G2/M phase and subsequent apoptosis.  FR901228 induced expression of hyperacetylated histone H3 after 3 h of treatment and overexpression of p21Waf-1 after 6 h.  In addn., FR901228 induced apoptosis by activating caspase-3, which led to cleavage of p21Waf-1 into a 15-kDa breakdown product and drove cancer cells from cell cycle arrest into apoptosis.  FR901228 also decreased the protein level of survivin dramatically.  Our results show that FR901228 markedly inhibits the growth of pancreatic cancer cells, not only through cell cycle arrest, but also through subsequent apoptosis; this was accompanied by caspase-3 activation, survivin degrdn., and p21Waf-1 cleavage.  FR901228 may prove clin. useful as an agent for refractory pancreatic cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTFEPQEEOKKbVg90H21EOLACvtfcHk0ljSDp1wvZyefQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitFantb4%253D&md5=1677c6b5dab5ba8bbd87957a33698609</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSato%26aufirst%3DN.%26aulast%3DOhta%26aufirst%3DT.%26aulast%3DKitagawa%26aufirst%3DH.%26aulast%3DKayahara%26aufirst%3DM.%26aulast%3DNinomiya%26aufirst%3DI.%26aulast%3DFushida%26aufirst%3DS.%26aulast%3DFujimura%26aufirst%3DT.%26aulast%3DNishimura%26aufirst%3DG.%26aulast%3DShimizu%26aufirst%3DK.%26aulast%3DMiwa%26aufirst%3DK.%26atitle%3DFr901228%252C%2520a%2520Novel%2520Histone%2520Deacetylase%2520Inhibitor%252C%2520Induces%2520Cell%2520Cycle%2520Arrest%2520and%2520Subsequent%2520Apoptosis%2520in%2520Refractory%2520Human%2520Pancreatic%2520Cancer%2520Cells%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2004%26volume%3D24%26spage%3D679%26epage%3D685" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, Y.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harimoto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rikimaru, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirabe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimachi, K.</span></span> <span> </span><span class="NLM_article-title">Histone, Deacetylase Inhibitor Trichostatin a Induces Cell-Cycle Arrest/Apoptosis and Hepatocyte Differentiation in Human Hepatoma Cells</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">572</span>– <span class="NLM_lpage">576</span>, <span class="refDoi"> DOI: 10.1002/ijc.10699</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1002%2Fijc.10699" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=12494463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmtFKgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2003&pages=572-576&author=Y.-i.+Yamashitaauthor=M.+Shimadaauthor=N.+Harimotoauthor=T.+Rikimaruauthor=K.+Shirabeauthor=S.+Tanakaauthor=K.+Sugimachi&title=Histone%2C+Deacetylase+Inhibitor+Trichostatin+a+Induces+Cell-Cycle+Arrest%2FApoptosis+and+Hepatocyte+Differentiation+in+Human+Hepatoma+Cells&doi=10.1002%2Fijc.10699"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells</span></div><div class="casAuthors">Yamashita, Yo-Ichi; Shimada, Mitsuo; Harimoto, Norifumi; Rikimaru, Tatsuya; Shirabe, Ken; Tanaka, Shinj; Sugimachi, Keizo</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">572-576</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Remodeling of the chromatin template by inhibition of HDAC activities represents a potential transcriptional therapy for neoplastic disease.  A no. of HDAC inhibitors that modulate in vitro cell growth and differentiation have been developed.  We analyzed the effects of TSA, a specific and potent HDAC inhibitor, on the human hepatoma cell lines HepG2 and Huh-7.  TSA increased levels of acetylated histones H3 and H4 in both HepG2 and Huh-7.  It inhibited cell proliferation in vitro and induced G0/G1 arrest in HepG2 and apoptosis in Huh-7.  Gene expression of liver-specific functions and liver-enriched transcription factors was upregulated by TSA.  TSA upregulated the ammonia removal rate and the albumin synthesis rate of HepG2 and Huh-7.  Our results indicate that TSA can induce cell-cycle arrest/apoptosis and hepatocyte differentiation in human liver cancer cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXjd-pQWjkdrVg90H21EOLACvtfcHk0liwUW_jPNMrWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmtFKgsA%253D%253D&md5=9fd1a3ce76c6a60b15800dcdad3304a0</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1002%2Fijc.10699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.10699%26sid%3Dliteratum%253Aachs%26aulast%3DYamashita%26aufirst%3DY.-i.%26aulast%3DShimada%26aufirst%3DM.%26aulast%3DHarimoto%26aufirst%3DN.%26aulast%3DRikimaru%26aufirst%3DT.%26aulast%3DShirabe%26aufirst%3DK.%26aulast%3DTanaka%26aufirst%3DS.%26aulast%3DSugimachi%26aufirst%3DK.%26atitle%3DHistone%252C%2520Deacetylase%2520Inhibitor%2520Trichostatin%2520a%2520Induces%2520Cell-Cycle%2520Arrest%252FApoptosis%2520and%2520Hepatocyte%2520Differentiation%2520in%2520Human%2520Hepatoma%2520Cells%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2003%26volume%3D103%26spage%3D572%26epage%3D576%26doi%3D10.1002%2Fijc.10699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jennings, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fierke, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, S. M.</span></span> <span> </span><span class="NLM_article-title">Dual-Mode Hdac Prodrug for Covalent Modification and Subsequent Inhibitor Release</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4812</span>– <span class="NLM_lpage">4821</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00539</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00539" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotlCitLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4812-4821&author=K.+B.+Danielauthor=E.+D.+Sullivanauthor=Y.+Chenauthor=J.+C.+Chanauthor=P.+A.+Jenningsauthor=C.+A.+Fierkeauthor=S.+M.+Cohen&title=Dual-Mode+Hdac+Prodrug+for+Covalent+Modification+and+Subsequent+Inhibitor+Release&doi=10.1021%2Facs.jmedchem.5b00539"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release</span></div><div class="casAuthors">Daniel, Kevin B.; Sullivan, Eric D.; Chen, Yao; Chan, Joshua C.; Jennings, Patricia A.; Fierke, Carol A.; Cohen, Seth M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4812-4821</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylase inhibitors (HDACi) target abnormal epigenetic states assocd. with a variety of pathologies, including cancer.  Here, the development of a prodrug of the canonical broad-spectrum HDACi suberoylanilide hydroxamic acid (SAHA) is described.  Although hydroxamic acids are utilized universally in the development of metalloenzyme inhibitors, they are considered to be poor pharmacophores with reduced activity in vivo.  We developed a prodrug of SAHA by appending a promoiety, sensitive to thiols, to the hydroxamic acid warhead (termed SAHA-TAP).  After incubation of SAHA-TAP with an HDAC, the thiol of a conserved HDAC cysteine residue becomes covalently tagged with the promoiety, initiating a cascade reaction that leads to the release of SAHA.  Mass spectrometry and enzyme kinetics expts. validate that the cysteine residue is covalently appended with the TAP promoiety.  SAHA-TAP demonstrates cytotoxicity activity against various cancer cell lines.  This strategy represents an original prodrug design with a dual mode of action for HDAC inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra4pNKro-RWLVg90H21EOLACvtfcHk0liwUW_jPNMrWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotlCitLw%253D&md5=985fb1b3e17240ab6484c33e737f47e2</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00539%26sid%3Dliteratum%253Aachs%26aulast%3DDaniel%26aufirst%3DK.%2BB.%26aulast%3DSullivan%26aufirst%3DE.%2BD.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DChan%26aufirst%3DJ.%2BC.%26aulast%3DJennings%26aufirst%3DP.%2BA.%26aulast%3DFierke%26aufirst%3DC.%2BA.%26aulast%3DCohen%26aufirst%3DS.%2BM.%26atitle%3DDual-Mode%2520Hdac%2520Prodrug%2520for%2520Covalent%2520Modification%2520and%2520Subsequent%2520Inhibitor%2520Release%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4812%26epage%3D4821%26doi%3D10.1021%2Facs.jmedchem.5b00539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thaler, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercurio, C.</span></span> <span> </span><span class="NLM_article-title">Towards Selective Inhibition of Histone Deacetylase Isoforms: What Has Been Achieved, Where We Are and What Will Be Next</span>. <i>Chemmedchem</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">523</span>– <span class="NLM_lpage">536</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201300413</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1002%2Fcmdc.201300413" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=24730063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFentrnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=523-536&author=F.+Thalerauthor=C.+Mercurio&title=Towards+Selective+Inhibition+of+Histone+Deacetylase+Isoforms%3A+What+Has+Been+Achieved%2C+Where+We+Are+and+What+Will+Be+Next&doi=10.1002%2Fcmdc.201300413"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Towards Selective Inhibition of Histone Deacetylase Isoforms: What Has Been Achieved, Where We Are and What Will Be Next</span></div><div class="casAuthors">Thaler, Florian; Mercurio, Ciro</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">523-536</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) are widely studied targets for the treatment of cancer and other diseases.  Up to now, over twenty HDAC inhibitors have entered clin. studies and two of them have already reached the market, namely the hydroxamic acid deriv. SAHA (vorinostat, Zolinza) and the cyclic depsipeptide FK228 (romidepsin, Istodax) that have been approved for the treatment of cutaneous T-cell lymphoma (CTCL).  A common aspect of the first HDAC inhibitors is the absence of any particular selectivity towards specific isoenzymes.  Some of mols. resulted to be "pan"-HDAC inhibitors, while others are class I selective.  In the meantime, the knowledge of HDAC biol. has continuously progressed.  Key advances in the structural biol. of various isoenzymes, reliable mol. homol. models as well as suitable biol. assays have provided new tools for drug discovery activities.  This Minireview aims at surveying these recent developments as well as the design, synthesis and biol. characterization of isoform-selective derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKncV8XbSHkrVg90H21EOLACvtfcHk0liwUW_jPNMrWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFentrnP&md5=72626d372ef5d953be388f3513c87e0b</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201300413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201300413%26sid%3Dliteratum%253Aachs%26aulast%3DThaler%26aufirst%3DF.%26aulast%3DMercurio%26aufirst%3DC.%26atitle%3DTowards%2520Selective%2520Inhibition%2520of%2520Histone%2520Deacetylase%2520Isoforms%253A%2520What%2520Has%2520Been%2520Achieved%252C%2520Where%2520We%2520Are%2520and%2520What%2520Will%2520Be%2520Next%26jtitle%3DChemmedchem%26date%3D2014%26volume%3D9%26spage%3D523%26epage%3D536%26doi%3D10.1002%2Fcmdc.201300413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackanson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase (Hdac) Inhibitors in Recent Clinical Trials for Cancer Therapy</span>. <i>Clin. Epigenet.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">117</span>, <span class="refDoi"> DOI: 10.1007/s13148-010-0012-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1007%2Fs13148-010-0012-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=21258646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVeqsrrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=117&author=J.+M.+Wagnerauthor=B.+Hackansonauthor=M.+Lubbertauthor=M.+Jung&title=Histone+Deacetylase+%28Hdac%29+Inhibitors+in+Recent+Clinical+Trials+for+Cancer+Therapy&doi=10.1007%2Fs13148-010-0012-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy</span></div><div class="casAuthors">Wagner, Julia M.; Hackanson, Bjoern; Luebbert, Michael; Jung, Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Epigenetics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">117-136</span>CODEN:
                <span class="NLM_cas:coden">CELPCI</span>;
        ISSN:<span class="NLM_cas:issn">1868-7075</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Heritable changes in gene expression that are not based upon alterations in the DNA sequence are defined as epigenetics.  The most common mechanisms of epigenetic regulation are the methylation of CpG islands within the DNA and the modification of amino acids in the N-terminal histone tails.  In the last years, it became evident that the onset of cancer and its progression may not occur only due to genetic mutations but also because of changes in the patterns of epigenetic modifications.  In contrast to genetic mutations, which are almost impossible to reverse, epigenetic changes are potentially reversible.  This implies that they are amenable to pharmacol. interventions.  Therefore, a lot of work in recent years has focussed on the development of small mol. enzyme inhibitors like DNA-methyltransferase inhibitors or inhibitors of histone-modifying enzymes.  These may reverse misregulated epigenetic states and be implemented in the treatment of cancer or other diseases, e.g., neurol. disorders.  Today, several epigenetic drugs are already approved by the FDA and the EMEA for cancer treatment and around ten histone deacetylase (HDAC) inhibitors are in clin. development.  This review will give an update on recent clin. trials of the HDAC inhibitors used systemically that were reported in 2009 and 2010 and will present an overview of different biomarkers to monitor the biol. effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp62EyFQbmSEbVg90H21EOLACvtfcHk0lh23Mle7Kj9gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVeqsrrF&md5=c2b02cc37f94c85c4496822b9bf13af9</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1007%2Fs13148-010-0012-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13148-010-0012-4%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DJ.%2BM.%26aulast%3DHackanson%26aufirst%3DB.%26aulast%3DLubbert%26aufirst%3DM.%26aulast%3DJung%26aufirst%3DM.%26atitle%3DHistone%2520Deacetylase%2520%2528Hdac%2529%2520Inhibitors%2520in%2520Recent%2520Clinical%2520Trials%2520for%2520Cancer%2520Therapy%26jtitle%3DClin.%2520Epigenet.%26date%3D2010%26volume%3D1%26spage%3D117%26doi%3D10.1007%2Fs13148-010-0012-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of Oral-Available Resveratrol-Caffeic Acid Based Hybrids Inhibiting Acetylated and Phosphorylated Stat3 Protein</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">1006</span>– <span class="NLM_lpage">1018</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.10.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1016%2Fj.ejmech.2016.10.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=27783972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslKgu7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2016&pages=1006-1018&author=S.+Liauthor=W.+Zhangauthor=Y.+Yangauthor=T.+Maauthor=J.+Guoauthor=S.+Wangauthor=W.+Yuauthor=L.+Kong&title=Discovery+of+Oral-Available+Resveratrol-Caffeic+Acid+Based+Hybrids+Inhibiting+Acetylated+and+Phosphorylated+Stat3+Protein&doi=10.1016%2Fj.ejmech.2016.10.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of oral-available resveratrol-caffeic acid based hybrids inhibiting acetylated and phosphorylated STAT3 protein</span></div><div class="casAuthors">Li, Shanshan; Zhang, Wenda; Yang, Yanwei; Ma, Ting; Guo, Jianpeng; Wang, Shanshan; Yu, Wenying; Kong, Lingyi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1006-1018</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Constitutive activation of STAT3 has been found in a wide variety of cancers and demonstrated as a very attractive therapeutic target.  Disrupting both acetylation and phosphorylation of STAT3 protein was hypothesized to greatly deactivate STAT3, therefore, treating cancers.  To demonstrate the hypothesis, two series of novel resveratrol-caffeic acid hybrids were designed aiming to regulate both acetylation and phosphorylation of STAT3 protein, which is also the first report of the synthetic inhibitors simultaneously regulating two biol. reactions of STAT3 to the knowledge.  Most of these compds. were demonstrated with preferential antitumor activity with low IC50 values against two cancer cell lines.  Particularly, compd. I was found as an excellent STAT3 inhibitor with over 50-fold better potency than resveratrol and caffeic acid.  Meanwhile, the novel derivs. significantly inhibited the proliferation and induced the apoptosis of tumor cells.  Mol. docking further disclosed the binding modes of STAT3 with the inhibitors.  In addn., compd. I orally and significantly suppressed breast cancer 4T1 xenograft tumor growth in vivo, indicating its great potential as an efficacious drug candidate for human cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHG6waQXaPa7Vg90H21EOLACvtfcHk0lh23Mle7Kj9gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslKgu7bO&md5=8eb67605addaebf623618d15ac46b7af</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.10.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.10.028%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DT.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DKong%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520Oral-Available%2520Resveratrol-Caffeic%2520Acid%2520Based%2520Hybrids%2520Inhibiting%2520Acetylated%2520and%2520Phosphorylated%2520Stat3%2520Protein%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D124%26spage%3D1006%26epage%3D1018%26doi%3D10.1016%2Fj.ejmech.2016.10.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Thangue, N. B.</span></span> <span> </span><span class="NLM_article-title">Hdac Inhibitors in Cancer Biology: Emerging Mechanisms and Clinical Applications</span>. <i>Immunol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">94</span>, <span class="refDoi"> DOI: 10.1038/icb.2011.100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1038%2Ficb.2011.100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=22124371" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC38Xkslykuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2012&pages=85-94&author=O.+Khanauthor=N.+B.+La+Thangue&title=Hdac+Inhibitors+in+Cancer+Biology%3A+Emerging+Mechanisms+and+Clinical+Applications&doi=10.1038%2Ficb.2011.100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications</span></div><div class="casAuthors">Khan, Omar; La Thangue, Nicholas B.</div><div class="citationInfo"><span class="NLM_cas:title">Immunology & Cell Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">85-94</span>CODEN:
                <span class="NLM_cas:coden">ICBIEZ</span>;
        ISSN:<span class="NLM_cas:issn">0818-9641</span>.
    
            (<span class="NLM_cas:orgname">NPG Nature Asia-Pacific</span>)
        </div><div class="casAbstract">A review.  Reversible acetylation mediated by histone deacetylases (HDACs) influences a broad repertoire of physiol. processes, many of which are aberrantly controlled in tumor cells.  As HDAC inhibition prompts tumor cells to enter apoptosis, small-mol. HDAC inhibitors have been developed as a new class of mechanism-based anti-cancer agent, many of which have entered clin. trials.  Although the clin. picture is evolving and the precise utility of HDAC inhibitors remains to be detd., it is noteworthy that certain tumor types undergo a favorable response, in particular hematol. malignancies.  Vorinostat and romidepsin have been approved for treating cutaneous T-cell lymphoma in patients with progressive, persistent or recurrent disease.  Here, we discuss developments in our understanding of mol. events that underlie the anti-cancer effects of HDAC inhibitors and relate this information to the emerging clin. picture for the application of these inhibitors in the treatment of cancer.  Immunol. and Cell Biol. (2012) 90, 85-94; doi:10.1038/icb.2011.100; published online 29 Nov. 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvd48xGUlskbVg90H21EOLACvtfcHk0lh23Mle7Kj9gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xkslykuw%253D%253D&md5=b9214c008e22696af4ee808b2e2af7f2</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Ficb.2011.100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Ficb.2011.100%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DO.%26aulast%3DLa%2BThangue%26aufirst%3DN.%2BB.%26atitle%3DHdac%2520Inhibitors%2520in%2520Cancer%2520Biology%253A%2520Emerging%2520Mechanisms%2520and%2520Clinical%2520Applications%26jtitle%3DImmunol.%2520Cell%2520Biol.%26date%3D2012%26volume%3D90%26spage%3D85%26epage%3D94%26doi%3D10.1038%2Ficb.2011.100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gryder, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodji, Q. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyelere, A. K.</span></span> <span> </span><span class="NLM_article-title">Targeted Cancer Therapy: Giving Histone Deacetylase Inhibitors All They Need to Succeed</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">505</span>– <span class="NLM_lpage">524</span>, <span class="refDoi"> DOI: 10.4155/fmc.12.3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.4155%2Ffmc.12.3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=22416777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC38XktVajsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=505-524&author=B.+E.+Gryderauthor=Q.+H.+Sodjiauthor=A.+K.+Oyelere&title=Targeted+Cancer+Therapy%3A+Giving+Histone+Deacetylase+Inhibitors+All+They+Need+to+Succeed&doi=10.4155%2Ffmc.12.3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed</span></div><div class="casAuthors">Gryder, Berkley E.; Sodji, Quaovi H.; Oyelere, Adegboyega K.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">505-524</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase inhibitors (HDACis) have now emerged as a powerful new class of small-mol. therapeutics acting through the regulation of the acetylation states of histone proteins (a form of epigenetic modulation) and other non-histone protein targets.  Over 490 clin. trials have been initiated in the last 10 years, culminating in the approval of two structurally distinct HDACis-SAHA (vorinostat, Zolinza) and FK228 (romidepsin, Istodax).  However, the current HDACis have serious limitations, including ineffectively low concns. in solid tumors and cardiac toxicity, which is hindering their progress in the clinic.  Herein, we review the primary paradigms being pursued to overcome these hindrances, including HDAC isoform selectivity, localized administration, and targeting cap groups to achieve selective tissue and cell type distribution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWwrW1IVCIULVg90H21EOLACvtfcHk0lhsu69uIPLAtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktVajsL8%253D&md5=234080d1b0862680a68062a03afee20c</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.4155%2Ffmc.12.3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.12.3%26sid%3Dliteratum%253Aachs%26aulast%3DGryder%26aufirst%3DB.%2BE.%26aulast%3DSodji%26aufirst%3DQ.%2BH.%26aulast%3DOyelere%26aufirst%3DA.%2BK.%26atitle%3DTargeted%2520Cancer%2520Therapy%253A%2520Giving%2520Histone%2520Deacetylase%2520Inhibitors%2520All%2520They%2520Need%2520to%2520Succeed%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2012%26volume%3D4%26spage%3D505%26epage%3D524%26doi%3D10.4155%2Ffmc.12.3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, H.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forrester, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of 7-(4-(3-Ethynylphenylamino)-7-Methoxyquinazolin-6-Yloxy)-N-Hydroxyheptan Amide (Cudc-101) as a Potent Multi-Acting Hdac, Egfr, and Her2 Inhibitor for the Treatment of Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2000</span>– <span class="NLM_lpage">2009</span>, <span class="refDoi"> DOI: 10.1021/jm901453q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901453q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhslSgsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2000-2009&author=X.+Caiauthor=H.-X.+Zhaiauthor=J.+Wangauthor=J.+Forresterauthor=H.+Quauthor=L.+Yinauthor=C.-J.+Laiauthor=R.+Baoauthor=C.+Qian&title=Discovery+of+7-%284-%283-Ethynylphenylamino%29-7-Methoxyquinazolin-6-Yloxy%29-N-Hydroxyheptan+Amide+%28Cudc-101%29+as+a+Potent+Multi-Acting+Hdac%2C+Egfr%2C+and+Her2+Inhibitor+for+the+Treatment+of+Cancer&doi=10.1021%2Fjm901453q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer</span></div><div class="casAuthors">Cai, Xiong; Zhai, Hai-Xiao; Wang, Jing; Forrester, Jeffrey; Qu, Hui; Yin, Ling; Lai, Cheng-Jung; Bao, Rudi; Qian, Changgeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2000-2009</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">By incorporating histone deacetylase (HDAC) inhibitory functionality into the pharmacophore of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) inhibitors, we synthesized a novel series of compds. with potent, multiacting HDAC, EGFR, and HER2 inhibition and identified 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide 8 (CUDC-101) as a drug candidate, which is now in clin. development. 8 displays potent in vitro inhibitory activity against HDAC, EGFR, and HER2 with an IC50 of 4.4, 2.4, and 15.7 nM, resp.  In most tumor cell lines tested, 8 exhibits efficient antiproliferative activity with greater potency than vorinostat (SAHA), erlotinib, lapatinib, and combinations of vorinostat/erlotinib and vorinostat/lapatinib.  In vivo, 8 promotes tumor regression or inhibition in various cancer xenograft models including nonsmall cell lung cancer (NSCLC), liver, breast, head and neck, colon, and pancreatic cancers.  These results suggest that a single compd. that simultaneously inhibits HDAC, EGFR, and HER2 may offer greater therapeutic benefits in cancer over single-acting agents through the interference with multiple pathways and potential synergy among HDAC and EGFR/HER2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodBQl1iMXW3rVg90H21EOLACvtfcHk0lhsu69uIPLAtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhslSgsb0%253D&md5=d4dc339f2fd750d52e511abf3dbf18bd</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm901453q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901453q%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DX.%26aulast%3DZhai%26aufirst%3DH.-X.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DForrester%26aufirst%3DJ.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DLai%26aufirst%3DC.-J.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DQian%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25207-%25284-%25283-Ethynylphenylamino%2529-7-Methoxyquinazolin-6-Yloxy%2529-N-Hydroxyheptan%2520Amide%2520%2528Cudc-101%2529%2520as%2520a%2520Potent%2520Multi-Acting%2520Hdac%252C%2520Egfr%252C%2520and%2520Her2%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2000%26epage%3D2009%26doi%3D10.1021%2Fjm901453q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span> <span> </span><span class="NLM_article-title">Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">473</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2016.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1016%2Fj.ccell.2016.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=27622335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWitrnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=459-473&author=H.+Zengauthor=J.+Quauthor=N.+Jinauthor=J.+Xuauthor=C.+Linauthor=Y.+Chenauthor=X.+Yangauthor=X.+Heauthor=S.+Tangauthor=X.+Lanauthor=X.+Yangauthor=Z.+Chenauthor=M.+Huangauthor=J.+Dingauthor=M.+Geng&title=Feedback+Activation+of+Leukemia+Inhibitory+Factor+Receptor+Limits+Response+to+Histone+Deacetylase+Inhibitors+in+Breast+Cancer&doi=10.1016%2Fj.ccell.2016.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer</span></div><div class="casAuthors">Zeng, Hanlin; Qu, Jia; Jin, Nan; Xu, Jun; Lin, Chenchu; Chen, Yi; Yang, Xinying; He, Xiang; Tang, Shuai; Lan, Xiaojing; Yang, Xiaotong; Chen, Ziqi; Huang, Min; Ding, Jian; Geng, Meiyu</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">459-473</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) inhibitors have demonstrated clin. benefits in subtypes of hematol. malignancies.  However, the efficacy of HDAC inhibitors in solid tumors remains uncertain.  This study takes breast cancer as a model to understand mechanisms accounting for limited response of HDAC inhibitors in solid tumors and to seek combination solns.  We discover that feedback activation of leukemia inhibitory factor receptor (LIFR) signaling in breast cancer limits the response to HDAC inhibition.  Mechanistically, HDAC inhibition increases histone acetylation at the LIFR gene promoter, which recruits bromodomain protein BRD4, upregulates LIFR expression, and activates JAK1-STAT3 signaling.  Importantly, JAK1 or BRD4 inhibition sensitizes breast cancer to HDAC inhibitors, implicating combination inhibition of HDAC with JAK1 or BRD4 as potential therapies for breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL24sYbhFYeLVg90H21EOLACvtfcHk0lhsu69uIPLAtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWitrnI&md5=9ce620c7a19519a95edd714f8012518c</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2016.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2016.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DH.%26aulast%3DQu%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DN.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DTang%26aufirst%3DS.%26aulast%3DLan%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DGeng%26aufirst%3DM.%26atitle%3DFeedback%2520Activation%2520of%2520Leukemia%2520Inhibitory%2520Factor%2520Receptor%2520Limits%2520Response%2520to%2520Histone%2520Deacetylase%2520Inhibitors%2520in%2520Breast%2520Cancer%26jtitle%3DCancer%2520Cell%26date%3D2016%26volume%3D30%26spage%3D459%26epage%3D473%26doi%3D10.1016%2Fj.ccell.2016.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong-Thi, M.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. X. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujulu, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J. J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohlson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (Jak) and Histone Deacetylase (Hdac) Based on Ruxolitinib and Vorinostat</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">8336</span>– <span class="NLM_lpage">8357</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00678</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00678" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=8336-8357&author=L.+Yaoauthor=N.+Mustafaauthor=E.+C.+Tanauthor=A.+Poulsenauthor=P.+Singhauthor=M.-D.+Duong-Thiauthor=J.+X.+T.+Leeauthor=P.+M.+Ramanujuluauthor=W.+J.+Chngauthor=J.+J.+Y.+Yenauthor=S.+Ohlsonauthor=B.+W.+Dymock&title=Design+and+Synthesis+of+Ligand+Efficient+Dual+Inhibitors+of+Janus+Kinase+%28Jak%29+and+Histone+Deacetylase+%28Hdac%29+Based+on+Ruxolitinib+and+Vorinostat&doi=10.1021%2Facs.jmedchem.7b00678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat</span></div><div class="casAuthors">Yao, Lianbin; Mustafa, Nurulhuda; Tan, Eng Chong; Poulsen, Anders; Singh, Prachi; Duong-Thi, Minh-Dao; Lee, Jeannie X. T.; Ramanujulu, Pondy Murugappan; Chng, Wee Joo; Yen, Jeffrey J. Y.; Ohlson, Sten; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8336-8357</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Concomitant inhibition of multiple oncogenic pathways is a desirable goal in cancer therapy.  To achieve such an outcome with a single mol. would simplify treatment regimes.  Herein the core features of ruxolitinib, a marketed JAK1/2 inhibitor, have been merged with the HDAC inhibitor vorinostat, leading to new mols. that are bispecific targeted JAK/HDAC inhibitors.  A preferred pyrazole substituted pyrrolopyrimidine, I (R = H), inhibits JAK1 and HDACs 1, 2, 3, 6, and 10 with IC50 values of less than 20 nM, is <100 nM potent against JAK2 and HDAC11, and is selective for the JAK family against a panel of 97 kinases.  Broad cellular antiproliferative potency of I (R = H) is supported by demonstration of JAK-STAT and HDAC pathway blockade in hematol. cell lines.  Me analog I (R = Me) has an even more selective profile.  This study provides new leads for assessment of JAK and HDAC pathway dual inhibition achieved with a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocWx3JXIW8YbVg90H21EOLACvtfcHk0ljpvy5dXcTqZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtLzJ&md5=5ac471ee0cc413b08b926803790de7f9</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00678%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DL.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DTan%26aufirst%3DE.%2BC.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DP.%26aulast%3DDuong-Thi%26aufirst%3DM.-D.%26aulast%3DLee%26aufirst%3DJ.%2BX.%2BT.%26aulast%3DRamanujulu%26aufirst%3DP.%2BM.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DYen%26aufirst%3DJ.%2BJ.%2BY.%26aulast%3DOhlson%26aufirst%3DS.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Ligand%2520Efficient%2520Dual%2520Inhibitors%2520of%2520Janus%2520Kinase%2520%2528Jak%2529%2520and%2520Histone%2520Deacetylase%2520%2528Hdac%2529%2520Based%2520on%2520Ruxolitinib%2520and%2520Vorinostat%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D8336%26epage%3D8357%26doi%3D10.1021%2Facs.jmedchem.7b00678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.</span></span> <span> </span><span class="NLM_article-title">Discovery of Thieno 2,3-D Pyrimidine-Based Hydroxamic Acid Derivatives as Bromodomain-Containing Protein 4/Histone Deacetylase Dual Inhibitors Induce Autophagic Cell Death in Colorectal Carcinoma Cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">3678</span>– <span class="NLM_lpage">3700</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b02178</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b02178" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksFajtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=3678-3700&author=Z.+Panauthor=X.+Liauthor=Y.+Wangauthor=Q.+Jiangauthor=L.+Jiangauthor=M.+Zhangauthor=N.+Zhangauthor=F.+Wuauthor=B.+Liuauthor=G.+He&title=Discovery+of+Thieno+2%2C3-D+Pyrimidine-Based+Hydroxamic+Acid+Derivatives+as+Bromodomain-Containing+Protein+4%2FHistone+Deacetylase+Dual+Inhibitors+Induce+Autophagic+Cell+Death+in+Colorectal+Carcinoma+Cells&doi=10.1021%2Facs.jmedchem.9b02178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Thieno[2,3-d]pyrimidine-Based Hydroxamic Acid Derivatives as Bromodomain-Containing Protein 4/Histone Deacetylase Dual Inhibitors Induce Autophagic Cell Death in Colorectal Carcinoma Cells</span></div><div class="casAuthors">Pan, Zhaoping; Li, Xiang; Wang, Yujia; Jiang, Qinglin; Jiang, Li; Zhang, Min; Zhang, Nan; Wu, Fengbo; Liu, Bo; He, Gu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3678-3700</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bromodomain-contg. protein 4 (BRD4) and histone deacetylases (HDAC) are both attractive epigenetic targets in cancer and other chronic diseases.  Based on the integrated fragment-based drug design, synthesis, and in vitro and in vivo evaluations, a series of novel thieno[2,3-d]pyrimidine-based hydroxamic acid derivs. are discovered as selective BRD4-HDAC dual inhibitors.  Compd. 17c is the most potent inhibitor for BRD4 and HDAC with IC50 values at nanomolar levels, as well as the expression level of c-Myc, and increases the acetylation of histone H3.  Moreover, 17c presents inhibitory effects on the proliferation of colorectal carcinoma (CRC) cells via inducing autophagic cell death.  It also has a good pharmacokinetic profile in rats and oral bioavailability of 40.5%.  In the HCT-116 xenograft in vivo models, 17c displays potent inhibitory efficiency on tumor growth by inducing autophagic cell death and suppressing IL6-JAK-STAT signaling pathways.  Our results suggest that the BRD4-HDAC dual inhibition might be an attractive therapeutic strategy for CRC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2FHKdnuD3QLVg90H21EOLACvtfcHk0ljpvy5dXcTqZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksFajtLs%253D&md5=ce6446afe48f80165d2b21aee04571f6</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b02178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b02178%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DWu%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DHe%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520Thieno%25202%252C3-D%2520Pyrimidine-Based%2520Hydroxamic%2520Acid%2520Derivatives%2520as%2520Bromodomain-Containing%2520Protein%25204%252FHistone%2520Deacetylase%2520Dual%2520Inhibitors%2520Induce%2520Autophagic%2520Cell%2520Death%2520in%2520Colorectal%2520Carcinoma%2520Cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D3678%26epage%3D3700%26doi%3D10.1021%2Facs.jmedchem.9b02178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muro-Cacho, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falcone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairclough, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laudano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levitzki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jove, R.</span></span> <span> </span><span class="NLM_article-title">Constitutive Activation of Stat3 by the Src and Jak Tyrosine Kinases Participates in Growth Regulation of Human Breast Carcinoma Cells</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2499</span>– <span class="NLM_lpage">2513</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1204349</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1038%2Fsj.onc.1204349" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=11420660" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjvFGmt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2001&pages=2499-2513&author=R.+Garciaauthor=T.+L.+Bowmanauthor=G.+Niuauthor=H.+Yuauthor=S.+Mintonauthor=C.+A.+Muro-Cachoauthor=C.+E.+Coxauthor=R.+Falconeauthor=R.+Faircloughauthor=S.+Parsonsauthor=A.+Laudanoauthor=A.+Gazitauthor=A.+Levitzkiauthor=A.+Krakerauthor=R.+Jove&title=Constitutive+Activation+of+Stat3+by+the+Src+and+Jak+Tyrosine+Kinases+Participates+in+Growth+Regulation+of+Human+Breast+Carcinoma+Cells&doi=10.1038%2Fsj.onc.1204349"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells</span></div><div class="casAuthors">Garcia, Roy; Bowman, Tammy L.; Niu, Guilian; Yu, Hua; Minton, Sue; Muro-Cacho, Carlos A.; Cox, Charles E.; Falcone, Robert; Fairclough, Rita; Parsons, Sarah; Laudano, Andy; Gazit, Aviv; Levitzki, Alexander; Kraker, Alan; Jove, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2499-2513</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Constitutive activation of signal transducer and activator of transcription (STAT) proteins has been detected in a wide variety of human primary tumor specimens and tumor cell lines including blood malignancies, head and neck cancer, and breast cancer.  We have previously demonstrated a high frequency of Stat3 DNA-binding activity that is constitutively-induced by an unknown mechanism in human breast cancer cell lines possessing elevated EGF receptor (EGF-R) and c-Src kinase activities.  Using tyrosine kinase selective inhibitors, we show here that Src and JAK family tyrosine kinases cooperate to mediate constitutive Stat3 activation in the absence of EGF stimulation in model human breast cancer cell lines.  Inhibition of Src or JAKs results in dose-dependent suppression of Stat3 DNA-binding activity, which is accompanied by growth inhibition and induction of programmed cell death.  In addn., transfection of a dominant-neg. form of Stat3 leads to growth inhibition involving apoptosis of breast cancer cells.  These results indicate that the biol. effects of the Src and JAK tyrosine kinase inhibitors are at least partially mediated by blocking Stat3 signaling.  While EGF-R kinase activity is not required for constitutive Stat3 activation in breast cancer cells, EGF stimulation further increases STAT DNA-binding activity, consistent with an important role for EGF-R in STAT signaling and malignant progression.  Anal. of primary breast tumor specimens from patients with advanced disease revealed that the majority exhibit elevated STAT DNA-binding activity compared to adjacent non-tumor tissues.  Our findings, taken together, suggest that tyrosine kinases transduce signals through Stat3 protein that contribute to the growth and survival of human breast cancer cells in culture and potentially in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5BSpinbxg3rVg90H21EOLACvtfcHk0lhrghhhzLZTZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjvFGmt7k%253D&md5=a941c45ef8fbf78234c6f66b741e7be2</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1204349&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1204349%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia%26aufirst%3DR.%26aulast%3DBowman%26aufirst%3DT.%2BL.%26aulast%3DNiu%26aufirst%3DG.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DMinton%26aufirst%3DS.%26aulast%3DMuro-Cacho%26aufirst%3DC.%2BA.%26aulast%3DCox%26aufirst%3DC.%2BE.%26aulast%3DFalcone%26aufirst%3DR.%26aulast%3DFairclough%26aufirst%3DR.%26aulast%3DParsons%26aufirst%3DS.%26aulast%3DLaudano%26aufirst%3DA.%26aulast%3DGazit%26aufirst%3DA.%26aulast%3DLevitzki%26aufirst%3DA.%26aulast%3DKraker%26aufirst%3DA.%26aulast%3DJove%26aufirst%3DR.%26atitle%3DConstitutive%2520Activation%2520of%2520Stat3%2520by%2520the%2520Src%2520and%2520Jak%2520Tyrosine%2520Kinases%2520Participates%2520in%2520Growth%2520Regulation%2520of%2520Human%2520Breast%2520Carcinoma%2520Cells%26jtitle%3DOncogene%26date%3D2001%26volume%3D20%26spage%3D2499%26epage%3D2513%26doi%3D10.1038%2Fsj.onc.1204349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boengler, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilfikerkleiner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drexler, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heusch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, R.</span></span> <span> </span><span class="NLM_article-title">The Myocardial Jak/Stat Pathway: From Protection to Failure</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">172</span>– <span class="NLM_lpage">185</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2008.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1016%2Fj.pharmthera.2008.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=18786563" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Knsb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2008&pages=172-185&author=K.+Boenglerauthor=D.+Hilfikerkleinerauthor=H.+Drexlerauthor=G.+Heuschauthor=R.+Schulz&title=The+Myocardial+Jak%2FStat+Pathway%3A+From+Protection+to+Failure&doi=10.1016%2Fj.pharmthera.2008.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The myocardial JAK/STAT pathway: From protection to failure</span></div><div class="casAuthors">Boengler, Kerstin; Hilfiker-Kleiner, Denise; Drexler, Helmut; Heusch, Gerd; Schulz, Rainer</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">172-185</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Subsequent signal transduction involves activation of the janus kinase (JAK) and signal transducer and activator of transcription (STAT) proteins.  STAT proteins are translocated into the nucleus, where they bind to the promoter region of target genes and are thereby involved in regulating the transcription of target genes.  In the first part, the present review focuses on the role of STAT3 in ischemia/reperfusion injury and in cardioprotection by ischemic pre- and postconditioning.  In the heart, ischemia induces an increase in IL-6 cytokines, which is assocd. with activation of STAT3.  Genetic modification of the myocardial STAT3 protein content shows a protective role of STAT3 on infarct size after ischemia/reperfusion injury.  The cardioprotection by both early and late ischemic preconditioning as well as by ischemic postconditioning involves an activation of STAT3 and is dependent on STAT3 protein level.  Whereas the infarct-sparing effect of late preconditioning is clearly mediated by an increase in transcription-mediated protein synthesis, early preconditioning is independent of gene transcription, suggesting a role of STAT3 independent of transcriptional regulation.  Possibly, STAT3 plays a role in modifying mitochondrial function, organelles central for the cardioprotection by pre- and postconditioning.  In the second part, the role of STAT3 in physiol. stresses such as aging and pregnancy, as well as in pathophysiol. situations such as myocardial infarction and heart failure is summarized.  Furthermore, the requirements for the use of STAT3 as a target for treatment strategies of cardiovascular diseases is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCSELFwPuAVLVg90H21EOLACvtfcHk0lhrghhhzLZTZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Knsb3J&md5=914abdaa6c7d463b42bd27cfa9aed73d</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2008.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2008.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DBoengler%26aufirst%3DK.%26aulast%3DHilfikerkleiner%26aufirst%3DD.%26aulast%3DDrexler%26aufirst%3DH.%26aulast%3DHeusch%26aufirst%3DG.%26aulast%3DSchulz%26aufirst%3DR.%26atitle%3DThe%2520Myocardial%2520Jak%252FStat%2520Pathway%253A%2520From%2520Protection%2520to%2520Failure%26jtitle%3DPharmacol.%2520Ther.%26date%3D2008%26volume%3D120%26spage%3D172%26epage%3D185%26doi%3D10.1016%2Fj.pharmthera.2008.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jove, R.</span></span> <span> </span><span class="NLM_article-title">Stats in Cancer Inflammation and Immunity: A Leading Role for Stat3</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">798</span>– <span class="NLM_lpage">809</span>, <span class="refDoi"> DOI: 10.1038/nrc2734</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1038%2Fnrc2734" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=19851315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlSjur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=798-809&author=H.+Yuauthor=D.+Pardollauthor=R.+Jove&title=Stats+in+Cancer+Inflammation+and+Immunity%3A+A+Leading+Role+for+Stat3&doi=10.1038%2Fnrc2734"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">STATs in cancer inflammation and immunity: a leading role for STAT3</span></div><div class="casAuthors">Yu, Hua; Pardoll, Drew; Jove, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">798-809</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Commensurate with their roles in regulating cytokine-dependent inflammation and immunity, signal transducer and activator of transcription (STAT) proteins are central in detg. whether immune responses in the tumor microenvironment promote or inhibit cancer.  Persistently activated STAT3 and, to some extent, STAT5 increase tumor cell proliferation, survival and invasion while suppressing anti-tumor immunity.  The persistent activation of STAT3 also mediates tumor-promoting inflammation.  STAT3 has this dual role in tumor inflammation and immunity by promoting pro-oncogenic inflammatory pathways, including nuclear factor-κB (NF-κB) and interleukin-6 (IL-6)-GP130-Janus kinase (JAK) pathways, and by opposing STAT1- and NF-κB-mediated T helper 1 anti-tumor immune responses.  Consequently, STAT3 is a promising target to redirect inflammation for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYvEMN5YrxbbVg90H21EOLACvtfcHk0ljQGd1zgJUjTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlSjur%252FP&md5=e431d0bd9eabd8f1ef703211be3d5cc9</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnrc2734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2734%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%26aulast%3DPardoll%26aufirst%3DD.%26aulast%3DJove%26aufirst%3DR.%26atitle%3DStats%2520in%2520Cancer%2520Inflammation%2520and%2520Immunity%253A%2520A%2520Leading%2520Role%2520for%2520Stat3%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D798%26epage%3D809%26doi%3D10.1038%2Fnrc2734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neamati, N.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Inhibitors of Signal Transducer and Activator of Transcription 3 (Stat3) Protein</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6645</span>– <span class="NLM_lpage">6668</span>, <span class="refDoi"> DOI: 10.1021/jm300207s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300207s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC38Xnsl2msrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6645-6668&author=B.+Debnathauthor=S.+Xuauthor=N.+Neamati&title=Small+Molecule+Inhibitors+of+Signal+Transducer+and+Activator+of+Transcription+3+%28Stat3%29+Protein&doi=10.1021%2Fjm300207s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Inhibitors of Signal Transducer and Activator of Transcription 3 (Stat3) Protein</span></div><div class="casAuthors">Debnath, Bikash; Xu, Shili; Neamati, Nouri</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6645-6668</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Signal transducer and activator of transcription 3 (Stat3) is a transcription factor belonging to the STAT protein family, members of which regulate a wide variety of biol. processes, including cell growth, proliferation, survival, differentiation, development, movement and inflammation in response to extracellular signaling mols. such as cytokines and growth factors.  Receptor assocd. tyrosine kinases phosphorylate Stat3 protein at Tyr705 and enable it to dimerize and subsequently enter the nucleus where it activates the transcription of its target genes.  Accumulating evidence has established Stat3's role in oncogenesis, cardiovascular diseases, rheumatoid arthritis, fibrotic, and Alzheimer's diseases.  Thus, Stat3 inhibition is a promising therapeutic approach not only for cancer, but also for other diseases.  Although Stat3 has been considered as an important therapeutic target, progress in discovery and development of effective and specific Stat3 inhibitors remains slow.  In this article we summarize Stat3 inhibitors published between 2006 and 2011.  New strategies along with novel technologies are required to achieve breakthrough in the development of Stat3 inhibitors that can be translated into clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWWQl9gV1-ZLVg90H21EOLACvtfcHk0ljQGd1zgJUjTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xnsl2msrc%253D&md5=f5f3ac9f8fc2326c75edd2a9c136275b</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm300207s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300207s%26sid%3Dliteratum%253Aachs%26aulast%3DDebnath%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DNeamati%26aufirst%3DN.%26atitle%3DSmall%2520Molecule%2520Inhibitors%2520of%2520Signal%2520Transducer%2520and%2520Activator%2520of%2520Transcription%25203%2520%2528Stat3%2529%2520Protein%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6645%26epage%3D6668%26doi%3D10.1021%2Fjm300207s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowe, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.-L.</span></span> <span> </span><span class="NLM_article-title">Stat3 Inhibition, a Novel Approach to Enhancing Targeted Therapy in Human Cancers</span>. <i>Int. J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">1181</span>– <span class="NLM_lpage">1191</span>, <span class="refDoi"> DOI: 10.3892/ijo.2012.1568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.3892%2Fijo.2012.1568" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=22842992" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFyntLjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2012&pages=1181-1191&author=X.+Wangauthor=P.+J.+Croweauthor=D.+Goldsteinauthor=J.-L.+Yang&title=Stat3+Inhibition%2C+a+Novel+Approach+to+Enhancing+Targeted+Therapy+in+Human+Cancers&doi=10.3892%2Fijo.2012.1568"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (review)</span></div><div class="casAuthors">Wang, Xiaochun; Crowe, Philip J.; Goldstein, David; Yang, Jia-Lin</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1181-1191</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1019-6439</span>.
    
            (<span class="NLM_cas:orgname">International Journal of Oncology</span>)
        </div><div class="casAbstract">A review.  Signal transducer and activator of transcription 3 (STAT3) regulates many crit. functions in human normal and malignant tissues, such as differentiation, proliferation, survival, angiogenesis and immune function.  Constitutive activation of STAT3 is implicated in a wide range of human cancers.  As such, STAT3 has been studied as a tumor therapeutic target.  This review aimed principally to summarize the updated research on STAT3 inhibition studies and their therapeutic potential in solid tumors.  Recent literature assocd. with STAT3 inhibition was reviewed through PubMed and Medline database, followed by crit. comparison and anal.  Constitutive activation of STAT3 has been identified as abnormal and oncogenic.  The pathway of STAT3 activation and signal transduction identifies 3 approaches for inhibition: modulating upstream pos. or neg. regulators, regulating RNA (DN-STAT3, anti-sense RNA, siRNA and microRNA) or targeting STAT3 protein at different domains.  The last approach using small mol. STAT3 inhibitors has been the most examd. so far with both preclin. and clin. studies.  Targeting STAT3 using a specific inhibitor may be a useful cancer treatment approach, with the potential for a broad clin. impact.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnx1B_eI0cs7Vg90H21EOLACvtfcHk0ljQGd1zgJUjTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFyntLjF&md5=91d64864c492ebe00e5d6a1cc6072284</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.3892%2Fijo.2012.1568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.2012.1568%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DCrowe%26aufirst%3DP.%2BJ.%26aulast%3DGoldstein%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DJ.-L.%26atitle%3DStat3%2520Inhibition%252C%2520a%2520Novel%2520Approach%2520to%2520Enhancing%2520Targeted%2520Therapy%2520in%2520Human%2520Cancers%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2012%26volume%3D41%26spage%3D1181%26epage%3D1191%26doi%3D10.3892%2Fijo.2012.1568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel Stat3 Small Molecule Inhibitors Via in Silico Site-Directed Fragment-Based Drug Design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">4402</span>– <span class="NLM_lpage">4412</span>, <span class="refDoi"> DOI: 10.1021/jm400080c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400080c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntVOktbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4402-4412&author=W.+Yuauthor=H.+Xiaoauthor=J.+Linauthor=C.+Li&title=Discovery+of+Novel+Stat3+Small+Molecule+Inhibitors+Via+in+Silico+Site-Directed+Fragment-Based+Drug+Design&doi=10.1021%2Fjm400080c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel STAT3 Small Molecule Inhibitors via in Silico Site-Directed Fragment-Based Drug Design</span></div><div class="casAuthors">Yu, Wenying; Xiao, Hui; Lin, Jiayuh; Li, Chenglong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4402-4412</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Constitutive activation of signal transducer and activator of transcription 3 (STAT3) has been validated as an attractive therapeutic target for cancer therapy.  To stop both STAT3 activation and dimerization, a viable strategy is to design inhibitors blocking its SH2 domain phosphotyrosine binding site that is responsible for both actions.  A new fragment-based drug design (FBDD) strategy, in silico site-directed FBDD, was applied in this study.  A designed novel compd., 5,8-dioxo-6-(pyridin-3-ylamino)-5,8-dihydronaphthalene-1-sulfonamide (LY5), was confirmed to bind to STAT3 SH2 by fluorescence polarization assay.  In addn., four out of the five chosen compds. have IC50 values lower than 5 μM for the U2OS cancer cells. 8 (LY5) has an IC50 range in 0.5-1.4 μM in various cancer cell lines. 8 also suppresses tumor growth in an in vivo mouse model.  This study has demonstrated the utility of this approach and could be used to other drug targets in general.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq76v3IMxJHwLVg90H21EOLACvtfcHk0ljQGd1zgJUjTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntVOktbk%253D&md5=7231b2e9682f9e9046debcaa461a1d59</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm400080c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400080c%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DW.%26aulast%3DXiao%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520Novel%2520Stat3%2520Small%2520Molecule%2520Inhibitors%2520Via%2520in%2520Silico%2520Site-Directed%2520Fragment-Based%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4402%26epage%3D4412%26doi%3D10.1021%2Fjm400080c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siveen, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sikka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surana, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, B. K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sethi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishayee, A.</span></span> <span> </span><span class="NLM_article-title">Targeting the Stat3 Signaling Pathway in Cancer: Role of Synthetic and Natural Inhibitors</span>. <i>Biochim. Biophys. Acta Rev. Canc.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>1845</i></span>,  <span class="NLM_fpage">136</span>– <span class="NLM_lpage">154</span>, <span class="refDoi"> DOI: 10.1016/j.bbcan.2013.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1016%2Fj.bbcan.2013.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=24388873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmt1agu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1845&publication_year=2014&pages=136-154&author=K.+S.+Siveenauthor=S.+Sikkaauthor=R.+Suranaauthor=X.+Daiauthor=J.+Zhangauthor=A.+P.+Kumarauthor=B.+K.+H.+Tanauthor=G.+Sethiauthor=A.+Bishayee&title=Targeting+the+Stat3+Signaling+Pathway+in+Cancer%3A+Role+of+Synthetic+and+Natural+Inhibitors&doi=10.1016%2Fj.bbcan.2013.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors</span></div><div class="casAuthors">Siveen, Kodappully Sivaraman; Sikka, Sakshi; Surana, Rohit; Dai, Xiaoyun; Zhang, Jingwen; Kumar, Alan Prem; Tan, Benny K. H.; Sethi, Gautam; Bishayee, Anupam</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Reviews on Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">1845</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">136-154</span>CODEN:
                <span class="NLM_cas:coden">BBACEU</span>;
        ISSN:<span class="NLM_cas:issn">0304-419X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Signal transducers and activators of transcription (STATs) comprise a family of cytoplasmic transcription factors that mediate intracellular signaling that is usually generated at cell surface receptors and thereby transmit it to the nucleus.  Numerous studies have demonstrated constitutive activation of STAT3 in a wide variety of human tumors, including hematol. malignancies (leukemias, lymphomas, and multiple myeloma) as well as diverse solid tumors (such as head and neck, breast, lung, gastric, hepatocellular, colorectal and prostate cancers).  There is strong evidence to suggest that aberrant STAT3 signaling promotes initiation and progression of human cancers by either inhibiting apoptosis or inducing cell proliferation, angiogenesis, invasion, and metastasis.  Suppression of STAT3 activation results in the induction of apoptosis in tumor cells, and accordingly its pharmacol. modulation by tyrosine kinase inhibitors, antisense oligonucleotides, decoy nucleotides, dominant neg. proteins, RNA interference and chemopreventive agents have been employed to suppress the proliferation of various human cancer cells in culture and tumorigenicity in vivo.  However, the identification and development of novel drugs that can target deregulated STAT3 activation effectively remains an important scientific and clin. challenge.  This review presents the evidence for crit. roles of STAT3 in oncogenesis and discusses the potential for development of novel cancer therapies based on mechanistic understanding of STAT3 signaling cascade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeL6KQ0obpY7Vg90H21EOLACvtfcHk0lgr26K8UZD8gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmt1agu7Y%253D&md5=c2514f54684fb89a2f5ac489425f42d5</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.bbcan.2013.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbcan.2013.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DSiveen%26aufirst%3DK.%2BS.%26aulast%3DSikka%26aufirst%3DS.%26aulast%3DSurana%26aufirst%3DR.%26aulast%3DDai%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DKumar%26aufirst%3DA.%2BP.%26aulast%3DTan%26aufirst%3DB.%2BK.%2BH.%26aulast%3DSethi%26aufirst%3DG.%26aulast%3DBishayee%26aufirst%3DA.%26atitle%3DTargeting%2520the%2520Stat3%2520Signaling%2520Pathway%2520in%2520Cancer%253A%2520Role%2520of%2520Synthetic%2520and%2520Natural%2520Inhibitors%26jtitle%3DBiochim.%2520Biophys.%2520Acta%2520Rev.%2520Canc.%26date%3D2014%26volume%3D1845%26spage%3D136%26epage%3D154%26doi%3D10.1016%2Fj.bbcan.2013.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.-y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2718</span>– <span class="NLM_lpage">2731</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01489</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01489" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjsFalurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2718-2731&author=W.+Yuauthor=C.+Liauthor=W.+Zhangauthor=Y.+Xiaauthor=S.+Liauthor=J.-y.+Linauthor=K.+Yuauthor=M.+Liuauthor=L.+Yangauthor=J.+Luoauthor=Y.+Chenauthor=H.+Sunauthor=L.+Kong&title=Discovery+of+an+Orally+Selective+Inhibitor+of+Signal+Transducer+and+Activator+of+Transcription+3+Using+Advanced+Multiple+Ligand+Simultaneous+Docking&doi=10.1021%2Facs.jmedchem.6b01489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking</span></div><div class="casAuthors">Yu, Wenying; Li, Chenglong; Zhang, Wenda; Xia, Yuanzheng; Li, Shanshan; Lin, Jia-yuh; Yu, Keqin; Liu, Mu; Yang, Lei; Luo, Jianguang; Chen, Yijun; Sun, Hongbin; Kong, Lingyi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2718-2731</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Targeting signal transducer and activator of transcription 3 (STAT3) is a potential anticancer strategy.  However, STAT3 inhibitors with good selectivity and bioavailability are rare.  The aim of this study was to discover selective direct STAT3 inhibitors with good drug-likeness.  By advanced multiple ligand simultaneous docking (AMLSD) method, compd. 9 (5,8-dioxo-6-((2-(piperazin-1-yl)phenyl)amino)-5,8-dihydronaphthalene-1-sulfonamide) was designed as an orally-bioavailable STAT3 inhibitor, which presented superior druggability and selectivity to other representative STAT3 inhibitors.  Compd. 9 directly and selectively inhibited the pY705 site of STAT3 with an affinity (Ki) of 440nM.  The IC50 of 9 for breast cancer cell MDA-MB-231 was 184-fold lower than its IC50 for normal breast epithelial cell MCF-10A.  Compd. 9 in vivo induced significant antitumor responses better than Gefitinib and its therapeutic index should be over 100, indicating good safety of 9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiT8F_tCrky7Vg90H21EOLACvtfcHk0lgr26K8UZD8gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjsFalurw%253D&md5=d9554e49fd17a559e8c7171f36c53607</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01489%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DXia%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DJ.-y.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DKong%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520an%2520Orally%2520Selective%2520Inhibitor%2520of%2520Signal%2520Transducer%2520and%2520Activator%2520of%2520Transcription%25203%2520Using%2520Advanced%2520Multiple%2520Ligand%2520Simultaneous%2520Docking%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2718%26epage%3D2731%26doi%3D10.1021%2Facs.jmedchem.6b01489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of Monocarbonyl Curcumin-Btp Hybrids as Stat3 Inhibitors for Drug-Sensitive and Drug-Resistant Breast Cancer Therapy</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">46352</span>, <span class="refDoi"> DOI: 10.1038/srep46352</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1038%2Fsrep46352" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=28397855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtVyitbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=46352&author=W.+Zhangauthor=J.+Guoauthor=S.+Liauthor=T.+Maauthor=D.+Xuauthor=C.+Hanauthor=F.+Liuauthor=W.+Yuauthor=L.+Kong&title=Discovery+of+Monocarbonyl+Curcumin-Btp+Hybrids+as+Stat3+Inhibitors+for+Drug-Sensitive+and+Drug-Resistant+Breast+Cancer+Therapy&doi=10.1038%2Fsrep46352"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of monocarbonyl curcumin-BTP hybrids as STAT3 inhibitors for drug-sensitive and drug-resistant breast cancer therapy</span></div><div class="casAuthors">Zhang, Wenda; Guo, Jianpeng; Li, Shanshan; Ma, Ting; Xu, Dingqiao; Han, Chao; Liu, Feiyan; Yu, Wenying; Kong, Lingyi</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">46352</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) is a well-known antitumor target.  Exogenous ROS insult can lead to selective cytotoxicity against cancer cells.  A combination of STAT3 inhibition and "oxidn. therapy" may be a new strategy to address the multidrug-resistance issue due to their important roles in the survival and drug resistance of cancer cells.  Here, a series of novel curcumin-BTP hybrids were designed and evaluated as STAT3 inhibitors with ROS prodn. activity.  Compd. 6b exerted the best antitumor activity and selectivity for MCF-7 and MCF-7/DOX cells (IC50 = 0.52 μM and 0.40 μM, resp.), while its IC50 value for MCF-10A breast epithelial cells was 7.72 μM.  Furthermore, compd. 6b suppressed STAT3 phosphorylation, nuclear translocation and DNA-binding activity and the expression of STAT3 specific oncogenes.  Increases in the level of IL-6-induced p-STAT3 were also inhibited by 6b without influencing IFN-γ-induced p-STAT1 expression.  Addnl., 6b effectively promoted intracellular ROS accumulation, induced cancer cell apoptosis and cell cycle arrest, abolished the colony formation ability of breast cancer cells, and inhibited P-gp expression in MCF-7/DOX cells.  Finally, 6b suppressed the growth of implanted human breast cancer in vivo.  Our findings highlight that 6b may be a promising therapeutic agent for drug-sensitive and drug-resistant breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxX6NWyOZ_v7Vg90H21EOLACvtfcHk0lgXFnl7f3R8Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtVyitbc%253D&md5=aa97b030e4e00945730f51a47f41837e</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fsrep46352&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep46352%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DMa%26aufirst%3DT.%26aulast%3DXu%26aufirst%3DD.%26aulast%3DHan%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DKong%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520Monocarbonyl%2520Curcumin-Btp%2520Hybrids%2520as%2520Stat3%2520Inhibitors%2520for%2520Drug-Sensitive%2520and%2520Drug-Resistant%2520Breast%2520Cancer%2520Therapy%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D46352%26doi%3D10.1038%2Fsrep46352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.</span></span> <span> </span><span class="NLM_article-title">Antagonizing Stat3 Activation with Benzo B Thiophene 1, 1-Dioxide Based Small Molecules</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">538</span>– <span class="NLM_lpage">550</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.09.068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1016%2Fj.ejmech.2016.09.068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=27718470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1ejtL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2017&pages=538-550&author=W.+Zhangauthor=T.+Maauthor=S.+Liauthor=Y.+Yangauthor=J.+Guoauthor=W.+Yuauthor=L.+Kong&title=Antagonizing+Stat3+Activation+with+Benzo+B+Thiophene+1%2C+1-Dioxide+Based+Small+Molecules&doi=10.1016%2Fj.ejmech.2016.09.068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Antagonizing STAT3 activation with benzo[b]thiophene 1, 1-dioxide based small molecules</span></div><div class="casAuthors">Zhang, Wenda; Ma, Ting; Li, Shanshan; Yang, Yanwei; Guo, Jianpeng; Yu, Wenying; Kong, Lingyi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">538-550</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">STAT3 is an attractive therapeutic target for cancer therapy.  However, due to low potency or poor druggability, none of its inhibitors are clin. available.  Herein, a series of aminobenzo[b]thiophene 1,1-dioxides with good drug-likeness properties were designed, synthesized and evaluated as STAT3 inhibitors.  Most of them exhibited higher antitumor activity than the small-mol. STAT3 inhibitor, Stattic.  Compd. I was the most potent and had an IC50 range in 0.33-0.75 μM in various cancer cell lines.  The overexpressed and IL-6 induced phosphorylation levels of STAT3 were both inhibited by I without influencing the phosphorylation levels of the upstream kinases Src and Jak2. 15 also suppressed the expressions of STAT3 downstream gene, Bcl-2.  I also suppressed the expressions of STAT3 downstream gene, Bcl-2.  I effectively increased the ROS levels of cancer cells, induced cancer cell apoptosis, and abolished the colony formation ability of cancer cells without affecting bypass kinase p-Erk.  Furthermore, I in vivo induced significant antitumor responses, and exhibited less toxicity than Doxorubicin.  Together, this study described a class of new STAT3 inhibitors as antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4EWN80TpUpbVg90H21EOLACvtfcHk0lgXFnl7f3R8Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1ejtL7I&md5=395e6ea180776127e98bc2a92f3d603b</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.09.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.09.068%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DMa%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DKong%26aufirst%3DL.%26atitle%3DAntagonizing%2520Stat3%2520Activation%2520with%2520Benzo%2520B%2520Thiophene%25201%252C%25201-Dioxide%2520Based%2520Small%2520Molecules%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D125%26spage%3D538%26epage%3D550%26doi%3D10.1016%2Fj.ejmech.2016.09.068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of New Benzensulfonamide Derivatives as Tripedal Stat3 Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">752</span>– <span class="NLM_lpage">764</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.03.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1016%2Fj.ejmech.2018.03.053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=29674294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnslSru7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2018&pages=752-764&author=J.+Guoauthor=W.+Yuauthor=G.+Caiauthor=W.+Zhangauthor=S.+Liauthor=J.+Zhuauthor=D.+Songauthor=L.+Kong&title=Discovery+of+New+Benzensulfonamide+Derivatives+as+Tripedal+Stat3+Inhibitors&doi=10.1016%2Fj.ejmech.2018.03.053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of new benzensulfonamide derivatives as tripedal STAT3 inhibitors</span></div><div class="casAuthors">Guo, Jianpeng; Yu, Wenying; Cai, Guiping; Zhang, Wenda; Li, Shanshan; Zhu, Jiawen; Song, Dongmei; Kong, Lingyi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">752-764</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Persistent activated STAT3 has a striking correlation with cancer development and inhibition of STAT3 signaling pathway is a novel therapeutic way for human cancers.  Among STAT family, STAT1 and STAT3 play opposite roles in tumorigenesis.  However, the discovery of selective STAT3 inhibitors is still challenging to date.  In this study, a series of small-mol. (MW<500) benzensulfanilamide derivs. were designed to selectively suppress STAT3 activation for anti-cancer treatment.  The most potent compd. 11 inhibited both overexpressed and IL-6 induced STAT3 phosphorylation, whereas 11 displayed little effect on the phosphorylation of other STAT isoforms STAT1, STAT5, demonstrating 11 was a selective STAT3 inhibitor.  Meanwhile, 11 dismissed STAT3 DNA binding activity and colony formation.  In addn., 11 elevated the ROS level and induced apoptosis of cancer cells.  Furthermore, 11 effectively suppressed tumor growth in an in vivo mouse-xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjwneUbz5BgbVg90H21EOLACvtfcHk0lgXFnl7f3R8Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnslSru7w%253D&md5=9f46716463f5610a25bffcfb85b2031a</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.053%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DCai%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DSong%26aufirst%3DD.%26aulast%3DKong%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520New%2520Benzensulfonamide%2520Derivatives%2520as%2520Tripedal%2520Stat3%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D151%26spage%3D752%26epage%3D764%26doi%3D10.1016%2Fj.ejmech.2018.03.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.</span></span> <span> </span><span class="NLM_article-title">A New Synthetic Derivative of Cryptotanshinone Kyz3 as Stat3 Inhibitor for Triple-Negative Breast Cancer Therapy</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1098</span>, <span class="refDoi"> DOI: 10.1038/s41419-018-1139-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1038%2Fs41419-018-1139-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=30368518" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A280%3ADC%252BB3cvktVGitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1098&author=W.+Zhangauthor=W.+Yuauthor=G.+Caiauthor=J.+Zhuauthor=C.+Zhangauthor=S.+Liauthor=J.+Guoauthor=G.+Yinauthor=C.+Chenauthor=L.+Kong&title=A+New+Synthetic+Derivative+of+Cryptotanshinone+Kyz3+as+Stat3+Inhibitor+for+Triple-Negative+Breast+Cancer+Therapy&doi=10.1038%2Fs41419-018-1139-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">A new synthetic derivative of cryptotanshinone KYZ3 as STAT3 inhibitor for triple-negative breast cancer therapy</span></div><div class="casAuthors">Zhang Wenda; Yu Wenying; Cai Guiping; Zhu Jiawen; Zhang Chao; Li Shanshan; Guo Jianpeng; Yin Guoping; Chen Chen; Kong Lingyi</div><div class="citationInfo"><span class="NLM_cas:title">Cell death & disease</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1098</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Silencing STAT3 is confirmed as a promising therapeutic strategy for triple-negative breast cancer (TNBC) therapy to address the issue of its poor prognosis.  In this study, the natural product cryptotanshinone was firstly remodeled and modified as a more effective STAT3 inhibitor by structure-based strategy.  The synthetic derivative KYZ3 had 22-24-fold increase in antitumor activity than cryptotanshinone on two TNBC cell lines but had little effect on normal breast epithelial MCF-10A cells.  Further investigation showed that KYZ3 inhibited persistent STAT3 phosphorylation.  It also prevented the STAT3 protein nuclear translocation to regulate the expressions of the target oncogenes including Bax and Bcl-2.  Furthermore, KYZ3 inhibited TNBC cell metastasis by decreasing the levels of MMP-9 which were directly regulated by activated STAT3.  A STAT3 plasmid transfecting assay suggested that KYZ3 induced tumor cell apoptosis mainly by targeting STAT3.  Finally, KYZ3 suppressed the growth of tumors resulting from subcutaneous implantation of MDA-MB-231 cells in vivo.  Taken together, KYZ3 may be a promising cancer therapeutic agent for TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT8cW2iZzjIi7YtC3U5jeOifW6udTcc2ea2y8In5Tw2prntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvktVGitg%253D%253D&md5=6900636d864146ab6c03dd4378075316</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fs41419-018-1139-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41419-018-1139-z%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DCai%26aufirst%3DG.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DYin%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DKong%26aufirst%3DL.%26atitle%3DA%2520New%2520Synthetic%2520Derivative%2520of%2520Cryptotanshinone%2520Kyz3%2520as%2520Stat3%2520Inhibitor%2520for%2520Triple-Negative%2520Breast%2520Cancer%2520Therapy%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2018%26volume%3D9%26spage%3D1098%26doi%3D10.1038%2Fs41419-018-1139-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of Fluorescent Coumarin-Benzo B Thiophene 1, 1-Dioxide Conjugates as Mitochondria-Targeting Antitumor Stat3 Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">236</span>– <span class="NLM_lpage">251</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.04.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1016%2Fj.ejmech.2019.04.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=31048139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC1MXovVOju7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2019&pages=236-251&author=G.+Caiauthor=W.+Yuauthor=D.+Songauthor=W.+Zhangauthor=J.+Guoauthor=J.+Zhuauthor=Y.+Renauthor=L.+Kong&title=Discovery+of+Fluorescent+Coumarin-Benzo+B+Thiophene+1%2C+1-Dioxide+Conjugates+as+Mitochondria-Targeting+Antitumor+Stat3+Inhibitors&doi=10.1016%2Fj.ejmech.2019.04.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of fluorescent coumarin-benzo[b]thiophene 1, 1-dioxide conjugates as mitochondria-targeting antitumor STAT3 inhibitors</span></div><div class="casAuthors">Cai, Guiping; Yu, Wenying; Song, Dongmei; Zhang, Wenda; Guo, Jianpeng; Zhu, Jiawen; Ren, Yuhao; Kong, Lingyi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">236-251</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">STAT3 has been extensively studied as a potential antitumor target.  Though studies on regulating STAT3 mainly focus on the inhibition of STAT3 phosphorylation at Tyr705 residue, the phosphorylation at Ser727 residue of STAT3 protein is also closely assocd. with the mitochondrial import of STAT3 protein.  N, N-diethyl-7-aminocoumarin is a fluorescent mitochondria-targeting probe.  In this study, a series of STAT3 inhibitors were developed by connecting N, N-diethyl-7-aminocoumarin fluorophore with benzo [b]thiophene 1, 1-dioxide moiety.  All designed compds. displayed potent anti-proliferative activity against cancer cells.  The representative compd. 7a(I) was mainly accumulated in mitochondria visualized by its fluorescence.  STAT3 phosphorylation was inhibited by I at both Tyr705 and Ser727 residues.  I inhibited STAT3 phosphorylation whereas had no influence on the phosphorylation levels of STAT1, JAK2, Src and Erk1/2, indicating good selectivity of I.  Moreover, I down-regulated the expression of STAT3 target genes Bcl-2 and Cyclin D1, increased ROS prodn. and remarkably reduced the mitochondrial membrane potential to induce mitochondrial apoptotic pathway.  Furthermore, I in vivo suppressed breast cancer 4T1 implanted tumor growth.  Taken together, these results highlighted that I might be a promising mitochondria-targeting STAT3 inhibitor for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqliPyZjY43-rVg90H21EOLACvtfcHk0ljMGk8iyDE_Bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXovVOju7o%253D&md5=5c1e2def16a6656c2d56cfe59168053c</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.04.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.04.024%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DG.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DSong%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DKong%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520Fluorescent%2520Coumarin-Benzo%2520B%2520Thiophene%25201%252C%25201-Dioxide%2520Conjugates%2520as%2520Mitochondria-Targeting%2520Antitumor%2520Stat3%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D174%26spage%3D236%26epage%3D251%26doi%3D10.1016%2Fj.ejmech.2019.04.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glackin, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dellinger, T. H.</span></span> <span> </span><span class="NLM_article-title">Pterostilbene Suppresses Ovarian Cancer Growth Via Induction of Apoptosis and Blockade of Cell Cycle Progression Involving Inhibition of the Stat3 Pathway</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1983</span>, <span class="refDoi"> DOI: 10.3390/ijms19071983</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.3390%2Fijms19071983" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFKlsb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=1983&author=W.+Wenauthor=G.+Loweauthor=C.+M.+Robertsauthor=J.+Finlayauthor=E.+S.+Hanauthor=C.+A.+Glackinauthor=T.+H.+Dellinger&title=Pterostilbene+Suppresses+Ovarian+Cancer+Growth+Via+Induction+of+Apoptosis+and+Blockade+of+Cell+Cycle+Progression+Involving+Inhibition+of+the+Stat3+Pathway&doi=10.3390%2Fijms19071983"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Pterostilbene suppresses ovarian cancer growth via induction of apoptosis and blockade of cell cycle progression involving inhibition of the STAT3 pathway</span></div><div class="casAuthors">Wen, Wei; Lowe, Gina; Roberts, Cai M.; Finlay, James; Han, Ernest S.; Glackin, Carlotta A.; Dellinger, Thanh Hue</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1983/1-1983/12</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A growing body of evidence has demonstrated the promising anti-tumor effects of resveratrol in ovarian cancer cells, including its inhibitory effects on STAT3 activation.  Nonetheless, the low bioavailability of resveratrol has reduced its attractiveness as a potential anti-cancer treatment.  In contrast, pterostilbene, a stilbenoid and resveratrol analog, has demonstrated superior bioavailability, while possessing significant antitumor activity in multiple solid tumors.  In this study, the therapeutic potential of pterostilbene was evaluated in ovarian cancer cells.  Further mol. study has shown that pterostilbene effectively suppressed phosphorylation of STAT3, as well as STAT3 downstream genes that regulate cell cycle and apoptosis, indicating that inhibition of STAT3 pathway may be involved in its anti-tumor activity.  The addn. of pterostilbene to the commonly used chemotherapy cisplatin demonstrated synergistic antiproliferative activity in several ovarian cancer cell lines.  Pterostilbene addnl. inhibited cell migration in multiple ovarian cancer cell lines.  The above results suggest that pterostilbene facilitates significant anti-tumor activity in ovarian cancer via anti-proliferative and pro-apoptotic mechanisms, possibly via downregulation of JAK/STAT3 pathway.  Pterostilbene thus presents as an attractive non-toxic alternative for potential adjuvant or maintenance chemotherapy in ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJSeyyDGs9IrVg90H21EOLACvtfcHk0ljMGk8iyDE_Bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFKlsb3O&md5=4134fbeb7185678e2da0bdcbd6cee181</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.3390%2Fijms19071983&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms19071983%26sid%3Dliteratum%253Aachs%26aulast%3DWen%26aufirst%3DW.%26aulast%3DLowe%26aufirst%3DG.%26aulast%3DRoberts%26aufirst%3DC.%2BM.%26aulast%3DFinlay%26aufirst%3DJ.%26aulast%3DHan%26aufirst%3DE.%2BS.%26aulast%3DGlackin%26aufirst%3DC.%2BA.%26aulast%3DDellinger%26aufirst%3DT.%2BH.%26atitle%3DPterostilbene%2520Suppresses%2520Ovarian%2520Cancer%2520Growth%2520Via%2520Induction%2520of%2520Apoptosis%2520and%2520Blockade%2520of%2520Cell%2520Cycle%2520Progression%2520Involving%2520Inhibition%2520of%2520the%2520Stat3%2520Pathway%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2018%26volume%3D19%26spage%3D1983%26doi%3D10.3390%2Fijms19071983" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, P.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagabhushanam, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, M.-H.</span></span> <span> </span><span class="NLM_article-title">3 ’-Hydroxypterostilbene Suppresses Colitis-Associated Tumorigenesis by Inhibition of Il-6/Stat3 Signaling in Mice</span>. <i>J. Agric. Food Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">9655</span>– <span class="NLM_lpage">9664</span>, <span class="refDoi"> DOI: 10.1021/acs.jafc.7b03712</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jafc.7b03712" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1CqtL3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2017&pages=9655-9664&author=C.-S.+Laiauthor=G.+Yangauthor=S.+Liauthor=P.-S.+Leeauthor=B.+N.+Wangauthor=M.-C.+Chungauthor=K.+Nagabhushanamauthor=C.-T.+Hoauthor=M.-H.+Pan&title=3+%E2%80%99-Hydroxypterostilbene+Suppresses+Colitis-Associated+Tumorigenesis+by+Inhibition+of+Il-6%2FStat3+Signaling+in+Mice&doi=10.1021%2Facs.jafc.7b03712"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">3'-Hydroxypterostilbene Suppresses Colitis-Associated Tumorigenesis by Inhibition of IL-6/STAT3 Signaling in Mice</span></div><div class="casAuthors">Lai, Ching-Shu; Yang, Guliang; Li, Shiming; Lee, Pei-Sheng; Wang, Bi-Ni; Chung, Min-Ching; Nagabhushanam, Kalyanam; Ho, Chi-Tang; Pan, Min-Hsiung</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Agricultural and Food Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">9655-9664</span>CODEN:
                <span class="NLM_cas:coden">JAFCAU</span>;
        ISSN:<span class="NLM_cas:issn">0021-8561</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">3'-Hydroxypterostilbene (trans-3,5-dimethoxy-3',4'-hydroxystilbene) presents in Sphaerophysa salsula, Pterocarpus marsupium, and honey bee propolis and has been reported to exhibit several biol. activities.  Herein, the authors aimed to explore the chemopreventive effects of dietary 3'-hydroxypterostilbene and underlying mol. mechanisms on colitis-assocd. cancer using the azoxymethane (AOM)/dextran sodium sulfate (DSS) model.  3'-Hydroxypterostilbene administration effectively ameliorated the colon shortening and no. of tumors in AOM/DSS-treated mice (3.2±1.2 of the high-dose treatment vs. 13.8±5.3 of the AOM/DSS group, p < 0.05).  Mol. anal. exhibited the anti-inflammatory activity of 3'-hydroxypterostilbene by a significant decrease in the levels of inducible nitric oxide synthase, cyclooxygenase-2, and interleukin-6 (IL-6) (p < 0.05).  Moreover, dietary 3'-hydroxypterostilbene also significantly diminished IL-6/signal transducer and activator of transcription signaling and restored colonic suppressor of cytokine signaling 3 levels in the colonic tissue of mice (p < 0.05).  Collectively, these results demonstrated for the first time the in vivo chemopreventive efficacy and mol. mechanisms of dietary 3'-hydroxypterostilbene against colitis-assocd. colonic tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBzhnqQkC-QbVg90H21EOLACvtfcHk0lg3bXij3MQTkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1CqtL3P&md5=613efde5fbdcd6d2d5e56829bb5479c4</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Facs.jafc.7b03712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jafc.7b03712%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DC.-S.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DP.-S.%26aulast%3DWang%26aufirst%3DB.%2BN.%26aulast%3DChung%26aufirst%3DM.-C.%26aulast%3DNagabhushanam%26aufirst%3DK.%26aulast%3DHo%26aufirst%3DC.-T.%26aulast%3DPan%26aufirst%3DM.-H.%26atitle%3D3%2520%25E2%2580%2599-Hydroxypterostilbene%2520Suppresses%2520Colitis-Associated%2520Tumorigenesis%2520by%2520Inhibition%2520of%2520Il-6%252FStat3%2520Signaling%2520in%2520Mice%26jtitle%3DJ.%2520Agric.%2520Food%2520Chem.%26date%3D2017%26volume%3D65%26spage%3D9655%26epage%3D9664%26doi%3D10.1021%2Facs.jafc.7b03712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riche, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEwen, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riche, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wofford, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschamp, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griswold, M.</span></span> <span> </span><span class="NLM_article-title">Analysis of Safety from a Human Clinical Trial with Pterostilbene</span>. <i>J. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2013</i></span>,  <span class="NLM_fpage">463595</span>, <span class="refDoi"> DOI: 10.1155/2013/463595</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1155%2F2013%2F463595" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=23431291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A280%3ADC%252BC3svgsVKhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2013&publication_year=2013&pages=463595&author=D.+M.+Richeauthor=C.+L.+McEwenauthor=K.+D.+Richeauthor=J.+J.+Shermanauthor=M.+R.+Woffordauthor=D.+Deschampauthor=M.+Griswold&title=Analysis+of+Safety+from+a+Human+Clinical+Trial+with+Pterostilbene&doi=10.1155%2F2013%2F463595"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of safety from a human clinical trial with pterostilbene</span></div><div class="casAuthors">Riche Daniel M; McEwen Corey L; Riche Krista D; Sherman Justin J; Wofford Marion R; Deschamp David; Griswold Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of toxicology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">2013</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">463595</span>
        ISSN:<span class="NLM_cas:issn">1687-8191</span>.
    </div><div class="casAbstract">Objectives.  The purpose of this trial was to evaluate the safety of long-term pterostilbene administration in humans.  Methodology.  The trial was a prospective, randomized, double-blind placebo-controlled intervention trial enrolling patients with hypercholesterolemia (defined as a baseline total cholesterol ≥200 mg/dL and/or baseline low-density lipoprotein cholesterol ≥100 mg/dL).  Eighty subjects were divided equally into one of four groups: (1) pterostilbene 125 mg twice daily, (2) pterostilbene 50 mg twice daily, (3) pterostilbene 50 mg + grape extract (GE) 100 mg twice daily, and (4) matching placebo twice daily for 6-8 weeks.  Safety markers included biochemical and subjective measures.  Linear mixed models were used to estimate primary safety measure treatment effects.  Results.  The majority of patients completed the trial (91.3%).  The average age was 54 years.  The majority of patients were females (71%) and Caucasians (70%).  There were no adverse drug reactions (ADRs) on hepatic, renal, or glucose markers based on biochemical analysis.  There were no statistically significant self-reported or major ADRs.  Conclusion.  Pterostilbene is generally safe for use in humans up to 250 mg/day.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTZJGbrCaVVVRJ5E29YNGvQfW6udTcc2eaxdOL3Mvlx2rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3svgsVKhsw%253D%253D&md5=5e3c5ede66637fddb8c637cdc0757b47</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1155%2F2013%2F463595&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2013%252F463595%26sid%3Dliteratum%253Aachs%26aulast%3DRiche%26aufirst%3DD.%2BM.%26aulast%3DMcEwen%26aufirst%3DC.%2BL.%26aulast%3DRiche%26aufirst%3DK.%2BD.%26aulast%3DSherman%26aufirst%3DJ.%2BJ.%26aulast%3DWofford%26aufirst%3DM.%2BR.%26aulast%3DDeschamp%26aufirst%3DD.%26aulast%3DGriswold%26aufirst%3DM.%26atitle%3DAnalysis%2520of%2520Safety%2520from%2520a%2520Human%2520Clinical%2520Trial%2520with%2520Pterostilbene%26jtitle%3DJ.%2520Toxicol.%26date%3D2013%26volume%3D2013%26spage%3D463595%26doi%3D10.1155%2F2013%2F463595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picó, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mañes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asensi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asensio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrela, J. M.</span></span> <span> </span><span class="NLM_article-title">Dietary Administration of High Doses of Pterostilbene and Quercetin to Mice Is Not Toxic</span>. <i>J. Agric. Food Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3180</span>– <span class="NLM_lpage">3186</span>, <span class="refDoi"> DOI: 10.1021/jf803579e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jf803579e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjt1Gqurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2009&pages=3180-3186&author=M.+J.+Ruizauthor=M.+Fern%C3%A1ndezauthor=Y.+Pic%C3%B3author=J.+Ma%C3%B1esauthor=M.+Asensiauthor=C.+Cardaauthor=G.+Asensioauthor=J.+M.+Estrela&title=Dietary+Administration+of+High+Doses+of+Pterostilbene+and+Quercetin+to+Mice+Is+Not+Toxic&doi=10.1021%2Fjf803579e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Dietary Administration of High Doses of Pterostilbene and Quercetin to Mice Is Not Toxic</span></div><div class="casAuthors">Ruiz, M. J.; Fernandez, M.; Pico, Y.; Manes, J.; Asensi, M.; Carda, C.; Asensio, G.; Estrela, J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Agricultural and Food Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3180-3186</span>CODEN:
                <span class="NLM_cas:coden">JAFCAU</span>;
        ISSN:<span class="NLM_cas:issn">0021-8561</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The aim of this study is to evaluate possible harmful effects of high doses of t-pterostilbene (t-PTER) and quercetin (QUER) in Swiss mice.  Mice were fed during 28 days at doses of 0, 30, 300, and 3000 mg/kg body wt./day of t-PTER, QUER, or a mixt. of both, t-PTER + QUER, which are equiv. to 5, 50, and 500 times, resp., the estd. mean human intake of these polyphenols (25 mg/day).  Daily oral administration of QUER, t-PTER, or a mixt. of both of them did not cause mortality during the exptl. period.  There were no differences in food and water consumption on sex.  No significant body wt. gain in the male or female groups was obsd.  Red blood cell no. and the hematocrit increased after polyphenols administration compared to control groups.  Biochem. parameters were not affected.  Histopathol. examn. revealed no alterations in clin. signs or organ wt. at any dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxJmJPNnBaSLVg90H21EOLACvtfcHk0lg3bXij3MQTkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjt1Gqurg%253D&md5=1f673f6cdb23f96431f0a43517e7d526</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fjf803579e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjf803579e%26sid%3Dliteratum%253Aachs%26aulast%3DRuiz%26aufirst%3DM.%2BJ.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DM.%26aulast%3DPic%25C3%25B3%26aufirst%3DY.%26aulast%3DMa%25C3%25B1es%26aufirst%3DJ.%26aulast%3DAsensi%26aufirst%3DM.%26aulast%3DCarda%26aufirst%3DC.%26aulast%3DAsensio%26aufirst%3DG.%26aulast%3DEstrela%26aufirst%3DJ.%2BM.%26atitle%3DDietary%2520Administration%2520of%2520High%2520Doses%2520of%2520Pterostilbene%2520and%2520Quercetin%2520to%2520Mice%2520Is%2520Not%2520Toxic%26jtitle%3DJ.%2520Agric.%2520Food%2520Chem.%26date%3D2009%26volume%3D57%26spage%3D3180%26epage%3D3186%26doi%3D10.1021%2Fjf803579e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leland, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, M.-H.</span></span> <span> </span><span class="NLM_article-title">Occurrence, Bioavailability, Anti-Inflammatory, and Anticancer Effects of Pterostilbene</span>. <i>J. Agric. Food Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">12788</span>– <span class="NLM_lpage">12799</span>, <span class="refDoi"> DOI: 10.1021/acs.jafc.9b07860</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jafc.9b07860" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjt1ynsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2020&pages=12788-12799&author=W.-S.+Linauthor=J.+V.+Lelandauthor=C.-T.+Hoauthor=M.-H.+Pan&title=Occurrence%2C+Bioavailability%2C+Anti-Inflammatory%2C+and+Anticancer+Effects+of+Pterostilbene&doi=10.1021%2Facs.jafc.9b07860"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Occurrence, Bioavailability, Anti-inflammatory, and Anticancer Effects of Pterostilbene</span></div><div class="casAuthors">Lin, Wei-Sheng; Leland, Jane Valorie; Ho, Chi-Tang; Pan, Min-Hsiung</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Agricultural and Food Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">12788-12799</span>CODEN:
                <span class="NLM_cas:coden">JAFCAU</span>;
        ISSN:<span class="NLM_cas:issn">0021-8561</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Supplementation with natural compds. found in fruits and vegetables has long been assocd. with a reduced risk of several types of cancer.  Pterostilbene is a natural stilbenoid and a dimethylated analog of resveratrol which is found primarily in blueberries.  Pterostilbene exhibits a range of pharmacol. properties, particularly anti-inflammatory and anticancer effects.  Due to two methoxy groups in its skeleton, pterostilbene is more lipophilic than resveratrol and thus possesses higher intestinal permeability and cellular uptake and enhanced stability.  Moreover, pterostilbene exhibits less toxicity and fewer adverse effects, providing it with superior potential in cancer chemoprevention and chemotherapy applications.  Numerous research studies have demonstrated that pterostilbene possesses detoxification activities, mediating the anti-inflammation response, regulating the cell cycle, augmenting apoptosis, enhancing autophagy, and inhibiting tumor angiogenesis, invasion, and metastasis by modulating signal transduction pathways which block multiple stages of carcinogenesis.  In this review, we illustrate that pterostilbene is a natural compd. having bioavailability.  The extensive metab. of pterostilbene will be discussed.  We also summarize recent research on pterostilbene's anti-inflammatory and anticancer properties in the multistage carcinogenesis process and related mol. mechanism and conclude that it should contribute to improved cancer management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiDslD0pbUK7Vg90H21EOLACvtfcHk0liiPd8PF3CsXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjt1ynsbs%253D&md5=6d036321a2e4e8cca57073a6e925bc7c</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facs.jafc.9b07860&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jafc.9b07860%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DW.-S.%26aulast%3DLeland%26aufirst%3DJ.%2BV.%26aulast%3DHo%26aufirst%3DC.-T.%26aulast%3DPan%26aufirst%3DM.-H.%26atitle%3DOccurrence%252C%2520Bioavailability%252C%2520Anti-Inflammatory%252C%2520and%2520Anticancer%2520Effects%2520of%2520Pterostilbene%26jtitle%3DJ.%2520Agric.%2520Food%2520Chem.%26date%3D2020%26volume%3D68%26spage%3D12788%26epage%3D12799%26doi%3D10.1021%2Facs.jafc.9b07860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of Bazedoxifene Analogues Targeting Glycoprotein 130</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>199</i></span>,  <span class="NLM_fpage">112375</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112375</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1016%2Fj.ejmech.2020.112375" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=32388278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BB3cXptVemtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=199&publication_year=2020&pages=112375&author=D.+Songauthor=W.+Yuauthor=Y.+Renauthor=J.+Zhuauthor=C.+Wanauthor=G.+Caiauthor=J.+Guoauthor=W.+Zhangauthor=L.+Kong&title=Discovery+of+Bazedoxifene+Analogues+Targeting+Glycoprotein+130&doi=10.1016%2Fj.ejmech.2020.112375"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of bazedoxifene analogues targeting glycoprotein 130</span></div><div class="casAuthors">Song, Dongmei; Yu, Wenying; Ren, Yuhao; Zhu, Jiawen; Wan, Chengying; Cai, Guiping; Guo, Jianpeng; Zhang, Wenda; Kong, Lingyi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">199</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112375</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Deregulation of GP130 in signal transduction is involved in multiple types of human diseases, esp. in cancers, indicating that GP130 is an attractive target for cancer therapy.  However, GP130 was conventionally considered as an undruggable target thus the discovery of GP130 PPI inhibitors is extremely challenging.  By the aid of structure-based drug design, in this study, two series of bazedoxifene based analogs were designed to target GP130 D1 domain and block the IL-6/GP130/STAT3 signaling pathway for antitumor treatment.  Most of these designed compds. displayed potent anti-proliferative activity against cancer cells.  The representative compd. 10a was demonstrated to directly bind to GP130 protein with an affinity (KD) value of 3.8μM via both SPR and DARTS methods.  Subsequently, mol. docking study predicted that 10a targeted D1 domain of GP130 and co-IP assay demonstrated that 10a did not inhibit IL-6R/GP130 interaction, which meant 10a did not bind to the D2 and D3 domains of GP130.  Moreover, 10a selectively inhibited JAK2 and STAT3 phosphorylation as well as IL-6 induced STAT3 phosphorylation. 10a effectively inhibited tumor cell viability, migration and promoted apoptosis.  Furthermore, 10a effectively suppressed xenograft model tumor growth in vivo.  Taken together, this study described a new class of bazedoxifene derived GP130 inhibitors as antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriRN9ycYJhvrVg90H21EOLACvtfcHk0liiPd8PF3CsXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXptVemtrc%253D&md5=ba0799bd77a5af1fea9283f3a595f29a</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112375&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112375%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DC.%26aulast%3DCai%26aufirst%3DG.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DKong%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520Bazedoxifene%2520Analogues%2520Targeting%2520Glycoprotein%2520130%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D199%26spage%3D112375%26doi%3D10.1016%2Fj.ejmech.2020.112375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simic, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela Parada, X. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dellinger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guarente, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhee, E. P.</span></span> <span> </span><span class="NLM_article-title">Nicotinamide Riboside with Pterostilbene (Nrpt) Increases Nad(+) in Patients with Acute Kidney Injury (Aki): A Randomized, Double-Blind, Placebo-Controlled, Stepwise Safety Study of Escalating Doses of Nrpt in Patients with Aki</span>. <i>BMC Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">342</span>, <span class="refDoi"> DOI: 10.1186/s12882-020-02006-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1186%2Fs12882-020-02006-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=32791973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1WisbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=342&author=P.+Simicauthor=X.+F.+Vela+Paradaauthor=S.+M.+Parikhauthor=R.+Dellingerauthor=L.+P.+Guarenteauthor=E.+P.+Rhee&title=Nicotinamide+Riboside+with+Pterostilbene+%28Nrpt%29+Increases+Nad%28%2B%29+in+Patients+with+Acute+Kidney+Injury+%28Aki%29%3A+A+Randomized%2C+Double-Blind%2C+Placebo-Controlled%2C+Stepwise+Safety+Study+of+Escalating+Doses+of+Nrpt+in+Patients+with+Aki&doi=10.1186%2Fs12882-020-02006-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Nicotinamide riboside with pterostilbene (NRPT) increases NAD positive in patients with acute kidney injury (AKI): a randomized, double-blind, placebo-controlled, stepwise safety study of escalating doses of NRPT in patients with AKI</span></div><div class="casAuthors">Simic, Petra; Vela Parada, Xavier Fernando; Parikh, Samir M.; Dellinger, Ryan; Guarente, Leonard P.; Rhee, Eugene P.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Nephrology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">342</span>CODEN:
                <span class="NLM_cas:coden">BNMEB7</span>;
        ISSN:<span class="NLM_cas:issn">1471-2369</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Preclin. studies have identified both NAD+ and sirtuin augmentation as potential strategies for the prevention and treatment of AKI.  Nicotinamide riboside (NR) is a NAD+ precursor vitamin and pterostilbene (PT) is potent sirtuin activator found in blueberries.  Here, we tested the effect of combined NR and PT (NRPT) on whole blood NAD+ levels and safety parameters in patients with AKI.  We conducted a randomized, double-blind, placebo-controlled study of escalating doses of NRPT in 24 hospitalized patients with AKI.  The study was comprised of four Steps during which NRPT (5 subjects) or placebo (1 subject) was given twice a day for 2 days.  NRPT dosing was increased in each Step: Step 1250/50 mg, Step 2500/100 mg, Step 3750/150 mg and Step 41,000/200 mg.  Blood NAD+ levels were measured by liq. chromatog.-mass spectrometry and safety was assessed by history, phys. exam, and clin. lab. testing.  AKI resulted in a 50% redn. in whole blood NAD+ levels at 48 h compared to 0 h in patients receiving placebo (p = 0.05).  There was a trend for increase in NAD+ levels in all NRPT Steps individually at 48 h compared to 0 h, but only the change in Step 2 reached statistical significance (47%, p = 0.04), and there was considerable interindividual variability in the NAD+ response to treatment.  Considering all Steps together, NRPT treatment increased NAD+ levels by 37% at 48 h compared to 0 h (p = 0.002).  All safety lab. tests were unchanged by NRPT treatment, including creatinine, estd. glomerular filtration rate (eGFR), electrolytes, liver function tests, and blood counts.  Three of 20 patients receiving NRPT reported minor gastrointestinal side effects.  NRPT increases whole blood NAD+ levels in hospitalized patients with AKI.  In addn., NRPT up to a dose of 1000 mg/200 mg twice a day for 2 days is safe and well tolerated in these patients.  Further studies to assess the potential therapeutic benefit of NRPT in AKI are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY8QV7wPdaurVg90H21EOLACvtfcHk0liiPd8PF3CsXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1WisbjK&md5=3b0b32fd33d451a1dd77f8a513c8d801</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1186%2Fs12882-020-02006-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12882-020-02006-1%26sid%3Dliteratum%253Aachs%26aulast%3DSimic%26aufirst%3DP.%26aulast%3DVela%2BParada%26aufirst%3DX.%2BF.%26aulast%3DParikh%26aufirst%3DS.%2BM.%26aulast%3DDellinger%26aufirst%3DR.%26aulast%3DGuarente%26aufirst%3DL.%2BP.%26aulast%3DRhee%26aufirst%3DE.%2BP.%26atitle%3DNicotinamide%2520Riboside%2520with%2520Pterostilbene%2520%2528Nrpt%2529%2520Increases%2520Nad%2528%252B%2529%2520in%2520Patients%2520with%2520Acute%2520Kidney%2520Injury%2520%2528Aki%2529%253A%2520A%2520Randomized%252C%2520Double-Blind%252C%2520Placebo-Controlled%252C%2520Stepwise%2520Safety%2520Study%2520of%2520Escalating%2520Doses%2520of%2520Nrpt%2520in%2520Patients%2520with%2520Aki%26jtitle%3DBMC%2520Nephrol.%26date%3D2020%26volume%3D21%26spage%3D342%26doi%3D10.1186%2Fs12882-020-02006-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galloway, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagrutta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richon, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, P. A.</span></span> <span> </span><span class="NLM_article-title">Nonclinical Safety Assessment of the Histone Deacetylase Inhibitor Vorinostat</span>. <i>Int. J. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1177/1091581809352111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1177%2F1091581809352111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=19903873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktVSgt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2010&pages=3-19&author=J.+S.+Kerrauthor=S.+Gallowayauthor=A.+Lagruttaauthor=M.+Armstrongauthor=T.+Millerauthor=V.+M.+Richonauthor=P.+A.+Andrews&title=Nonclinical+Safety+Assessment+of+the+Histone+Deacetylase+Inhibitor+Vorinostat&doi=10.1177%2F1091581809352111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Nonclinical safety assessment of the histone deacetylase inhibitor vorinostat</span></div><div class="casAuthors">Kerr, Janet S.; Galloway, Sheila; Lagrutta, Armando; Armstrong, Michael; Miller, Thomas; Richon, Victoria M.; Andrews, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Toxicology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-19</span>CODEN:
                <span class="NLM_cas:coden">IJTOFN</span>;
        ISSN:<span class="NLM_cas:issn">1091-5818</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Vorinostat (SAHA, Zolinza), a histone deacetylase inhibitor, is assessed in nonclin. studies to support its approval for cutaneous T-cell lymphoma.  Vorinostat is weakly mutagenic in the Ames assay; is clastogenic in rodent (ie, CHO) cells but not in normal human lymphocytes; and is weakly pos. in an in vivo mouse micronucleus assay.  No effects are obsd. on potassium ion currents in the hERG assay up to 300 μM (safety margin ∼ 300-fold the ∼ 1 μM serum concn. assocd. with the 400 mg/d max. recommended human dose).  No rat respiratory or central nervous system effects are found at 150 mg/kg (>2-fold max. recommended human dose).  No cardiovascular effects, including effects on QTc interval, are obsd. after a single oral dose (150 mg/kg) in dogs.  Vorinostat is orally dosed daily in rats (controls, 20, 50, or 150 mg/kg/d) and dogs (controls, 60, 80, or 100/125/160 mg/kg/d) for 26 wk with a 4-wk recovery.  Rat vorinostat-related adverse findings are decreased food consumption, wt. loss, and hematol. changes; a no obsd. adverse effects level is not established.  In dogs, adverse effects are primarily gastrointestinal; the no obsd. adverse effects level is 60 mg/kg/d (∼6-fold max. recommended human dose).  Toxicities are reversible and can be monitored in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr38wojohFu_LVg90H21EOLACvtfcHk0ljzBlQ6Uwv7jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktVSgt7c%253D&md5=23defc0d0b8e84cc3b8ff021eb4a429f</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1177%2F1091581809352111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1091581809352111%26sid%3Dliteratum%253Aachs%26aulast%3DKerr%26aufirst%3DJ.%2BS.%26aulast%3DGalloway%26aufirst%3DS.%26aulast%3DLagrutta%26aufirst%3DA.%26aulast%3DArmstrong%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DT.%26aulast%3DRichon%26aufirst%3DV.%2BM.%26aulast%3DAndrews%26aufirst%3DP.%2BA.%26atitle%3DNonclinical%2520Safety%2520Assessment%2520of%2520the%2520Histone%2520Deacetylase%2520Inhibitor%2520Vorinostat%26jtitle%3DInt.%2520J.%2520Toxicol.%26date%3D2010%26volume%3D29%26spage%3D3%26epage%3D19%26doi%3D10.1177%2F1091581809352111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chai, Y.</span></span> <span> </span><span class="NLM_article-title">Biosensor-Based Active Ingredients Recognition System for Screening Stat3 Ligands from Medical Herbs</span>. <i>Anal. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">8936</span>– <span class="NLM_lpage">8945</span>, <span class="refDoi"> DOI: 10.1021/acs.analchem.8b01103</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.analchem.8b01103" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1ektr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2018&pages=8936-8945&author=L.+Chenauthor=D.+Lvauthor=X.+Chenauthor=M.+Liuauthor=D.+Wangauthor=Y.+Liuauthor=Z.+Hongauthor=Z.+Zhuauthor=X.+Huauthor=Y.+Caoauthor=J.+Yangauthor=Y.+Chai&title=Biosensor-Based+Active+Ingredients+Recognition+System+for+Screening+Stat3+Ligands+from+Medical+Herbs&doi=10.1021%2Facs.analchem.8b01103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Biosensor-based active ingredients recognition system for screening STAT3 ligands from medical herbs</span></div><div class="casAuthors">Chen, Langdong; Lv, Diya; Chen, Xiaofei; Liu, Mingdong; Wang, Dongyao; Liu, Yue; Hong, Zhanying; Zhu, Zhenyu; Hu, Xiaoxia; Cao, Yan; Yang, Jianmin; Chai, Yifeng</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Chemistry (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">8936-8945</span>CODEN:
                <span class="NLM_cas:coden">ANCHAM</span>;
        ISSN:<span class="NLM_cas:issn">0003-2700</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A surface plasmon resonance (SPR) biosensor-based active ingredients recognition system (SPR-AIRS) was developed, validated, and applied to screen signal transducer and activator of transcription 3 (STAT3) ligands.  First, features of the screening system were investigated in four aspects: (1) specificity of the STAT3-immobilized chip, it shows that the chip could be applied to screen STAT3 ligands from complex mixt.; (2) linearity and limit of detection (LOD) of the system, the min. recovery cycle no. was detd. as 5 cycles; (3) saturability of the chip, the results indicate that it is necessary to select a proper concn. based on the compd.'s Kd value; (4) robustness of the system, it indicates that inactive compds. in the matrix could not interfere with active compds. in the process of screening.  Next, SPR-AIRS was applied to screen STAT3 ligands from medicinal herbs.  Nine candidate compds. were fished out.  Then SPR assay and mol. docking were performed to verify the interplay between STAT3 and candidate compds.  Apoptosis assay and luciferase report assay were performed to investigate the drug effect of candidate compds. on STAT3 activity.  Western blot results indicated that neobaicalein and polydatin could inhibit the phosphorylation of STAT3.  As far as we know, this is the first time that neobaicalein and polydatin are reported as effective STAT3 ligands.  In a conclusion, we have systemically demonstrated the feasibility of SPR biosensor-based screening method applying to complex drug systems, and our findings suggest that SPR-AIRS could be a sensitive and effective soln. for the discovery of active compds. from a complex matrix.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0ePmALYqkl7Vg90H21EOLACvtfcHk0ljzBlQ6Uwv7jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1ektr%252FM&md5=03d3eec683fffbd06e792e594efd0a1a</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Facs.analchem.8b01103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.analchem.8b01103%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26aulast%3DLv%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DHong%26aufirst%3DZ.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DChai%26aufirst%3DY.%26atitle%3DBiosensor-Based%2520Active%2520Ingredients%2520Recognition%2520System%2520for%2520Screening%2520Stat3%2520Ligands%2520from%2520Medical%2520Herbs%26jtitle%3DAnal.%2520Chem.%26date%3D2018%26volume%3D90%26spage%3D8936%26epage%3D8945%26doi%3D10.1021%2Facs.analchem.8b01103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/medium/jm1c00136_0021.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00136&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/medium/jm1c00136_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative HDACi.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00136&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/medium/jm1c00136_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. HDAC-BRD4-LIFR-JAK-STAT3 signal cascade.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00136&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/medium/jm1c00136_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structures of PTE, SAHA, and merged molecules. Compound <b>14</b> had high ligand efficiency.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00136&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/medium/jm1c00136_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0016.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>11–18</b>: (a) Ethyl Bromoalkanoate, Potassium Carbonate, DMF, 60 °C, Overnight; (b) Bromobenzoate, Potassium Carbonate, DMF, 60 °C, Overnight; and (c) Hydroxylamine Solution (50% NH<sub>2</sub>OH), Potassium Hydroxide, THF–MeOH, Ice Bath to Room Temperature (rt), 12 h</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00136&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/medium/jm1c00136_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0017.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compound <b>19</b>: (a) Triethyl Phosphite, Reflux, 40 min; (b) DMF, NaOCH<sub>3</sub>, Ice Bath to rt, 12 h; (c) Ethyl Acetate, Stannous Chloride Dihydrate, Reflux, 5 h; (d) Methyl 4-Formylcinnamate, NaB(OAc)<sub>3</sub>H, Acetic Acid, CH<sub>2</sub>Cl<sub>2</sub>, rt, Overnight; and (e) Hydroxylamine Solution (50% NH<sub>2</sub>OH), Potassium Hydroxide, THF–MeOH, Ice Bath to rt, 12 h</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00136&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/medium/jm1c00136_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0018.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compound <b>20</b>: (a) 1,2-Dibromoethane, K<sub>2</sub>CO<sub>3</sub>, 80 °C, 6 h; (b) Ethyl 2-(piperazin-1-yl)acetate, KI, K<sub>2</sub>CO<sub>3</sub>, Reflux, 8 h; and (c) Hydroxylamine Solution (50% NH<sub>2</sub>OH), Potassium Hydroxide, THF–MeOH, Ice Bath to rt, 12 h</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00136&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/medium/jm1c00136_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0019.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthetic Route of Compound <b>21</b>: (a) MeOH–H<sub>2</sub>O (1:1, v/v), Sodium Ascorbate, CuSO<sub>4</sub>, 5 h; (b) CH<sub>3</sub>CN, K<sub>2</sub>CO<sub>3</sub>, Reflux, 8 h; and (c) Hydroxylamine Solution (50% NH<sub>2</sub>OH), Potassium Hydroxide, THF–MeOH, Ice Bath to rt, 12 h</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00136&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/medium/jm1c00136_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Compound <b>14</b> inhibited HDAC activity. (A) HDAC activities [IC<sub>50</sub> (nM)] of compound <b>14</b>. Data represented as mean ± SD from three independent experiments. (B) Levels of acetylated α-tubulin, acetylated histone H3, and GAPDH (the loading control) after 24 h incubation with compound <b>14</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00136&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/medium/jm1c00136_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>14</b> reduced STAT3 tyrosine phosphorylation in MDA-MB-231 cells. The expression of p-STAT3 was downregulated, while the expression of total STAT3 was unchanged.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00136&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/medium/jm1c00136_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Compound <b>14</b> affected the expression of STAT3-regulated oncogenes. (A) Compound <b>14</b> reduced the levels of STAT3 downstream proteins. (B) Compound <b>14</b> reduced the levels of STAT3 downstream mRNA. The data were obtained by real-time quantitative RT-PCR, normalized based on the levels of GAPDH, and are expressed as the mean ± SD from three independent experiments. ** <i>p</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00136&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/medium/jm1c00136_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Kinetic analysis of compound <b>14</b> against STAT3. An SPR assay was conducted on Biacore T200 utilizing a CM5 chip. Kinetic curve fitting and <i>K</i><sub>D</sub> calculation were done by Biacore S200 Evaluation Software.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00136&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/medium/jm1c00136_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Influence of compound <b>14</b> on JAK and Src. (A) The level of p-JAK1 slightly increased at 10 μM. (B) Levels of p-Src and total Src were not significantly changed.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00136&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/medium/jm1c00136_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Compound <b>14</b> induced tumor cell apoptosis <i>in vitro</i>. After being treated with compound <b>14</b> (0.5–5 μM), cells were fixed and stained with Hoechst 33342 and observed under a fluorescence microscope.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00136&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/medium/jm1c00136_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. (A) Compound <b>14</b> induced tumor cell apoptosis <i>in vitro</i>. After incubation with compound <b>14</b> (0–10 μM), cells were analyzed using flow cytometry. (B) Levels of Caspase3/7, PARP, cleaved Caspase3/7, and cleaved PARP after incubation with compound <b>14</b> (0.5–5 μM) for 24 h. GAPDH was used as a control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00136&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/medium/jm1c00136_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Colony formation assay. MDA-MB-231 cells were incubated with compound <b>14</b> with different doses. Afterward, the medium was replaced by the drug-free medium, and the cells continued to be cultured for 15 days.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00136&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/medium/jm1c00136_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0013.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Wound Healing Assay. MDA-MB-231 cells were cultured in a 6-well plate (3 × 10<sup>5</sup>/well), scratched in the middle of each well with a 10 μL plastic pipette tip to create a mechanical wound. Then, the culture medium was changed to a fresh medium with different concentrations of compound <b>14</b>. Images were taken at 0 and 24 h after scraping by a phase-contrast microscope.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00136&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/medium/jm1c00136_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0014.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Molecular docking. Docking model between compound <b>14</b> and the SH2 domain of STAT3 protein (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1BG1">1BG1</a>) was produced by Autodock 4.2. (A) Carbon atoms of the inhibitor are light brown, oxygen atoms are red, and nitrogen atoms are blue. (B) Hydrogen bonds are marked as blue lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00136&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/medium/jm1c00136_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0015.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. <i>In vivo</i> antitumor assay. Compound <b>14</b> suppressed the growth of the transplanted tumor. (A) Tumor weight was measured by an electronic balance. (B) Growing curves of mice’s tumor volume. (C) Curves of body weights. (D) Mice’s tumor tissue. * <i>p</i> < 0.05, ** <i>p</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00136/20210602/images/large/jm1c00136_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00136&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i65">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15830" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15830" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 46 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, S.</span></span> <span> </span><span class="NLM_article-title">World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, Who Press, 2015</span>. <i>Adv. Nutr.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">418</span>– <span class="NLM_lpage">419</span>, <span class="refDoi"> DOI: 10.3945/an.116.012211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.3945%2Fan.116.012211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=26980827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A280%3ADC%252BC28fgslGhug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=418-419&author=S.+McGuire&title=World+Cancer+Report+2014.+Geneva%2C+Switzerland%3A+World+Health+Organization%2C+International+Agency+for+Research+on+Cancer%2C+Who+Press%2C+2015&doi=10.3945%2Fan.116.012211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015</span></div><div class="casAuthors">McGuire Shelley</div><div class="citationInfo"><span class="NLM_cas:title">Advances in nutrition (Bethesda, Md.)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">418-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTrQN7I_r2GkZ0d-O_J5C0AfW6udTcc2ebyQrRlm0xZvrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28fgslGhug%253D%253D&md5=fb111acc7e8cd67cdb11adaef7a981cd</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3945%2Fan.116.012211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3945%252Fan.116.012211%26sid%3Dliteratum%253Aachs%26aulast%3DMcGuire%26aufirst%3DS.%26atitle%3DWorld%2520Cancer%2520Report%25202014.%2520Geneva%252C%2520Switzerland%253A%2520World%2520Health%2520Organization%252C%2520International%2520Agency%2520for%2520Research%2520on%2520Cancer%252C%2520Who%2520Press%252C%25202015%26jtitle%3DAdv.%2520Nutr.%26date%3D2016%26volume%3D7%26spage%3D418%26epage%3D419%26doi%3D10.3945%2Fan.116.012211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al-Lazikani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerji, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span> <span> </span><span class="NLM_article-title">Combinatorial Drug Therapy for Cancer in the Post-Genomic Era</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">679</span>– <span class="NLM_lpage">692</span>, <span class="refDoi"> DOI: 10.1038/nbt.2284</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1038%2Fnbt.2284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=22781697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvFGmtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=679-692&author=B.+Al-Lazikaniauthor=U.+Banerjiauthor=P.+Workman&title=Combinatorial+Drug+Therapy+for+Cancer+in+the+Post-Genomic+Era&doi=10.1038%2Fnbt.2284"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Combinatorial drug therapy for cancer in the post-genomic era</span></div><div class="casAuthors">Al-Lazikani, Bissan; Banerji, Udai; Workman, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">679-692</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Over the past decade, whole genome sequencing and other 'omics' technologies have defined pathogenic driver mutations to which tumor cells are addicted.  Such addictions, synthetic lethalities and other tumor vulnerabilities have yielded novel targets for a new generation of cancer drugs to treat discrete, genetically defined patient subgroups.  This personalized cancer medicine strategy could eventually replace the conventional one-size-fits-all cytotoxic chemotherapy approach.  However, the extraordinary intratumor genetic heterogeneity in cancers revealed by deep sequencing explains why de novo and acquired resistance arise with molecularly targeted drugs and cytotoxic chemotherapy, limiting their utility.  One soln. to the enduring challenge of polygenic cancer drug resistance is rational combinatorial targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon5IOOPfsgR7Vg90H21EOLACvtfcHk0liOR10_uxRYLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvFGmtLg%253D&md5=a61b1b222a7146a92366f57cb0e708ca</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2284%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Lazikani%26aufirst%3DB.%26aulast%3DBanerji%26aufirst%3DU.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DCombinatorial%2520Drug%2520Therapy%2520for%2520Cancer%2520in%2520the%2520Post-Genomic%2520Era%26jtitle%3DNat.%2520Biotechnol.%26date%3D2012%26volume%3D30%26spage%3D679%26epage%3D692%26doi%3D10.1038%2Fnbt.2284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheffler, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroeze, W. K.</span></span> <span> </span><span class="NLM_article-title">Magic Shotguns Versus Magic Bullets: Selectively Non-Selective Drugs for Mood Disorders and Schizophrenia</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">353</span>– <span class="NLM_lpage">359</span>, <span class="refDoi"> DOI: 10.1038/nrd1346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1038%2Fnrd1346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=15060530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Gkt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=353-359&author=B.+L.+Rothauthor=D.+J.+Shefflerauthor=W.+K.+Kroeze&title=Magic+Shotguns+Versus+Magic+Bullets%3A+Selectively+Non-Selective+Drugs+for+Mood+Disorders+and+Schizophrenia&doi=10.1038%2Fnrd1346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia</span></div><div class="casAuthors">Roth, Bryan L.; Sheffler, Douglas J.; Kroeze, Wesley K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">353-359</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Most common central nervous system disorders - such as depression, bipolar disorder, and schizophrenia - seem to be polygenic in origin, and the most effective medications have exceedingly complex pharmacologies.  Attempts to develop more effective treatments for diseases such as schizophrenia and depression by discovering drugs selective for single mol. targets (i.e., 'magic bullets') have, not surprisingly, been largely unsuccessful.  Here the authors propose that designing selectively non-selective drugs (i.e., 'magic shotguns') that interact with several mol. targets will lead to new and more effective medications for a variety of central nervous system disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnSsuUXzmbirVg90H21EOLACvtfcHk0lgQkVwqzXd6RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Gkt78%253D&md5=77196583acccca65457fec7a67218463</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrd1346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1346%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DSheffler%26aufirst%3DD.%2BJ.%26aulast%3DKroeze%26aufirst%3DW.%2BK.%26atitle%3DMagic%2520Shotguns%2520Versus%2520Magic%2520Bullets%253A%2520Selectively%2520Non-Selective%2520Drugs%2520for%2520Mood%2520Disorders%2520and%2520Schizophrenia%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D353%26epage%3D359%26doi%3D10.1038%2Fnrd1346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knight, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">Targeting the Cancer Kinome through Polypharmacology</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">130</span>– <span class="NLM_lpage">137</span>, <span class="refDoi"> DOI: 10.1038/nrc2787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1038%2Fnrc2787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=20094047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=130-137&author=Z.+A.+Knightauthor=H.+Linauthor=K.+M.+Shokat&title=Targeting+the+Cancer+Kinome+through+Polypharmacology&doi=10.1038%2Fnrc2787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the cancer kinome through polypharmacology</span></div><div class="casAuthors">Knight, Zachary A.; Lin, Henry; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-137</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Kinase inhibitors are the largest class of new cancer drugs.  However, it is already apparent that most tumors can escape from the inhibition of any single kinase.  If it is necessary to inhibit multiple kinases, how do we choose which ones.  In this Opinion article, we discuss some of the strategies that are currently being used to identify new therapeutic combinations of kinase targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkDv2FeeH58rVg90H21EOLACvtfcHk0lgQkVwqzXd6RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D&md5=9aaa314e54b43889e147a9f11ac77072</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrc2787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2787%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DTargeting%2520the%2520Cancer%2520Kinome%2520through%2520Polypharmacology%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D130%26epage%3D137%26doi%3D10.1038%2Fnrc2787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brötz-Oesterhelt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunner, N. A.</span></span> <span> </span><span class="NLM_article-title">How Many Modes of Action Should an Antibiotic Have?</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">564</span>– <span class="NLM_lpage">573</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2008.06.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1016%2Fj.coph.2008.06.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=18621146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A280%3ADC%252BD1cjhsFygsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=564-573&author=H.+Br%C3%B6tz-Oesterheltauthor=N.+A.+Brunner&title=How+Many+Modes+of+Action+Should+an+Antibiotic+Have%3F&doi=10.1016%2Fj.coph.2008.06.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">How many modes of action should an antibiotic have?</span></div><div class="casAuthors">Brotz-Oesterhelt Heike; Brunner Nina A</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">564-73</span>
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    </div><div class="casAbstract">All antibiotics that have been successfully employed for decades as monotherapeutics in the treatment of bacterial infections rely on mechanisms of bacterial growth inhibition which are by far more complex than inhibition of a single enzyme.  Such successful antibiotics have in common that they address several targets in parallel and/or that their targets are encoded by multiple genes.  Such multiplicity of targets and of target genes has the advantage that the emergence of spontaneous target-related resistance is a comparatively slow process.  Recently registered antibiotics and novel antibiotics in development are discussed in the light of this promising concept of antibacterial polypharmacology.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQzIF5GvxYY_0HdcurJClFcfW6udTcc2eaAflOh08O0A7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cjhsFygsA%253D%253D&md5=820b32bfce47dd05c0a37bf310a7884e</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2008.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2008.06.008%26sid%3Dliteratum%253Aachs%26aulast%3DBr%25C3%25B6tz-Oesterhelt%26aufirst%3DH.%26aulast%3DBrunner%26aufirst%3DN.%2BA.%26atitle%3DHow%2520Many%2520Modes%2520of%2520Action%2520Should%2520an%2520Antibiotic%2520Have%253F%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2008%26volume%3D8%26spage%3D564%26epage%3D573%26doi%3D10.1016%2Fj.coph.2008.06.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujulu, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J. J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Janus Kinase 2 (Jak2) and Histone Deacetlyase (Hdac) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8233</span>– <span class="NLM_lpage">8262</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00157</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00157" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlyls7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8233-8262&author=E.+G.+Yangauthor=N.+Mustafaauthor=E.+C.+Tanauthor=A.+Poulsenauthor=P.+M.+Ramanujuluauthor=W.+J.+Chngauthor=J.+J.+Y.+Yenauthor=B.+W.+Dymock&title=Design+and+Synthesis+of+Janus+Kinase+2+%28Jak2%29+and+Histone+Deacetlyase+%28Hdac%29+Bispecific+Inhibitors+Based+on+Pacritinib+and+Evidence+of+Dual+Pathway+Inhibition+in+Hematological+Cell+Lines&doi=10.1021%2Facs.jmedchem.6b00157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines</span></div><div class="casAuthors">Yang, Eugene Guorong; Mustafa, Nurulhuda; Tan, Eng Chong; Poulsen, Anders; Ramanujulu, Pondy Murugappan; Chng, Wee Joo; Yen, Jeffrey J. Y.; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8233-8262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Blockage of more than one oncoprotein or pathway is now a std. approach in modern cancer therapy.  Multiple inhibition is typically achieved with two or more drugs.  Herein the authors describe a pharmacophore merging strategy combining the JAK2/FLT3 inhibitor pacritnib with the pan-HDAC inhibitor, vorinostat, to create bispecific single mols. with both JAK and HDAC targeted inhibition.  A preferred ether hydroxamate, compd. 51 (11-(4-(N-hydroxyheptanamide)oxy)-[4,1,9]dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12-(27),16,21,23-decaene) inhibits JAK2 and HDAC6 with low nanomolar potency, is <100 nM potent against HDACs 2 and 10, sub-micromolar potent against HDACs 1, 8 and 11, and >50-fold selective for JAK2 in a panel of 97 kinases.  Broad cellular antiproliferative potency is supported by demonstration of JAK-STAT and HDAC pathway blockade in several hematol. cell lines, inhibition of colony formation in HEL cells, and anal. of apoptosis.  This study provides new tool compds. for further exploration of dual JAK-HDAC pathway inhibition achieved with a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeUHzB39AGWrVg90H21EOLACvtfcHk0ljt4MablAn-xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlyls7rL&md5=aa9ae07a1ac1aa21d70ee0f24621fe82</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00157%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DE.%2BG.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DTan%26aufirst%3DE.%2BC.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DRamanujulu%26aufirst%3DP.%2BM.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DYen%26aufirst%3DJ.%2BJ.%2BY.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Janus%2520Kinase%25202%2520%2528Jak2%2529%2520and%2520Histone%2520Deacetlyase%2520%2528Hdac%2529%2520Bispecific%2520Inhibitors%2520Based%2520on%2520Pacritinib%2520and%2520Evidence%2520of%2520Dual%2520Pathway%2520Inhibition%2520in%2520Hematological%2520Cell%2520Lines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8233%26epage%3D8262%26doi%3D10.1021%2Facs.jmedchem.6b00157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span> <span> </span><span class="NLM_article-title">Network Pharmacology: The Next Paradigm in Drug Discovery</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">682</span>– <span class="NLM_lpage">690</span>, <span class="refDoi"> DOI: 10.1038/nchembio.118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1038%2Fnchembio.118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=18936753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=682-690&author=A.+L.+Hopkins&title=Network+Pharmacology%3A+The+Next+Paradigm+in+Drug+Discovery&doi=10.1038%2Fnchembio.118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Network pharmacology: the next paradigm in drug discovery</span></div><div class="casAuthors">Hopkins, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">682-690</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The dominant paradigm in drug discovery is the concept of designing maximally selective ligands to act on individual drug targets.  However, many effective drugs act via modulation of multiple proteins rather than single targets.  Advances in systems biol. are revealing a phenotypic robustness and a network structure that strongly suggests that exquisitely selective compds., compared with multi-target drugs, may exhibit lower than desired clin. efficacy.  This new appreciation of the role of polypharmacol. has significant implications for tackling the two major sources of attrition in drug development, efficacy and toxicity.  Integrating network biol. and polypharmacol. holds the promise of expanding the current opportunity space for druggable targets.  However, the rational design of polypharmacol. faces considerable challenges in the need for new methods to validate target combinations and optimize multiple structure-activity relationships while maintaining drug-like properties.  Advances in these areas are creating the foundation of the next paradigm in drug discovery: network pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqHy4FqkK-h7Vg90H21EOLACvtfcHk0ljt4MablAn-xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7fK&md5=03b8be3ddbcab7dc65afd17df7ee8395</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.118%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DNetwork%2520Pharmacology%253A%2520The%2520Next%2520Paradigm%2520in%2520Drug%2520Discovery%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D4%26spage%3D682%26epage%3D690%26doi%3D10.1038%2Fnchembio.118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ropero, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteller, M.</span></span> <span> </span><span class="NLM_article-title">The Role of Histone Deacetylases (Hdacs) in Human Cancer</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1016/j.molonc.2007.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1016%2Fj.molonc.2007.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=19383284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOitbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2007&pages=19-25&author=S.+Roperoauthor=M.+Esteller&title=The+Role+of+Histone+Deacetylases+%28Hdacs%29+in+Human+Cancer&doi=10.1016%2Fj.molonc.2007.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The role of histone deacetylases (HDACs) in human cancer</span></div><div class="casAuthors">Ropero, Santiago; Esteller, Manel</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-25</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The balance of histone acetylation and deacetylation is an epigenetic layer with a crit. role in the regulation of gene expression.  Histone acetylation induced by histone acetyl transferases (HATs) is assocd. with gene transcription, while histone hypoacetylation induced by histone deacetylase (HDAC) activity is assocd. with gene silencing.  Altered expression and mutations of genes that encode HDACs have been linked to tumor development since they both induce the aberrant transcription of key genes regulating important cellular functions such as cell proliferation, cell-cycle regulation and apoptosis.  Thus, HDACs are among the most promising therapeutic targets for cancer treatment, and they have inspired researchers to study and develop HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvbJD8bqroSLVg90H21EOLACvtfcHk0ljt4MablAn-xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOitbnI&md5=d925bcde258dce7d53cbb98563e1f2ae</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2007.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2007.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DRopero%26aufirst%3DS.%26aulast%3DEsteller%26aufirst%3DM.%26atitle%3DThe%2520Role%2520of%2520Histone%2520Deacetylases%2520%2528Hdacs%2529%2520in%2520Human%2520Cancer%26jtitle%3DMol.%2520Oncol.%26date%3D2007%26volume%3D1%26spage%3D19%26epage%3D25%26doi%3D10.1016%2Fj.molonc.2007.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marks, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richon, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rifkind, R. A.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">1210</span>– <span class="NLM_lpage">1216</span>, <span class="refDoi"> DOI: 10.1093/jnci/92.15.1210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1093%2Fjnci%2F92.15.1210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10922406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlvFyhsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2000&pages=1210-1216&author=P.+A.+Marksauthor=V.+M.+Richonauthor=R.+A.+Rifkind&title=Histone+Deacetylase+Inhibitors%3A+Inducers+of+Differentiation+or+Apoptosis+of+Transformed+Cells&doi=10.1093%2Fjnci%2F92.15.1210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells</span></div><div class="casAuthors">Marks, Paul A.; Richon, Victoria M.; Rifkind, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1210-1216</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review with 84 refs.  Histone deacetylase (HDAC) inhibitors have been shown to be potent inducers of growth arrest, differentiation, and/or apoptotic cell death of transformed cells in vitro and in vivo.  One class of HDAC inhibitors, hydroxamic acid-based hybrid polar compds. (HPCs), induce differentiation at micromolar or lower concns.  Studies (x-ray crystallog.) showed that the catalytic site of HDAC has a tubular structure with a zinc atom at its base and that these HDAC inhibitors, such as suberoylanilide hydroxamic acid and trichostatin A, fit into this structure with the hydroxamic moiety of the inhibitor binding to the zinc.  HDAC inhibitors cause acetylated histones to accumulate in both tumor and normal tissues, and this accumulation can be used as a marker of the biol. activity of the HDAC inhibitors.  Hydroxamic acid-based HPCs act selectively to inhibit tumor cell growth at levels that have little or no toxicity for normal cells.  These compds. also act selectively on gene expression, altering the expression of only about 2% of the genes expressed in cultured tumor cells.  In general, chromatin fractions enriched in actively transcribed genes are also enriched in highly acetylated core histones, whereas silent genes are assocd. with nucleosomes with a low level of acetylation.  However, HDACs can also acetylate proteins other than histones in nucleosomes.  The role that these other targets play in the induction of cell growth arrest, differentiation, and/or apoptotic cell death has not been detd.  Our working hypothesis is that inhibition of HDAC activity leads to the modulation of expression of a specific set of genes that, in turn, result in growth arrest, differentiation, and/or apoptotic cell death.  The hydroxamic acid-based HPCs are potentially effective agents for cancer therapy and, possibly, cancer chemoprevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoa7JHGYu0fJLVg90H21EOLACvtfcHk0lhhiM_D5jnwSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlvFyhsb8%253D&md5=413775f266f555bfc6539d052b4d2b15</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F92.15.1210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F92.15.1210%26sid%3Dliteratum%253Aachs%26aulast%3DMarks%26aufirst%3DP.%2BA.%26aulast%3DRichon%26aufirst%3DV.%2BM.%26aulast%3DRifkind%26aufirst%3DR.%2BA.%26atitle%3DHistone%2520Deacetylase%2520Inhibitors%253A%2520Inducers%2520of%2520Differentiation%2520or%2520Apoptosis%2520of%2520Transformed%2520Cells%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2000%26volume%3D92%26spage%3D1210%26epage%3D1216%26doi%3D10.1093%2Fjnci%2F92.15.1210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Vreese, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galle, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Depetter, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franceus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desmet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Hecke, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benoy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Den
Bosch, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Hooghe, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Potent and Selective Hdac6 Inhibitors Bearing a Cyclohexane- or Cycloheptane-Annulated 1,5-Benzothiazepine Scaffold</span>. <i>Chem.—Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">128</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1002/chem.201604167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1002%2Fchem.201604167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=27717044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFKjtrzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=128-136&author=R.+De%0AVreeseauthor=L.+Galleauthor=Y.+Depetterauthor=J.+Franceusauthor=T.+Desmetauthor=K.+Van+Heckeauthor=V.+Benoyauthor=L.+Van+Den%0ABoschauthor=M.+D%E2%80%99Hooghe&title=Synthesis+of+Potent+and+Selective+Hdac6+Inhibitors+Bearing+a+Cyclohexane-+or+Cycloheptane-Annulated+1%2C5-Benzothiazepine+Scaffold&doi=10.1002%2Fchem.201604167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Potent and Selective HDAC6 Inhibitors Bearing a Cyclohexane- or Cycloheptane-Annulated 1,5-Benzothiazepine Scaffold</span></div><div class="casAuthors">De Vreese, Rob; Galle, Lisa; Depetter, Yves; Franceus, Jorick; Desmet, Tom; Van Hecke, Kristof; Benoy, Veronick; Van Den Bosch, Ludo; D'hooghe, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">128-136</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Synthesis and isolation of (dihydrobenzo[b][1,4]thiazepinyl)methyl-N-hydroxybenzamides I [R = H, Cl, CF3; X = S, SO, SO2; n = 1, 2], a new class of HDAC6 inhibitors, is reported.  Evaluations of their HDAC-inhibiting activity resulted in the identification of I (X = SO2; n = 1; R = H, CF3) as highly potent and selective HDAC6 inhibitors with activity in the low nanomolar range, which also showed excellent selectivity on the enzymic and cellular levels.  Furthermore, four promising inhibitors were subjected to an Ames fluctuation assay, which revealed no mutagenic effects assocd. with these structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQAN_gYUuzi7Vg90H21EOLACvtfcHk0lhhiM_D5jnwSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFKjtrzF&md5=589c80b2c951fd8e59b931875b9087f0</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fchem.201604167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201604167%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BVreese%26aufirst%3DR.%26aulast%3DGalle%26aufirst%3DL.%26aulast%3DDepetter%26aufirst%3DY.%26aulast%3DFranceus%26aufirst%3DJ.%26aulast%3DDesmet%26aufirst%3DT.%26aulast%3DVan%2BHecke%26aufirst%3DK.%26aulast%3DBenoy%26aufirst%3DV.%26aulast%3DVan%2BDen%2BBosch%26aufirst%3DL.%26aulast%3DD%25E2%2580%2599Hooghe%26aufirst%3DM.%26atitle%3DSynthesis%2520of%2520Potent%2520and%2520Selective%2520Hdac6%2520Inhibitors%2520Bearing%2520a%2520Cyclohexane-%2520or%2520Cycloheptane-Annulated%25201%252C5-Benzothiazepine%2520Scaffold%26jtitle%3DChem.%25E2%2580%2594Eur.%2520J.%26date%3D2017%26volume%3D23%26spage%3D128%26epage%3D136%26doi%3D10.1002%2Fchem.201604167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Falkenberg, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylases and Their Inhibitors in Cancer, Neurological Diseases and Immune Disorders</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">673</span>– <span class="NLM_lpage">691</span>, <span class="refDoi"> DOI: 10.1038/nrd4360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1038%2Fnrd4360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=25131830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlKrtLjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=673-691&author=K.+J.+Falkenbergauthor=R.+W.+Johnstone&title=Histone+Deacetylases+and+Their+Inhibitors+in+Cancer%2C+Neurological+Diseases+and+Immune+Disorders&doi=10.1038%2Fnrd4360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders</span></div><div class="casAuthors">Falkenberg, Katrina J.; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">673-691</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Epigenetic aberrations, which are recognized as key drivers of several human diseases, are often caused by genetic defects that result in functional deregulation of epigenetic proteins, their altered expression and/or their atypical recruitment to certain gene promoters.  Importantly, epigenetic changes are reversible, and epigenetic enzymes and regulatory proteins can be targeted using small mols.  This Review discusses the role of altered expression and/or function of one class of epigenetic regulators - histone deacetylases (HDACs) - and their role in cancer, neurol. diseases and immune disorders.  We highlight the development of small-mol. HDAC inhibitors and their use in the lab., in preclin. models and in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXiWEG49LhebVg90H21EOLACvtfcHk0lhhiM_D5jnwSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlKrtLjI&md5=ccfb68fa3fd4685e2305cdf8a6a9c81a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnrd4360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4360%26sid%3Dliteratum%253Aachs%26aulast%3DFalkenberg%26aufirst%3DK.%2BJ.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DHistone%2520Deacetylases%2520and%2520Their%2520Inhibitors%2520in%2520Cancer%252C%2520Neurological%2520Diseases%2520and%2520Immune%2520Disorders%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D673%26epage%3D691%26doi%3D10.1038%2Fnrd4360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birkeland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lago, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johanson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, E.</span></span> <span> </span><span class="NLM_article-title">Induction and Superinduction of Growth Arrest and DNA Damage Gene 45 (Gadd45) Alpha and Beta Messenger Rnas by Histone Deacetylase Inhibitors Trichostatin a (Tsa) and Butyrate in Sw620 Human Colon Carcinoma Cells</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>188</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">140</span>, <span class="refDoi"> DOI: 10.1016/s0304-3835(02)00322-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1016%2FS0304-3835%2802%2900322-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=12406558" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BD38Xot1Wquro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=188&publication_year=2002&pages=127-140&author=Z.+Chenauthor=S.+Clarkauthor=M.+Birkelandauthor=C.-M.+Sungauthor=A.+Lagoauthor=R.+Liuauthor=R.+Kirkpatrickauthor=K.+Johansonauthor=J.+D.+Winklerauthor=E.+Hu&title=Induction+and+Superinduction+of+Growth+Arrest+and+DNA+Damage+Gene+45+%28Gadd45%29+Alpha+and+Beta+Messenger+Rnas+by+Histone+Deacetylase+Inhibitors+Trichostatin+a+%28Tsa%29+and+Butyrate+in+Sw620+Human+Colon+Carcinoma+Cells&doi=10.1016%2Fs0304-3835%2802%2900322-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Induction and superinduction of growth arrest and DNA damage gene 45 (GADD45) α and β messenger RNAs by histone deacetylase inhibitors trichostatin A (TSA) and butyrate in SW620 human colon carcinoma cells</span></div><div class="casAuthors">Chen, Zunxuan; Clark, Steven; Birkeland, Marian; Sung, Chiu-Mei; Lago, Amparo; Liu, Ronggang; Kirkpatrick, Robert; Johanson, Kyung; Winkler, James D.; Hu, Erding</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">188</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">127-140</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) inhibitors such as trichostatin (TSA) and butyrate have been shown to inhibit cancer cell proliferation, induce apoptosis and regulate the expression of genes involved in cell cycle.  Although the precise mechanism underlying HDAC inhibitor-induced cell growth arrest is not fully understood, induction of cell cycle related genes such as p21(cip/waf), is thought to be important.  Here we showed that in the SW620 human colon cancer cell line, TSA and butyrate induced the growth arrest and DNA damage gene 45α (GADD45α) and GADD45β.  Furthermore, GADD45β and p21(cip/waf) mRNA were induced in the absence of protein synthesis, indicating that both genes were immediate target genes for TSA.  Cyclohexamide and TSA super-induced the expression of GADD45α and β, but not p21(cip/waf).  Interestingly while mitogen-activated kinase (MEK) inhibitor PD98059 and p38 kinase inhibitor SB242235 were unable to affect GADD45 induction, two serine/threonine protein kinase inhibitors (H7 and H8) as well as curcumin completely blocked the super-induction.  Concomitant to the inhibition of GADD45 induction, H7 and H8 also blocked TSA-induced apoptosis.  Taken together, these results suggest that GADD45 induction may play important role in TSA-induced cellular effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ3d3QeDYT57Vg90H21EOLACvtfcHk0ljRxpRh2_O7ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xot1Wquro%253D&md5=4a0350a835870f0e8f81037b810be534</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FS0304-3835%2802%2900322-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0304-3835%252802%252900322-1%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DClark%26aufirst%3DS.%26aulast%3DBirkeland%26aufirst%3DM.%26aulast%3DSung%26aufirst%3DC.-M.%26aulast%3DLago%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DKirkpatrick%26aufirst%3DR.%26aulast%3DJohanson%26aufirst%3DK.%26aulast%3DWinkler%26aufirst%3DJ.%2BD.%26aulast%3DHu%26aufirst%3DE.%26atitle%3DInduction%2520and%2520Superinduction%2520of%2520Growth%2520Arrest%2520and%2520DNA%2520Damage%2520Gene%252045%2520%2528Gadd45%2529%2520Alpha%2520and%2520Beta%2520Messenger%2520Rnas%2520by%2520Histone%2520Deacetylase%2520Inhibitors%2520Trichostatin%2520a%2520%2528Tsa%2529%2520and%2520Butyrate%2520in%2520Sw620%2520Human%2520Colon%2520Carcinoma%2520Cells%26jtitle%3DCancer%2520Lett.%26date%3D2002%26volume%3D188%26spage%3D127%26epage%3D140%26doi%3D10.1016%2Fs0304-3835%2802%2900322-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sato, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitagawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayahara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ninomiya, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fushida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miwa, K.</span></span> <span> </span><span class="NLM_article-title">Fr901228, a Novel Histone Deacetylase Inhibitor, Induces Cell Cycle Arrest and Subsequent Apoptosis in Refractory Human Pancreatic Cancer Cells</span>. <i>Int. J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">679</span>– <span class="NLM_lpage">685</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=14767553" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitFantb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=679-685&author=N.+Satoauthor=T.+Ohtaauthor=H.+Kitagawaauthor=M.+Kayaharaauthor=I.+Ninomiyaauthor=S.+Fushidaauthor=T.+Fujimuraauthor=G.+Nishimuraauthor=K.+Shimizuauthor=K.+Miwa&title=Fr901228%2C+a+Novel+Histone+Deacetylase+Inhibitor%2C+Induces+Cell+Cycle+Arrest+and+Subsequent+Apoptosis+in+Refractory+Human+Pancreatic+Cancer+Cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells</span></div><div class="casAuthors">Sato, Nariatsu; Ohta, Tetsuo; Kitagawa, Hirohisa; Kayahara, Masato; Ninomiya, Itasu; Fushida, Sachio; Fujimura, Takashi; Nishimura, Gen-Ichi; Shimizu, Koichi; Miwa, Koichi</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">679-685</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1019-6439</span>.
    
            (<span class="NLM_cas:orgname">International Journal of Oncology</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) inhibitors have antiproliferative activity against human cancer cells via cell cycle arrest, differentiation, and apoptosis.  However, no report has focused on the apoptotic potential of HDAC inhibitors in refractory human pancreatic cancer.  This study was designed to examine the apoptotic potential of FR901228, a novel HDAC inhibitor, in five human pancreatic cancer cell lines: Capan-1, BxPC-3, HPAF, Panc-1, and MIAPaCa-2.  FR901228 markedly inhibited the proliferation of all five cell lines (IC50: 1-500 nM), with the greatest effect in MIAPaCa-2 cells.  Treatment of each cell line with FR901228 (10-100 nM) caused cell cycle arrest at the G1 or G2/M phase and subsequent apoptosis.  FR901228 induced expression of hyperacetylated histone H3 after 3 h of treatment and overexpression of p21Waf-1 after 6 h.  In addn., FR901228 induced apoptosis by activating caspase-3, which led to cleavage of p21Waf-1 into a 15-kDa breakdown product and drove cancer cells from cell cycle arrest into apoptosis.  FR901228 also decreased the protein level of survivin dramatically.  Our results show that FR901228 markedly inhibits the growth of pancreatic cancer cells, not only through cell cycle arrest, but also through subsequent apoptosis; this was accompanied by caspase-3 activation, survivin degrdn., and p21Waf-1 cleavage.  FR901228 may prove clin. useful as an agent for refractory pancreatic cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTFEPQEEOKKbVg90H21EOLACvtfcHk0ljRxpRh2_O7ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitFantb4%253D&md5=1677c6b5dab5ba8bbd87957a33698609</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSato%26aufirst%3DN.%26aulast%3DOhta%26aufirst%3DT.%26aulast%3DKitagawa%26aufirst%3DH.%26aulast%3DKayahara%26aufirst%3DM.%26aulast%3DNinomiya%26aufirst%3DI.%26aulast%3DFushida%26aufirst%3DS.%26aulast%3DFujimura%26aufirst%3DT.%26aulast%3DNishimura%26aufirst%3DG.%26aulast%3DShimizu%26aufirst%3DK.%26aulast%3DMiwa%26aufirst%3DK.%26atitle%3DFr901228%252C%2520a%2520Novel%2520Histone%2520Deacetylase%2520Inhibitor%252C%2520Induces%2520Cell%2520Cycle%2520Arrest%2520and%2520Subsequent%2520Apoptosis%2520in%2520Refractory%2520Human%2520Pancreatic%2520Cancer%2520Cells%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2004%26volume%3D24%26spage%3D679%26epage%3D685" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, Y.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harimoto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rikimaru, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirabe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimachi, K.</span></span> <span> </span><span class="NLM_article-title">Histone, Deacetylase Inhibitor Trichostatin a Induces Cell-Cycle Arrest/Apoptosis and Hepatocyte Differentiation in Human Hepatoma Cells</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">572</span>– <span class="NLM_lpage">576</span>, <span class="refDoi"> DOI: 10.1002/ijc.10699</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1002%2Fijc.10699" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=12494463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmtFKgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2003&pages=572-576&author=Y.-i.+Yamashitaauthor=M.+Shimadaauthor=N.+Harimotoauthor=T.+Rikimaruauthor=K.+Shirabeauthor=S.+Tanakaauthor=K.+Sugimachi&title=Histone%2C+Deacetylase+Inhibitor+Trichostatin+a+Induces+Cell-Cycle+Arrest%2FApoptosis+and+Hepatocyte+Differentiation+in+Human+Hepatoma+Cells&doi=10.1002%2Fijc.10699"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells</span></div><div class="casAuthors">Yamashita, Yo-Ichi; Shimada, Mitsuo; Harimoto, Norifumi; Rikimaru, Tatsuya; Shirabe, Ken; Tanaka, Shinj; Sugimachi, Keizo</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">572-576</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Remodeling of the chromatin template by inhibition of HDAC activities represents a potential transcriptional therapy for neoplastic disease.  A no. of HDAC inhibitors that modulate in vitro cell growth and differentiation have been developed.  We analyzed the effects of TSA, a specific and potent HDAC inhibitor, on the human hepatoma cell lines HepG2 and Huh-7.  TSA increased levels of acetylated histones H3 and H4 in both HepG2 and Huh-7.  It inhibited cell proliferation in vitro and induced G0/G1 arrest in HepG2 and apoptosis in Huh-7.  Gene expression of liver-specific functions and liver-enriched transcription factors was upregulated by TSA.  TSA upregulated the ammonia removal rate and the albumin synthesis rate of HepG2 and Huh-7.  Our results indicate that TSA can induce cell-cycle arrest/apoptosis and hepatocyte differentiation in human liver cancer cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXjd-pQWjkdrVg90H21EOLACvtfcHk0ljRxpRh2_O7ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmtFKgsA%253D%253D&md5=9fd1a3ce76c6a60b15800dcdad3304a0</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1002%2Fijc.10699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.10699%26sid%3Dliteratum%253Aachs%26aulast%3DYamashita%26aufirst%3DY.-i.%26aulast%3DShimada%26aufirst%3DM.%26aulast%3DHarimoto%26aufirst%3DN.%26aulast%3DRikimaru%26aufirst%3DT.%26aulast%3DShirabe%26aufirst%3DK.%26aulast%3DTanaka%26aufirst%3DS.%26aulast%3DSugimachi%26aufirst%3DK.%26atitle%3DHistone%252C%2520Deacetylase%2520Inhibitor%2520Trichostatin%2520a%2520Induces%2520Cell-Cycle%2520Arrest%252FApoptosis%2520and%2520Hepatocyte%2520Differentiation%2520in%2520Human%2520Hepatoma%2520Cells%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2003%26volume%3D103%26spage%3D572%26epage%3D576%26doi%3D10.1002%2Fijc.10699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jennings, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fierke, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, S. M.</span></span> <span> </span><span class="NLM_article-title">Dual-Mode Hdac Prodrug for Covalent Modification and Subsequent Inhibitor Release</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4812</span>– <span class="NLM_lpage">4821</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00539</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00539" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotlCitLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4812-4821&author=K.+B.+Danielauthor=E.+D.+Sullivanauthor=Y.+Chenauthor=J.+C.+Chanauthor=P.+A.+Jenningsauthor=C.+A.+Fierkeauthor=S.+M.+Cohen&title=Dual-Mode+Hdac+Prodrug+for+Covalent+Modification+and+Subsequent+Inhibitor+Release&doi=10.1021%2Facs.jmedchem.5b00539"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release</span></div><div class="casAuthors">Daniel, Kevin B.; Sullivan, Eric D.; Chen, Yao; Chan, Joshua C.; Jennings, Patricia A.; Fierke, Carol A.; Cohen, Seth M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4812-4821</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylase inhibitors (HDACi) target abnormal epigenetic states assocd. with a variety of pathologies, including cancer.  Here, the development of a prodrug of the canonical broad-spectrum HDACi suberoylanilide hydroxamic acid (SAHA) is described.  Although hydroxamic acids are utilized universally in the development of metalloenzyme inhibitors, they are considered to be poor pharmacophores with reduced activity in vivo.  We developed a prodrug of SAHA by appending a promoiety, sensitive to thiols, to the hydroxamic acid warhead (termed SAHA-TAP).  After incubation of SAHA-TAP with an HDAC, the thiol of a conserved HDAC cysteine residue becomes covalently tagged with the promoiety, initiating a cascade reaction that leads to the release of SAHA.  Mass spectrometry and enzyme kinetics expts. validate that the cysteine residue is covalently appended with the TAP promoiety.  SAHA-TAP demonstrates cytotoxicity activity against various cancer cell lines.  This strategy represents an original prodrug design with a dual mode of action for HDAC inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra4pNKro-RWLVg90H21EOLACvtfcHk0lgfarUr-A8E5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotlCitLw%253D&md5=985fb1b3e17240ab6484c33e737f47e2</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00539%26sid%3Dliteratum%253Aachs%26aulast%3DDaniel%26aufirst%3DK.%2BB.%26aulast%3DSullivan%26aufirst%3DE.%2BD.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DChan%26aufirst%3DJ.%2BC.%26aulast%3DJennings%26aufirst%3DP.%2BA.%26aulast%3DFierke%26aufirst%3DC.%2BA.%26aulast%3DCohen%26aufirst%3DS.%2BM.%26atitle%3DDual-Mode%2520Hdac%2520Prodrug%2520for%2520Covalent%2520Modification%2520and%2520Subsequent%2520Inhibitor%2520Release%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4812%26epage%3D4821%26doi%3D10.1021%2Facs.jmedchem.5b00539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thaler, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercurio, C.</span></span> <span> </span><span class="NLM_article-title">Towards Selective Inhibition of Histone Deacetylase Isoforms: What Has Been Achieved, Where We Are and What Will Be Next</span>. <i>Chemmedchem</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">523</span>– <span class="NLM_lpage">536</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201300413</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1002%2Fcmdc.201300413" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=24730063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFentrnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=523-536&author=F.+Thalerauthor=C.+Mercurio&title=Towards+Selective+Inhibition+of+Histone+Deacetylase+Isoforms%3A+What+Has+Been+Achieved%2C+Where+We+Are+and+What+Will+Be+Next&doi=10.1002%2Fcmdc.201300413"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Towards Selective Inhibition of Histone Deacetylase Isoforms: What Has Been Achieved, Where We Are and What Will Be Next</span></div><div class="casAuthors">Thaler, Florian; Mercurio, Ciro</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">523-536</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) are widely studied targets for the treatment of cancer and other diseases.  Up to now, over twenty HDAC inhibitors have entered clin. studies and two of them have already reached the market, namely the hydroxamic acid deriv. SAHA (vorinostat, Zolinza) and the cyclic depsipeptide FK228 (romidepsin, Istodax) that have been approved for the treatment of cutaneous T-cell lymphoma (CTCL).  A common aspect of the first HDAC inhibitors is the absence of any particular selectivity towards specific isoenzymes.  Some of mols. resulted to be "pan"-HDAC inhibitors, while others are class I selective.  In the meantime, the knowledge of HDAC biol. has continuously progressed.  Key advances in the structural biol. of various isoenzymes, reliable mol. homol. models as well as suitable biol. assays have provided new tools for drug discovery activities.  This Minireview aims at surveying these recent developments as well as the design, synthesis and biol. characterization of isoform-selective derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKncV8XbSHkrVg90H21EOLACvtfcHk0lgfarUr-A8E5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFentrnP&md5=72626d372ef5d953be388f3513c87e0b</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201300413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201300413%26sid%3Dliteratum%253Aachs%26aulast%3DThaler%26aufirst%3DF.%26aulast%3DMercurio%26aufirst%3DC.%26atitle%3DTowards%2520Selective%2520Inhibition%2520of%2520Histone%2520Deacetylase%2520Isoforms%253A%2520What%2520Has%2520Been%2520Achieved%252C%2520Where%2520We%2520Are%2520and%2520What%2520Will%2520Be%2520Next%26jtitle%3DChemmedchem%26date%3D2014%26volume%3D9%26spage%3D523%26epage%3D536%26doi%3D10.1002%2Fcmdc.201300413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackanson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase (Hdac) Inhibitors in Recent Clinical Trials for Cancer Therapy</span>. <i>Clin. Epigenet.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">117</span>, <span class="refDoi"> DOI: 10.1007/s13148-010-0012-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1007%2Fs13148-010-0012-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=21258646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVeqsrrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=117&author=J.+M.+Wagnerauthor=B.+Hackansonauthor=M.+Lubbertauthor=M.+Jung&title=Histone+Deacetylase+%28Hdac%29+Inhibitors+in+Recent+Clinical+Trials+for+Cancer+Therapy&doi=10.1007%2Fs13148-010-0012-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy</span></div><div class="casAuthors">Wagner, Julia M.; Hackanson, Bjoern; Luebbert, Michael; Jung, Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Epigenetics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">117-136</span>CODEN:
                <span class="NLM_cas:coden">CELPCI</span>;
        ISSN:<span class="NLM_cas:issn">1868-7075</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Heritable changes in gene expression that are not based upon alterations in the DNA sequence are defined as epigenetics.  The most common mechanisms of epigenetic regulation are the methylation of CpG islands within the DNA and the modification of amino acids in the N-terminal histone tails.  In the last years, it became evident that the onset of cancer and its progression may not occur only due to genetic mutations but also because of changes in the patterns of epigenetic modifications.  In contrast to genetic mutations, which are almost impossible to reverse, epigenetic changes are potentially reversible.  This implies that they are amenable to pharmacol. interventions.  Therefore, a lot of work in recent years has focussed on the development of small mol. enzyme inhibitors like DNA-methyltransferase inhibitors or inhibitors of histone-modifying enzymes.  These may reverse misregulated epigenetic states and be implemented in the treatment of cancer or other diseases, e.g., neurol. disorders.  Today, several epigenetic drugs are already approved by the FDA and the EMEA for cancer treatment and around ten histone deacetylase (HDAC) inhibitors are in clin. development.  This review will give an update on recent clin. trials of the HDAC inhibitors used systemically that were reported in 2009 and 2010 and will present an overview of different biomarkers to monitor the biol. effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp62EyFQbmSEbVg90H21EOLACvtfcHk0lgfarUr-A8E5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVeqsrrF&md5=c2b02cc37f94c85c4496822b9bf13af9</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1007%2Fs13148-010-0012-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13148-010-0012-4%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DJ.%2BM.%26aulast%3DHackanson%26aufirst%3DB.%26aulast%3DLubbert%26aufirst%3DM.%26aulast%3DJung%26aufirst%3DM.%26atitle%3DHistone%2520Deacetylase%2520%2528Hdac%2529%2520Inhibitors%2520in%2520Recent%2520Clinical%2520Trials%2520for%2520Cancer%2520Therapy%26jtitle%3DClin.%2520Epigenet.%26date%3D2010%26volume%3D1%26spage%3D117%26doi%3D10.1007%2Fs13148-010-0012-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of Oral-Available Resveratrol-Caffeic Acid Based Hybrids Inhibiting Acetylated and Phosphorylated Stat3 Protein</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">1006</span>– <span class="NLM_lpage">1018</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.10.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1016%2Fj.ejmech.2016.10.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=27783972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslKgu7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2016&pages=1006-1018&author=S.+Liauthor=W.+Zhangauthor=Y.+Yangauthor=T.+Maauthor=J.+Guoauthor=S.+Wangauthor=W.+Yuauthor=L.+Kong&title=Discovery+of+Oral-Available+Resveratrol-Caffeic+Acid+Based+Hybrids+Inhibiting+Acetylated+and+Phosphorylated+Stat3+Protein&doi=10.1016%2Fj.ejmech.2016.10.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of oral-available resveratrol-caffeic acid based hybrids inhibiting acetylated and phosphorylated STAT3 protein</span></div><div class="casAuthors">Li, Shanshan; Zhang, Wenda; Yang, Yanwei; Ma, Ting; Guo, Jianpeng; Wang, Shanshan; Yu, Wenying; Kong, Lingyi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1006-1018</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Constitutive activation of STAT3 has been found in a wide variety of cancers and demonstrated as a very attractive therapeutic target.  Disrupting both acetylation and phosphorylation of STAT3 protein was hypothesized to greatly deactivate STAT3, therefore, treating cancers.  To demonstrate the hypothesis, two series of novel resveratrol-caffeic acid hybrids were designed aiming to regulate both acetylation and phosphorylation of STAT3 protein, which is also the first report of the synthetic inhibitors simultaneously regulating two biol. reactions of STAT3 to the knowledge.  Most of these compds. were demonstrated with preferential antitumor activity with low IC50 values against two cancer cell lines.  Particularly, compd. I was found as an excellent STAT3 inhibitor with over 50-fold better potency than resveratrol and caffeic acid.  Meanwhile, the novel derivs. significantly inhibited the proliferation and induced the apoptosis of tumor cells.  Mol. docking further disclosed the binding modes of STAT3 with the inhibitors.  In addn., compd. I orally and significantly suppressed breast cancer 4T1 xenograft tumor growth in vivo, indicating its great potential as an efficacious drug candidate for human cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHG6waQXaPa7Vg90H21EOLACvtfcHk0livoRDhKsS0bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslKgu7bO&md5=8eb67605addaebf623618d15ac46b7af</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.10.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.10.028%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DT.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DKong%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520Oral-Available%2520Resveratrol-Caffeic%2520Acid%2520Based%2520Hybrids%2520Inhibiting%2520Acetylated%2520and%2520Phosphorylated%2520Stat3%2520Protein%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D124%26spage%3D1006%26epage%3D1018%26doi%3D10.1016%2Fj.ejmech.2016.10.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Thangue, N. B.</span></span> <span> </span><span class="NLM_article-title">Hdac Inhibitors in Cancer Biology: Emerging Mechanisms and Clinical Applications</span>. <i>Immunol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">94</span>, <span class="refDoi"> DOI: 10.1038/icb.2011.100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1038%2Ficb.2011.100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=22124371" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC38Xkslykuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2012&pages=85-94&author=O.+Khanauthor=N.+B.+La+Thangue&title=Hdac+Inhibitors+in+Cancer+Biology%3A+Emerging+Mechanisms+and+Clinical+Applications&doi=10.1038%2Ficb.2011.100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications</span></div><div class="casAuthors">Khan, Omar; La Thangue, Nicholas B.</div><div class="citationInfo"><span class="NLM_cas:title">Immunology & Cell Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">85-94</span>CODEN:
                <span class="NLM_cas:coden">ICBIEZ</span>;
        ISSN:<span class="NLM_cas:issn">0818-9641</span>.
    
            (<span class="NLM_cas:orgname">NPG Nature Asia-Pacific</span>)
        </div><div class="casAbstract">A review.  Reversible acetylation mediated by histone deacetylases (HDACs) influences a broad repertoire of physiol. processes, many of which are aberrantly controlled in tumor cells.  As HDAC inhibition prompts tumor cells to enter apoptosis, small-mol. HDAC inhibitors have been developed as a new class of mechanism-based anti-cancer agent, many of which have entered clin. trials.  Although the clin. picture is evolving and the precise utility of HDAC inhibitors remains to be detd., it is noteworthy that certain tumor types undergo a favorable response, in particular hematol. malignancies.  Vorinostat and romidepsin have been approved for treating cutaneous T-cell lymphoma in patients with progressive, persistent or recurrent disease.  Here, we discuss developments in our understanding of mol. events that underlie the anti-cancer effects of HDAC inhibitors and relate this information to the emerging clin. picture for the application of these inhibitors in the treatment of cancer.  Immunol. and Cell Biol. (2012) 90, 85-94; doi:10.1038/icb.2011.100; published online 29 Nov. 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvd48xGUlskbVg90H21EOLACvtfcHk0livoRDhKsS0bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xkslykuw%253D%253D&md5=b9214c008e22696af4ee808b2e2af7f2</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Ficb.2011.100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Ficb.2011.100%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DO.%26aulast%3DLa%2BThangue%26aufirst%3DN.%2BB.%26atitle%3DHdac%2520Inhibitors%2520in%2520Cancer%2520Biology%253A%2520Emerging%2520Mechanisms%2520and%2520Clinical%2520Applications%26jtitle%3DImmunol.%2520Cell%2520Biol.%26date%3D2012%26volume%3D90%26spage%3D85%26epage%3D94%26doi%3D10.1038%2Ficb.2011.100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gryder, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodji, Q. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyelere, A. K.</span></span> <span> </span><span class="NLM_article-title">Targeted Cancer Therapy: Giving Histone Deacetylase Inhibitors All They Need to Succeed</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">505</span>– <span class="NLM_lpage">524</span>, <span class="refDoi"> DOI: 10.4155/fmc.12.3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.4155%2Ffmc.12.3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=22416777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC38XktVajsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=505-524&author=B.+E.+Gryderauthor=Q.+H.+Sodjiauthor=A.+K.+Oyelere&title=Targeted+Cancer+Therapy%3A+Giving+Histone+Deacetylase+Inhibitors+All+They+Need+to+Succeed&doi=10.4155%2Ffmc.12.3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed</span></div><div class="casAuthors">Gryder, Berkley E.; Sodji, Quaovi H.; Oyelere, Adegboyega K.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">505-524</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase inhibitors (HDACis) have now emerged as a powerful new class of small-mol. therapeutics acting through the regulation of the acetylation states of histone proteins (a form of epigenetic modulation) and other non-histone protein targets.  Over 490 clin. trials have been initiated in the last 10 years, culminating in the approval of two structurally distinct HDACis-SAHA (vorinostat, Zolinza) and FK228 (romidepsin, Istodax).  However, the current HDACis have serious limitations, including ineffectively low concns. in solid tumors and cardiac toxicity, which is hindering their progress in the clinic.  Herein, we review the primary paradigms being pursued to overcome these hindrances, including HDAC isoform selectivity, localized administration, and targeting cap groups to achieve selective tissue and cell type distribution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWwrW1IVCIULVg90H21EOLACvtfcHk0livoRDhKsS0bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktVajsL8%253D&md5=234080d1b0862680a68062a03afee20c</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.4155%2Ffmc.12.3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.12.3%26sid%3Dliteratum%253Aachs%26aulast%3DGryder%26aufirst%3DB.%2BE.%26aulast%3DSodji%26aufirst%3DQ.%2BH.%26aulast%3DOyelere%26aufirst%3DA.%2BK.%26atitle%3DTargeted%2520Cancer%2520Therapy%253A%2520Giving%2520Histone%2520Deacetylase%2520Inhibitors%2520All%2520They%2520Need%2520to%2520Succeed%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2012%26volume%3D4%26spage%3D505%26epage%3D524%26doi%3D10.4155%2Ffmc.12.3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, H.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forrester, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of 7-(4-(3-Ethynylphenylamino)-7-Methoxyquinazolin-6-Yloxy)-N-Hydroxyheptan Amide (Cudc-101) as a Potent Multi-Acting Hdac, Egfr, and Her2 Inhibitor for the Treatment of Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2000</span>– <span class="NLM_lpage">2009</span>, <span class="refDoi"> DOI: 10.1021/jm901453q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901453q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhslSgsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2000-2009&author=X.+Caiauthor=H.-X.+Zhaiauthor=J.+Wangauthor=J.+Forresterauthor=H.+Quauthor=L.+Yinauthor=C.-J.+Laiauthor=R.+Baoauthor=C.+Qian&title=Discovery+of+7-%284-%283-Ethynylphenylamino%29-7-Methoxyquinazolin-6-Yloxy%29-N-Hydroxyheptan+Amide+%28Cudc-101%29+as+a+Potent+Multi-Acting+Hdac%2C+Egfr%2C+and+Her2+Inhibitor+for+the+Treatment+of+Cancer&doi=10.1021%2Fjm901453q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer</span></div><div class="casAuthors">Cai, Xiong; Zhai, Hai-Xiao; Wang, Jing; Forrester, Jeffrey; Qu, Hui; Yin, Ling; Lai, Cheng-Jung; Bao, Rudi; Qian, Changgeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2000-2009</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">By incorporating histone deacetylase (HDAC) inhibitory functionality into the pharmacophore of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) inhibitors, we synthesized a novel series of compds. with potent, multiacting HDAC, EGFR, and HER2 inhibition and identified 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide 8 (CUDC-101) as a drug candidate, which is now in clin. development. 8 displays potent in vitro inhibitory activity against HDAC, EGFR, and HER2 with an IC50 of 4.4, 2.4, and 15.7 nM, resp.  In most tumor cell lines tested, 8 exhibits efficient antiproliferative activity with greater potency than vorinostat (SAHA), erlotinib, lapatinib, and combinations of vorinostat/erlotinib and vorinostat/lapatinib.  In vivo, 8 promotes tumor regression or inhibition in various cancer xenograft models including nonsmall cell lung cancer (NSCLC), liver, breast, head and neck, colon, and pancreatic cancers.  These results suggest that a single compd. that simultaneously inhibits HDAC, EGFR, and HER2 may offer greater therapeutic benefits in cancer over single-acting agents through the interference with multiple pathways and potential synergy among HDAC and EGFR/HER2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodBQl1iMXW3rVg90H21EOLACvtfcHk0lj99qEud5QBBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhslSgsb0%253D&md5=d4dc339f2fd750d52e511abf3dbf18bd</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm901453q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901453q%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DX.%26aulast%3DZhai%26aufirst%3DH.-X.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DForrester%26aufirst%3DJ.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DLai%26aufirst%3DC.-J.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DQian%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25207-%25284-%25283-Ethynylphenylamino%2529-7-Methoxyquinazolin-6-Yloxy%2529-N-Hydroxyheptan%2520Amide%2520%2528Cudc-101%2529%2520as%2520a%2520Potent%2520Multi-Acting%2520Hdac%252C%2520Egfr%252C%2520and%2520Her2%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2000%26epage%3D2009%26doi%3D10.1021%2Fjm901453q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span> <span> </span><span class="NLM_article-title">Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">473</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2016.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1016%2Fj.ccell.2016.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=27622335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWitrnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=459-473&author=H.+Zengauthor=J.+Quauthor=N.+Jinauthor=J.+Xuauthor=C.+Linauthor=Y.+Chenauthor=X.+Yangauthor=X.+Heauthor=S.+Tangauthor=X.+Lanauthor=X.+Yangauthor=Z.+Chenauthor=M.+Huangauthor=J.+Dingauthor=M.+Geng&title=Feedback+Activation+of+Leukemia+Inhibitory+Factor+Receptor+Limits+Response+to+Histone+Deacetylase+Inhibitors+in+Breast+Cancer&doi=10.1016%2Fj.ccell.2016.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer</span></div><div class="casAuthors">Zeng, Hanlin; Qu, Jia; Jin, Nan; Xu, Jun; Lin, Chenchu; Chen, Yi; Yang, Xinying; He, Xiang; Tang, Shuai; Lan, Xiaojing; Yang, Xiaotong; Chen, Ziqi; Huang, Min; Ding, Jian; Geng, Meiyu</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">459-473</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) inhibitors have demonstrated clin. benefits in subtypes of hematol. malignancies.  However, the efficacy of HDAC inhibitors in solid tumors remains uncertain.  This study takes breast cancer as a model to understand mechanisms accounting for limited response of HDAC inhibitors in solid tumors and to seek combination solns.  We discover that feedback activation of leukemia inhibitory factor receptor (LIFR) signaling in breast cancer limits the response to HDAC inhibition.  Mechanistically, HDAC inhibition increases histone acetylation at the LIFR gene promoter, which recruits bromodomain protein BRD4, upregulates LIFR expression, and activates JAK1-STAT3 signaling.  Importantly, JAK1 or BRD4 inhibition sensitizes breast cancer to HDAC inhibitors, implicating combination inhibition of HDAC with JAK1 or BRD4 as potential therapies for breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL24sYbhFYeLVg90H21EOLACvtfcHk0lj99qEud5QBBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWitrnI&md5=9ce620c7a19519a95edd714f8012518c</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2016.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2016.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DH.%26aulast%3DQu%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DN.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DTang%26aufirst%3DS.%26aulast%3DLan%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DGeng%26aufirst%3DM.%26atitle%3DFeedback%2520Activation%2520of%2520Leukemia%2520Inhibitory%2520Factor%2520Receptor%2520Limits%2520Response%2520to%2520Histone%2520Deacetylase%2520Inhibitors%2520in%2520Breast%2520Cancer%26jtitle%3DCancer%2520Cell%26date%3D2016%26volume%3D30%26spage%3D459%26epage%3D473%26doi%3D10.1016%2Fj.ccell.2016.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong-Thi, M.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. X. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujulu, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J. J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohlson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (Jak) and Histone Deacetylase (Hdac) Based on Ruxolitinib and Vorinostat</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">8336</span>– <span class="NLM_lpage">8357</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00678</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00678" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=8336-8357&author=L.+Yaoauthor=N.+Mustafaauthor=E.+C.+Tanauthor=A.+Poulsenauthor=P.+Singhauthor=M.-D.+Duong-Thiauthor=J.+X.+T.+Leeauthor=P.+M.+Ramanujuluauthor=W.+J.+Chngauthor=J.+J.+Y.+Yenauthor=S.+Ohlsonauthor=B.+W.+Dymock&title=Design+and+Synthesis+of+Ligand+Efficient+Dual+Inhibitors+of+Janus+Kinase+%28Jak%29+and+Histone+Deacetylase+%28Hdac%29+Based+on+Ruxolitinib+and+Vorinostat&doi=10.1021%2Facs.jmedchem.7b00678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat</span></div><div class="casAuthors">Yao, Lianbin; Mustafa, Nurulhuda; Tan, Eng Chong; Poulsen, Anders; Singh, Prachi; Duong-Thi, Minh-Dao; Lee, Jeannie X. T.; Ramanujulu, Pondy Murugappan; Chng, Wee Joo; Yen, Jeffrey J. Y.; Ohlson, Sten; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8336-8357</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Concomitant inhibition of multiple oncogenic pathways is a desirable goal in cancer therapy.  To achieve such an outcome with a single mol. would simplify treatment regimes.  Herein the core features of ruxolitinib, a marketed JAK1/2 inhibitor, have been merged with the HDAC inhibitor vorinostat, leading to new mols. that are bispecific targeted JAK/HDAC inhibitors.  A preferred pyrazole substituted pyrrolopyrimidine, I (R = H), inhibits JAK1 and HDACs 1, 2, 3, 6, and 10 with IC50 values of less than 20 nM, is <100 nM potent against JAK2 and HDAC11, and is selective for the JAK family against a panel of 97 kinases.  Broad cellular antiproliferative potency of I (R = H) is supported by demonstration of JAK-STAT and HDAC pathway blockade in hematol. cell lines.  Me analog I (R = Me) has an even more selective profile.  This study provides new leads for assessment of JAK and HDAC pathway dual inhibition achieved with a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocWx3JXIW8YbVg90H21EOLACvtfcHk0lj99qEud5QBBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtLzJ&md5=5ac471ee0cc413b08b926803790de7f9</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00678%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DL.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DTan%26aufirst%3DE.%2BC.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DP.%26aulast%3DDuong-Thi%26aufirst%3DM.-D.%26aulast%3DLee%26aufirst%3DJ.%2BX.%2BT.%26aulast%3DRamanujulu%26aufirst%3DP.%2BM.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DYen%26aufirst%3DJ.%2BJ.%2BY.%26aulast%3DOhlson%26aufirst%3DS.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Ligand%2520Efficient%2520Dual%2520Inhibitors%2520of%2520Janus%2520Kinase%2520%2528Jak%2529%2520and%2520Histone%2520Deacetylase%2520%2528Hdac%2529%2520Based%2520on%2520Ruxolitinib%2520and%2520Vorinostat%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D8336%26epage%3D8357%26doi%3D10.1021%2Facs.jmedchem.7b00678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.</span></span> <span> </span><span class="NLM_article-title">Discovery of Thieno 2,3-D Pyrimidine-Based Hydroxamic Acid Derivatives as Bromodomain-Containing Protein 4/Histone Deacetylase Dual Inhibitors Induce Autophagic Cell Death in Colorectal Carcinoma Cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">3678</span>– <span class="NLM_lpage">3700</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b02178</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b02178" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksFajtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=3678-3700&author=Z.+Panauthor=X.+Liauthor=Y.+Wangauthor=Q.+Jiangauthor=L.+Jiangauthor=M.+Zhangauthor=N.+Zhangauthor=F.+Wuauthor=B.+Liuauthor=G.+He&title=Discovery+of+Thieno+2%2C3-D+Pyrimidine-Based+Hydroxamic+Acid+Derivatives+as+Bromodomain-Containing+Protein+4%2FHistone+Deacetylase+Dual+Inhibitors+Induce+Autophagic+Cell+Death+in+Colorectal+Carcinoma+Cells&doi=10.1021%2Facs.jmedchem.9b02178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Thieno[2,3-d]pyrimidine-Based Hydroxamic Acid Derivatives as Bromodomain-Containing Protein 4/Histone Deacetylase Dual Inhibitors Induce Autophagic Cell Death in Colorectal Carcinoma Cells</span></div><div class="casAuthors">Pan, Zhaoping; Li, Xiang; Wang, Yujia; Jiang, Qinglin; Jiang, Li; Zhang, Min; Zhang, Nan; Wu, Fengbo; Liu, Bo; He, Gu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3678-3700</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bromodomain-contg. protein 4 (BRD4) and histone deacetylases (HDAC) are both attractive epigenetic targets in cancer and other chronic diseases.  Based on the integrated fragment-based drug design, synthesis, and in vitro and in vivo evaluations, a series of novel thieno[2,3-d]pyrimidine-based hydroxamic acid derivs. are discovered as selective BRD4-HDAC dual inhibitors.  Compd. 17c is the most potent inhibitor for BRD4 and HDAC with IC50 values at nanomolar levels, as well as the expression level of c-Myc, and increases the acetylation of histone H3.  Moreover, 17c presents inhibitory effects on the proliferation of colorectal carcinoma (CRC) cells via inducing autophagic cell death.  It also has a good pharmacokinetic profile in rats and oral bioavailability of 40.5%.  In the HCT-116 xenograft in vivo models, 17c displays potent inhibitory efficiency on tumor growth by inducing autophagic cell death and suppressing IL6-JAK-STAT signaling pathways.  Our results suggest that the BRD4-HDAC dual inhibition might be an attractive therapeutic strategy for CRC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2FHKdnuD3QLVg90H21EOLACvtfcHk0ljevMLecSKDxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksFajtLs%253D&md5=ce6446afe48f80165d2b21aee04571f6</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b02178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b02178%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DWu%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DHe%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520Thieno%25202%252C3-D%2520Pyrimidine-Based%2520Hydroxamic%2520Acid%2520Derivatives%2520as%2520Bromodomain-Containing%2520Protein%25204%252FHistone%2520Deacetylase%2520Dual%2520Inhibitors%2520Induce%2520Autophagic%2520Cell%2520Death%2520in%2520Colorectal%2520Carcinoma%2520Cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D3678%26epage%3D3700%26doi%3D10.1021%2Facs.jmedchem.9b02178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muro-Cacho, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falcone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairclough, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laudano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levitzki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jove, R.</span></span> <span> </span><span class="NLM_article-title">Constitutive Activation of Stat3 by the Src and Jak Tyrosine Kinases Participates in Growth Regulation of Human Breast Carcinoma Cells</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2499</span>– <span class="NLM_lpage">2513</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1204349</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1038%2Fsj.onc.1204349" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=11420660" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjvFGmt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2001&pages=2499-2513&author=R.+Garciaauthor=T.+L.+Bowmanauthor=G.+Niuauthor=H.+Yuauthor=S.+Mintonauthor=C.+A.+Muro-Cachoauthor=C.+E.+Coxauthor=R.+Falconeauthor=R.+Faircloughauthor=S.+Parsonsauthor=A.+Laudanoauthor=A.+Gazitauthor=A.+Levitzkiauthor=A.+Krakerauthor=R.+Jove&title=Constitutive+Activation+of+Stat3+by+the+Src+and+Jak+Tyrosine+Kinases+Participates+in+Growth+Regulation+of+Human+Breast+Carcinoma+Cells&doi=10.1038%2Fsj.onc.1204349"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells</span></div><div class="casAuthors">Garcia, Roy; Bowman, Tammy L.; Niu, Guilian; Yu, Hua; Minton, Sue; Muro-Cacho, Carlos A.; Cox, Charles E.; Falcone, Robert; Fairclough, Rita; Parsons, Sarah; Laudano, Andy; Gazit, Aviv; Levitzki, Alexander; Kraker, Alan; Jove, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2499-2513</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Constitutive activation of signal transducer and activator of transcription (STAT) proteins has been detected in a wide variety of human primary tumor specimens and tumor cell lines including blood malignancies, head and neck cancer, and breast cancer.  We have previously demonstrated a high frequency of Stat3 DNA-binding activity that is constitutively-induced by an unknown mechanism in human breast cancer cell lines possessing elevated EGF receptor (EGF-R) and c-Src kinase activities.  Using tyrosine kinase selective inhibitors, we show here that Src and JAK family tyrosine kinases cooperate to mediate constitutive Stat3 activation in the absence of EGF stimulation in model human breast cancer cell lines.  Inhibition of Src or JAKs results in dose-dependent suppression of Stat3 DNA-binding activity, which is accompanied by growth inhibition and induction of programmed cell death.  In addn., transfection of a dominant-neg. form of Stat3 leads to growth inhibition involving apoptosis of breast cancer cells.  These results indicate that the biol. effects of the Src and JAK tyrosine kinase inhibitors are at least partially mediated by blocking Stat3 signaling.  While EGF-R kinase activity is not required for constitutive Stat3 activation in breast cancer cells, EGF stimulation further increases STAT DNA-binding activity, consistent with an important role for EGF-R in STAT signaling and malignant progression.  Anal. of primary breast tumor specimens from patients with advanced disease revealed that the majority exhibit elevated STAT DNA-binding activity compared to adjacent non-tumor tissues.  Our findings, taken together, suggest that tyrosine kinases transduce signals through Stat3 protein that contribute to the growth and survival of human breast cancer cells in culture and potentially in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5BSpinbxg3rVg90H21EOLACvtfcHk0ljevMLecSKDxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjvFGmt7k%253D&md5=a941c45ef8fbf78234c6f66b741e7be2</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1204349&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1204349%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia%26aufirst%3DR.%26aulast%3DBowman%26aufirst%3DT.%2BL.%26aulast%3DNiu%26aufirst%3DG.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DMinton%26aufirst%3DS.%26aulast%3DMuro-Cacho%26aufirst%3DC.%2BA.%26aulast%3DCox%26aufirst%3DC.%2BE.%26aulast%3DFalcone%26aufirst%3DR.%26aulast%3DFairclough%26aufirst%3DR.%26aulast%3DParsons%26aufirst%3DS.%26aulast%3DLaudano%26aufirst%3DA.%26aulast%3DGazit%26aufirst%3DA.%26aulast%3DLevitzki%26aufirst%3DA.%26aulast%3DKraker%26aufirst%3DA.%26aulast%3DJove%26aufirst%3DR.%26atitle%3DConstitutive%2520Activation%2520of%2520Stat3%2520by%2520the%2520Src%2520and%2520Jak%2520Tyrosine%2520Kinases%2520Participates%2520in%2520Growth%2520Regulation%2520of%2520Human%2520Breast%2520Carcinoma%2520Cells%26jtitle%3DOncogene%26date%3D2001%26volume%3D20%26spage%3D2499%26epage%3D2513%26doi%3D10.1038%2Fsj.onc.1204349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boengler, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilfikerkleiner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drexler, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heusch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, R.</span></span> <span> </span><span class="NLM_article-title">The Myocardial Jak/Stat Pathway: From Protection to Failure</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">172</span>– <span class="NLM_lpage">185</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2008.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1016%2Fj.pharmthera.2008.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=18786563" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Knsb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2008&pages=172-185&author=K.+Boenglerauthor=D.+Hilfikerkleinerauthor=H.+Drexlerauthor=G.+Heuschauthor=R.+Schulz&title=The+Myocardial+Jak%2FStat+Pathway%3A+From+Protection+to+Failure&doi=10.1016%2Fj.pharmthera.2008.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The myocardial JAK/STAT pathway: From protection to failure</span></div><div class="casAuthors">Boengler, Kerstin; Hilfiker-Kleiner, Denise; Drexler, Helmut; Heusch, Gerd; Schulz, Rainer</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">172-185</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Subsequent signal transduction involves activation of the janus kinase (JAK) and signal transducer and activator of transcription (STAT) proteins.  STAT proteins are translocated into the nucleus, where they bind to the promoter region of target genes and are thereby involved in regulating the transcription of target genes.  In the first part, the present review focuses on the role of STAT3 in ischemia/reperfusion injury and in cardioprotection by ischemic pre- and postconditioning.  In the heart, ischemia induces an increase in IL-6 cytokines, which is assocd. with activation of STAT3.  Genetic modification of the myocardial STAT3 protein content shows a protective role of STAT3 on infarct size after ischemia/reperfusion injury.  The cardioprotection by both early and late ischemic preconditioning as well as by ischemic postconditioning involves an activation of STAT3 and is dependent on STAT3 protein level.  Whereas the infarct-sparing effect of late preconditioning is clearly mediated by an increase in transcription-mediated protein synthesis, early preconditioning is independent of gene transcription, suggesting a role of STAT3 independent of transcriptional regulation.  Possibly, STAT3 plays a role in modifying mitochondrial function, organelles central for the cardioprotection by pre- and postconditioning.  In the second part, the role of STAT3 in physiol. stresses such as aging and pregnancy, as well as in pathophysiol. situations such as myocardial infarction and heart failure is summarized.  Furthermore, the requirements for the use of STAT3 as a target for treatment strategies of cardiovascular diseases is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCSELFwPuAVLVg90H21EOLACvtfcHk0ljevMLecSKDxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Knsb3J&md5=914abdaa6c7d463b42bd27cfa9aed73d</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2008.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2008.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DBoengler%26aufirst%3DK.%26aulast%3DHilfikerkleiner%26aufirst%3DD.%26aulast%3DDrexler%26aufirst%3DH.%26aulast%3DHeusch%26aufirst%3DG.%26aulast%3DSchulz%26aufirst%3DR.%26atitle%3DThe%2520Myocardial%2520Jak%252FStat%2520Pathway%253A%2520From%2520Protection%2520to%2520Failure%26jtitle%3DPharmacol.%2520Ther.%26date%3D2008%26volume%3D120%26spage%3D172%26epage%3D185%26doi%3D10.1016%2Fj.pharmthera.2008.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jove, R.</span></span> <span> </span><span class="NLM_article-title">Stats in Cancer Inflammation and Immunity: A Leading Role for Stat3</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">798</span>– <span class="NLM_lpage">809</span>, <span class="refDoi"> DOI: 10.1038/nrc2734</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1038%2Fnrc2734" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=19851315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlSjur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=798-809&author=H.+Yuauthor=D.+Pardollauthor=R.+Jove&title=Stats+in+Cancer+Inflammation+and+Immunity%3A+A+Leading+Role+for+Stat3&doi=10.1038%2Fnrc2734"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">STATs in cancer inflammation and immunity: a leading role for STAT3</span></div><div class="casAuthors">Yu, Hua; Pardoll, Drew; Jove, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">798-809</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Commensurate with their roles in regulating cytokine-dependent inflammation and immunity, signal transducer and activator of transcription (STAT) proteins are central in detg. whether immune responses in the tumor microenvironment promote or inhibit cancer.  Persistently activated STAT3 and, to some extent, STAT5 increase tumor cell proliferation, survival and invasion while suppressing anti-tumor immunity.  The persistent activation of STAT3 also mediates tumor-promoting inflammation.  STAT3 has this dual role in tumor inflammation and immunity by promoting pro-oncogenic inflammatory pathways, including nuclear factor-κB (NF-κB) and interleukin-6 (IL-6)-GP130-Janus kinase (JAK) pathways, and by opposing STAT1- and NF-κB-mediated T helper 1 anti-tumor immune responses.  Consequently, STAT3 is a promising target to redirect inflammation for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYvEMN5YrxbbVg90H21EOLACvtfcHk0lh6uiHULKiDcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlSjur%252FP&md5=e431d0bd9eabd8f1ef703211be3d5cc9</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnrc2734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2734%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%26aulast%3DPardoll%26aufirst%3DD.%26aulast%3DJove%26aufirst%3DR.%26atitle%3DStats%2520in%2520Cancer%2520Inflammation%2520and%2520Immunity%253A%2520A%2520Leading%2520Role%2520for%2520Stat3%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D798%26epage%3D809%26doi%3D10.1038%2Fnrc2734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neamati, N.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Inhibitors of Signal Transducer and Activator of Transcription 3 (Stat3) Protein</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6645</span>– <span class="NLM_lpage">6668</span>, <span class="refDoi"> DOI: 10.1021/jm300207s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300207s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC38Xnsl2msrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6645-6668&author=B.+Debnathauthor=S.+Xuauthor=N.+Neamati&title=Small+Molecule+Inhibitors+of+Signal+Transducer+and+Activator+of+Transcription+3+%28Stat3%29+Protein&doi=10.1021%2Fjm300207s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Inhibitors of Signal Transducer and Activator of Transcription 3 (Stat3) Protein</span></div><div class="casAuthors">Debnath, Bikash; Xu, Shili; Neamati, Nouri</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6645-6668</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Signal transducer and activator of transcription 3 (Stat3) is a transcription factor belonging to the STAT protein family, members of which regulate a wide variety of biol. processes, including cell growth, proliferation, survival, differentiation, development, movement and inflammation in response to extracellular signaling mols. such as cytokines and growth factors.  Receptor assocd. tyrosine kinases phosphorylate Stat3 protein at Tyr705 and enable it to dimerize and subsequently enter the nucleus where it activates the transcription of its target genes.  Accumulating evidence has established Stat3's role in oncogenesis, cardiovascular diseases, rheumatoid arthritis, fibrotic, and Alzheimer's diseases.  Thus, Stat3 inhibition is a promising therapeutic approach not only for cancer, but also for other diseases.  Although Stat3 has been considered as an important therapeutic target, progress in discovery and development of effective and specific Stat3 inhibitors remains slow.  In this article we summarize Stat3 inhibitors published between 2006 and 2011.  New strategies along with novel technologies are required to achieve breakthrough in the development of Stat3 inhibitors that can be translated into clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWWQl9gV1-ZLVg90H21EOLACvtfcHk0lh6uiHULKiDcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xnsl2msrc%253D&md5=f5f3ac9f8fc2326c75edd2a9c136275b</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm300207s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300207s%26sid%3Dliteratum%253Aachs%26aulast%3DDebnath%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DNeamati%26aufirst%3DN.%26atitle%3DSmall%2520Molecule%2520Inhibitors%2520of%2520Signal%2520Transducer%2520and%2520Activator%2520of%2520Transcription%25203%2520%2528Stat3%2529%2520Protein%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6645%26epage%3D6668%26doi%3D10.1021%2Fjm300207s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowe, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.-L.</span></span> <span> </span><span class="NLM_article-title">Stat3 Inhibition, a Novel Approach to Enhancing Targeted Therapy in Human Cancers</span>. <i>Int. J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">1181</span>– <span class="NLM_lpage">1191</span>, <span class="refDoi"> DOI: 10.3892/ijo.2012.1568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.3892%2Fijo.2012.1568" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=22842992" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFyntLjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2012&pages=1181-1191&author=X.+Wangauthor=P.+J.+Croweauthor=D.+Goldsteinauthor=J.-L.+Yang&title=Stat3+Inhibition%2C+a+Novel+Approach+to+Enhancing+Targeted+Therapy+in+Human+Cancers&doi=10.3892%2Fijo.2012.1568"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (review)</span></div><div class="casAuthors">Wang, Xiaochun; Crowe, Philip J.; Goldstein, David; Yang, Jia-Lin</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1181-1191</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1019-6439</span>.
    
            (<span class="NLM_cas:orgname">International Journal of Oncology</span>)
        </div><div class="casAbstract">A review.  Signal transducer and activator of transcription 3 (STAT3) regulates many crit. functions in human normal and malignant tissues, such as differentiation, proliferation, survival, angiogenesis and immune function.  Constitutive activation of STAT3 is implicated in a wide range of human cancers.  As such, STAT3 has been studied as a tumor therapeutic target.  This review aimed principally to summarize the updated research on STAT3 inhibition studies and their therapeutic potential in solid tumors.  Recent literature assocd. with STAT3 inhibition was reviewed through PubMed and Medline database, followed by crit. comparison and anal.  Constitutive activation of STAT3 has been identified as abnormal and oncogenic.  The pathway of STAT3 activation and signal transduction identifies 3 approaches for inhibition: modulating upstream pos. or neg. regulators, regulating RNA (DN-STAT3, anti-sense RNA, siRNA and microRNA) or targeting STAT3 protein at different domains.  The last approach using small mol. STAT3 inhibitors has been the most examd. so far with both preclin. and clin. studies.  Targeting STAT3 using a specific inhibitor may be a useful cancer treatment approach, with the potential for a broad clin. impact.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnx1B_eI0cs7Vg90H21EOLACvtfcHk0lh6uiHULKiDcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFyntLjF&md5=91d64864c492ebe00e5d6a1cc6072284</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.3892%2Fijo.2012.1568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.2012.1568%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DCrowe%26aufirst%3DP.%2BJ.%26aulast%3DGoldstein%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DJ.-L.%26atitle%3DStat3%2520Inhibition%252C%2520a%2520Novel%2520Approach%2520to%2520Enhancing%2520Targeted%2520Therapy%2520in%2520Human%2520Cancers%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2012%26volume%3D41%26spage%3D1181%26epage%3D1191%26doi%3D10.3892%2Fijo.2012.1568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel Stat3 Small Molecule Inhibitors Via in Silico Site-Directed Fragment-Based Drug Design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">4402</span>– <span class="NLM_lpage">4412</span>, <span class="refDoi"> DOI: 10.1021/jm400080c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400080c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntVOktbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4402-4412&author=W.+Yuauthor=H.+Xiaoauthor=J.+Linauthor=C.+Li&title=Discovery+of+Novel+Stat3+Small+Molecule+Inhibitors+Via+in+Silico+Site-Directed+Fragment-Based+Drug+Design&doi=10.1021%2Fjm400080c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel STAT3 Small Molecule Inhibitors via in Silico Site-Directed Fragment-Based Drug Design</span></div><div class="casAuthors">Yu, Wenying; Xiao, Hui; Lin, Jiayuh; Li, Chenglong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4402-4412</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Constitutive activation of signal transducer and activator of transcription 3 (STAT3) has been validated as an attractive therapeutic target for cancer therapy.  To stop both STAT3 activation and dimerization, a viable strategy is to design inhibitors blocking its SH2 domain phosphotyrosine binding site that is responsible for both actions.  A new fragment-based drug design (FBDD) strategy, in silico site-directed FBDD, was applied in this study.  A designed novel compd., 5,8-dioxo-6-(pyridin-3-ylamino)-5,8-dihydronaphthalene-1-sulfonamide (LY5), was confirmed to bind to STAT3 SH2 by fluorescence polarization assay.  In addn., four out of the five chosen compds. have IC50 values lower than 5 μM for the U2OS cancer cells. 8 (LY5) has an IC50 range in 0.5-1.4 μM in various cancer cell lines. 8 also suppresses tumor growth in an in vivo mouse model.  This study has demonstrated the utility of this approach and could be used to other drug targets in general.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq76v3IMxJHwLVg90H21EOLACvtfcHk0ljzgD_QzPyyPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntVOktbk%253D&md5=7231b2e9682f9e9046debcaa461a1d59</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm400080c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400080c%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DW.%26aulast%3DXiao%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520Novel%2520Stat3%2520Small%2520Molecule%2520Inhibitors%2520Via%2520in%2520Silico%2520Site-Directed%2520Fragment-Based%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4402%26epage%3D4412%26doi%3D10.1021%2Fjm400080c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siveen, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sikka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surana, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, B. K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sethi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishayee, A.</span></span> <span> </span><span class="NLM_article-title">Targeting the Stat3 Signaling Pathway in Cancer: Role of Synthetic and Natural Inhibitors</span>. <i>Biochim. Biophys. Acta Rev. Canc.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>1845</i></span>,  <span class="NLM_fpage">136</span>– <span class="NLM_lpage">154</span>, <span class="refDoi"> DOI: 10.1016/j.bbcan.2013.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1016%2Fj.bbcan.2013.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=24388873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmt1agu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1845&publication_year=2014&pages=136-154&author=K.+S.+Siveenauthor=S.+Sikkaauthor=R.+Suranaauthor=X.+Daiauthor=J.+Zhangauthor=A.+P.+Kumarauthor=B.+K.+H.+Tanauthor=G.+Sethiauthor=A.+Bishayee&title=Targeting+the+Stat3+Signaling+Pathway+in+Cancer%3A+Role+of+Synthetic+and+Natural+Inhibitors&doi=10.1016%2Fj.bbcan.2013.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors</span></div><div class="casAuthors">Siveen, Kodappully Sivaraman; Sikka, Sakshi; Surana, Rohit; Dai, Xiaoyun; Zhang, Jingwen; Kumar, Alan Prem; Tan, Benny K. H.; Sethi, Gautam; Bishayee, Anupam</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Reviews on Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">1845</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">136-154</span>CODEN:
                <span class="NLM_cas:coden">BBACEU</span>;
        ISSN:<span class="NLM_cas:issn">0304-419X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Signal transducers and activators of transcription (STATs) comprise a family of cytoplasmic transcription factors that mediate intracellular signaling that is usually generated at cell surface receptors and thereby transmit it to the nucleus.  Numerous studies have demonstrated constitutive activation of STAT3 in a wide variety of human tumors, including hematol. malignancies (leukemias, lymphomas, and multiple myeloma) as well as diverse solid tumors (such as head and neck, breast, lung, gastric, hepatocellular, colorectal and prostate cancers).  There is strong evidence to suggest that aberrant STAT3 signaling promotes initiation and progression of human cancers by either inhibiting apoptosis or inducing cell proliferation, angiogenesis, invasion, and metastasis.  Suppression of STAT3 activation results in the induction of apoptosis in tumor cells, and accordingly its pharmacol. modulation by tyrosine kinase inhibitors, antisense oligonucleotides, decoy nucleotides, dominant neg. proteins, RNA interference and chemopreventive agents have been employed to suppress the proliferation of various human cancer cells in culture and tumorigenicity in vivo.  However, the identification and development of novel drugs that can target deregulated STAT3 activation effectively remains an important scientific and clin. challenge.  This review presents the evidence for crit. roles of STAT3 in oncogenesis and discusses the potential for development of novel cancer therapies based on mechanistic understanding of STAT3 signaling cascade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeL6KQ0obpY7Vg90H21EOLACvtfcHk0ljzgD_QzPyyPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmt1agu7Y%253D&md5=c2514f54684fb89a2f5ac489425f42d5</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.bbcan.2013.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbcan.2013.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DSiveen%26aufirst%3DK.%2BS.%26aulast%3DSikka%26aufirst%3DS.%26aulast%3DSurana%26aufirst%3DR.%26aulast%3DDai%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DKumar%26aufirst%3DA.%2BP.%26aulast%3DTan%26aufirst%3DB.%2BK.%2BH.%26aulast%3DSethi%26aufirst%3DG.%26aulast%3DBishayee%26aufirst%3DA.%26atitle%3DTargeting%2520the%2520Stat3%2520Signaling%2520Pathway%2520in%2520Cancer%253A%2520Role%2520of%2520Synthetic%2520and%2520Natural%2520Inhibitors%26jtitle%3DBiochim.%2520Biophys.%2520Acta%2520Rev.%2520Canc.%26date%3D2014%26volume%3D1845%26spage%3D136%26epage%3D154%26doi%3D10.1016%2Fj.bbcan.2013.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.-y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2718</span>– <span class="NLM_lpage">2731</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01489</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01489" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjsFalurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2718-2731&author=W.+Yuauthor=C.+Liauthor=W.+Zhangauthor=Y.+Xiaauthor=S.+Liauthor=J.-y.+Linauthor=K.+Yuauthor=M.+Liuauthor=L.+Yangauthor=J.+Luoauthor=Y.+Chenauthor=H.+Sunauthor=L.+Kong&title=Discovery+of+an+Orally+Selective+Inhibitor+of+Signal+Transducer+and+Activator+of+Transcription+3+Using+Advanced+Multiple+Ligand+Simultaneous+Docking&doi=10.1021%2Facs.jmedchem.6b01489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking</span></div><div class="casAuthors">Yu, Wenying; Li, Chenglong; Zhang, Wenda; Xia, Yuanzheng; Li, Shanshan; Lin, Jia-yuh; Yu, Keqin; Liu, Mu; Yang, Lei; Luo, Jianguang; Chen, Yijun; Sun, Hongbin; Kong, Lingyi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2718-2731</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Targeting signal transducer and activator of transcription 3 (STAT3) is a potential anticancer strategy.  However, STAT3 inhibitors with good selectivity and bioavailability are rare.  The aim of this study was to discover selective direct STAT3 inhibitors with good drug-likeness.  By advanced multiple ligand simultaneous docking (AMLSD) method, compd. 9 (5,8-dioxo-6-((2-(piperazin-1-yl)phenyl)amino)-5,8-dihydronaphthalene-1-sulfonamide) was designed as an orally-bioavailable STAT3 inhibitor, which presented superior druggability and selectivity to other representative STAT3 inhibitors.  Compd. 9 directly and selectively inhibited the pY705 site of STAT3 with an affinity (Ki) of 440nM.  The IC50 of 9 for breast cancer cell MDA-MB-231 was 184-fold lower than its IC50 for normal breast epithelial cell MCF-10A.  Compd. 9 in vivo induced significant antitumor responses better than Gefitinib and its therapeutic index should be over 100, indicating good safety of 9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiT8F_tCrky7Vg90H21EOLACvtfcHk0ljzgD_QzPyyPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjsFalurw%253D&md5=d9554e49fd17a559e8c7171f36c53607</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01489%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DXia%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DJ.-y.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DKong%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520an%2520Orally%2520Selective%2520Inhibitor%2520of%2520Signal%2520Transducer%2520and%2520Activator%2520of%2520Transcription%25203%2520Using%2520Advanced%2520Multiple%2520Ligand%2520Simultaneous%2520Docking%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2718%26epage%3D2731%26doi%3D10.1021%2Facs.jmedchem.6b01489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of Monocarbonyl Curcumin-Btp Hybrids as Stat3 Inhibitors for Drug-Sensitive and Drug-Resistant Breast Cancer Therapy</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">46352</span>, <span class="refDoi"> DOI: 10.1038/srep46352</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1038%2Fsrep46352" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=28397855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtVyitbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=46352&author=W.+Zhangauthor=J.+Guoauthor=S.+Liauthor=T.+Maauthor=D.+Xuauthor=C.+Hanauthor=F.+Liuauthor=W.+Yuauthor=L.+Kong&title=Discovery+of+Monocarbonyl+Curcumin-Btp+Hybrids+as+Stat3+Inhibitors+for+Drug-Sensitive+and+Drug-Resistant+Breast+Cancer+Therapy&doi=10.1038%2Fsrep46352"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of monocarbonyl curcumin-BTP hybrids as STAT3 inhibitors for drug-sensitive and drug-resistant breast cancer therapy</span></div><div class="casAuthors">Zhang, Wenda; Guo, Jianpeng; Li, Shanshan; Ma, Ting; Xu, Dingqiao; Han, Chao; Liu, Feiyan; Yu, Wenying; Kong, Lingyi</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">46352</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) is a well-known antitumor target.  Exogenous ROS insult can lead to selective cytotoxicity against cancer cells.  A combination of STAT3 inhibition and "oxidn. therapy" may be a new strategy to address the multidrug-resistance issue due to their important roles in the survival and drug resistance of cancer cells.  Here, a series of novel curcumin-BTP hybrids were designed and evaluated as STAT3 inhibitors with ROS prodn. activity.  Compd. 6b exerted the best antitumor activity and selectivity for MCF-7 and MCF-7/DOX cells (IC50 = 0.52 μM and 0.40 μM, resp.), while its IC50 value for MCF-10A breast epithelial cells was 7.72 μM.  Furthermore, compd. 6b suppressed STAT3 phosphorylation, nuclear translocation and DNA-binding activity and the expression of STAT3 specific oncogenes.  Increases in the level of IL-6-induced p-STAT3 were also inhibited by 6b without influencing IFN-γ-induced p-STAT1 expression.  Addnl., 6b effectively promoted intracellular ROS accumulation, induced cancer cell apoptosis and cell cycle arrest, abolished the colony formation ability of breast cancer cells, and inhibited P-gp expression in MCF-7/DOX cells.  Finally, 6b suppressed the growth of implanted human breast cancer in vivo.  Our findings highlight that 6b may be a promising therapeutic agent for drug-sensitive and drug-resistant breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxX6NWyOZ_v7Vg90H21EOLACvtfcHk0ljHOqXPNGoT-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtVyitbc%253D&md5=aa97b030e4e00945730f51a47f41837e</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fsrep46352&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep46352%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DMa%26aufirst%3DT.%26aulast%3DXu%26aufirst%3DD.%26aulast%3DHan%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DKong%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520Monocarbonyl%2520Curcumin-Btp%2520Hybrids%2520as%2520Stat3%2520Inhibitors%2520for%2520Drug-Sensitive%2520and%2520Drug-Resistant%2520Breast%2520Cancer%2520Therapy%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D46352%26doi%3D10.1038%2Fsrep46352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.</span></span> <span> </span><span class="NLM_article-title">Antagonizing Stat3 Activation with Benzo B Thiophene 1, 1-Dioxide Based Small Molecules</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">538</span>– <span class="NLM_lpage">550</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.09.068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1016%2Fj.ejmech.2016.09.068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=27718470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1ejtL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2017&pages=538-550&author=W.+Zhangauthor=T.+Maauthor=S.+Liauthor=Y.+Yangauthor=J.+Guoauthor=W.+Yuauthor=L.+Kong&title=Antagonizing+Stat3+Activation+with+Benzo+B+Thiophene+1%2C+1-Dioxide+Based+Small+Molecules&doi=10.1016%2Fj.ejmech.2016.09.068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Antagonizing STAT3 activation with benzo[b]thiophene 1, 1-dioxide based small molecules</span></div><div class="casAuthors">Zhang, Wenda; Ma, Ting; Li, Shanshan; Yang, Yanwei; Guo, Jianpeng; Yu, Wenying; Kong, Lingyi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">538-550</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">STAT3 is an attractive therapeutic target for cancer therapy.  However, due to low potency or poor druggability, none of its inhibitors are clin. available.  Herein, a series of aminobenzo[b]thiophene 1,1-dioxides with good drug-likeness properties were designed, synthesized and evaluated as STAT3 inhibitors.  Most of them exhibited higher antitumor activity than the small-mol. STAT3 inhibitor, Stattic.  Compd. I was the most potent and had an IC50 range in 0.33-0.75 μM in various cancer cell lines.  The overexpressed and IL-6 induced phosphorylation levels of STAT3 were both inhibited by I without influencing the phosphorylation levels of the upstream kinases Src and Jak2. 15 also suppressed the expressions of STAT3 downstream gene, Bcl-2.  I also suppressed the expressions of STAT3 downstream gene, Bcl-2.  I effectively increased the ROS levels of cancer cells, induced cancer cell apoptosis, and abolished the colony formation ability of cancer cells without affecting bypass kinase p-Erk.  Furthermore, I in vivo induced significant antitumor responses, and exhibited less toxicity than Doxorubicin.  Together, this study described a class of new STAT3 inhibitors as antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4EWN80TpUpbVg90H21EOLACvtfcHk0ljHOqXPNGoT-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1ejtL7I&md5=395e6ea180776127e98bc2a92f3d603b</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.09.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.09.068%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DMa%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DKong%26aufirst%3DL.%26atitle%3DAntagonizing%2520Stat3%2520Activation%2520with%2520Benzo%2520B%2520Thiophene%25201%252C%25201-Dioxide%2520Based%2520Small%2520Molecules%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D125%26spage%3D538%26epage%3D550%26doi%3D10.1016%2Fj.ejmech.2016.09.068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of New Benzensulfonamide Derivatives as Tripedal Stat3 Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">752</span>– <span class="NLM_lpage">764</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.03.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1016%2Fj.ejmech.2018.03.053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=29674294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnslSru7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2018&pages=752-764&author=J.+Guoauthor=W.+Yuauthor=G.+Caiauthor=W.+Zhangauthor=S.+Liauthor=J.+Zhuauthor=D.+Songauthor=L.+Kong&title=Discovery+of+New+Benzensulfonamide+Derivatives+as+Tripedal+Stat3+Inhibitors&doi=10.1016%2Fj.ejmech.2018.03.053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of new benzensulfonamide derivatives as tripedal STAT3 inhibitors</span></div><div class="casAuthors">Guo, Jianpeng; Yu, Wenying; Cai, Guiping; Zhang, Wenda; Li, Shanshan; Zhu, Jiawen; Song, Dongmei; Kong, Lingyi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">752-764</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Persistent activated STAT3 has a striking correlation with cancer development and inhibition of STAT3 signaling pathway is a novel therapeutic way for human cancers.  Among STAT family, STAT1 and STAT3 play opposite roles in tumorigenesis.  However, the discovery of selective STAT3 inhibitors is still challenging to date.  In this study, a series of small-mol. (MW<500) benzensulfanilamide derivs. were designed to selectively suppress STAT3 activation for anti-cancer treatment.  The most potent compd. 11 inhibited both overexpressed and IL-6 induced STAT3 phosphorylation, whereas 11 displayed little effect on the phosphorylation of other STAT isoforms STAT1, STAT5, demonstrating 11 was a selective STAT3 inhibitor.  Meanwhile, 11 dismissed STAT3 DNA binding activity and colony formation.  In addn., 11 elevated the ROS level and induced apoptosis of cancer cells.  Furthermore, 11 effectively suppressed tumor growth in an in vivo mouse-xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjwneUbz5BgbVg90H21EOLACvtfcHk0ljHOqXPNGoT-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnslSru7w%253D&md5=9f46716463f5610a25bffcfb85b2031a</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.053%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DCai%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DSong%26aufirst%3DD.%26aulast%3DKong%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520New%2520Benzensulfonamide%2520Derivatives%2520as%2520Tripedal%2520Stat3%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D151%26spage%3D752%26epage%3D764%26doi%3D10.1016%2Fj.ejmech.2018.03.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.</span></span> <span> </span><span class="NLM_article-title">A New Synthetic Derivative of Cryptotanshinone Kyz3 as Stat3 Inhibitor for Triple-Negative Breast Cancer Therapy</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1098</span>, <span class="refDoi"> DOI: 10.1038/s41419-018-1139-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1038%2Fs41419-018-1139-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=30368518" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A280%3ADC%252BB3cvktVGitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1098&author=W.+Zhangauthor=W.+Yuauthor=G.+Caiauthor=J.+Zhuauthor=C.+Zhangauthor=S.+Liauthor=J.+Guoauthor=G.+Yinauthor=C.+Chenauthor=L.+Kong&title=A+New+Synthetic+Derivative+of+Cryptotanshinone+Kyz3+as+Stat3+Inhibitor+for+Triple-Negative+Breast+Cancer+Therapy&doi=10.1038%2Fs41419-018-1139-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">A new synthetic derivative of cryptotanshinone KYZ3 as STAT3 inhibitor for triple-negative breast cancer therapy</span></div><div class="casAuthors">Zhang Wenda; Yu Wenying; Cai Guiping; Zhu Jiawen; Zhang Chao; Li Shanshan; Guo Jianpeng; Yin Guoping; Chen Chen; Kong Lingyi</div><div class="citationInfo"><span class="NLM_cas:title">Cell death & disease</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1098</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Silencing STAT3 is confirmed as a promising therapeutic strategy for triple-negative breast cancer (TNBC) therapy to address the issue of its poor prognosis.  In this study, the natural product cryptotanshinone was firstly remodeled and modified as a more effective STAT3 inhibitor by structure-based strategy.  The synthetic derivative KYZ3 had 22-24-fold increase in antitumor activity than cryptotanshinone on two TNBC cell lines but had little effect on normal breast epithelial MCF-10A cells.  Further investigation showed that KYZ3 inhibited persistent STAT3 phosphorylation.  It also prevented the STAT3 protein nuclear translocation to regulate the expressions of the target oncogenes including Bax and Bcl-2.  Furthermore, KYZ3 inhibited TNBC cell metastasis by decreasing the levels of MMP-9 which were directly regulated by activated STAT3.  A STAT3 plasmid transfecting assay suggested that KYZ3 induced tumor cell apoptosis mainly by targeting STAT3.  Finally, KYZ3 suppressed the growth of tumors resulting from subcutaneous implantation of MDA-MB-231 cells in vivo.  Taken together, KYZ3 may be a promising cancer therapeutic agent for TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT8cW2iZzjIi7YtC3U5jeOifW6udTcc2eYz6OLbYFt3cbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvktVGitg%253D%253D&md5=6900636d864146ab6c03dd4378075316</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fs41419-018-1139-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41419-018-1139-z%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DCai%26aufirst%3DG.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DYin%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DKong%26aufirst%3DL.%26atitle%3DA%2520New%2520Synthetic%2520Derivative%2520of%2520Cryptotanshinone%2520Kyz3%2520as%2520Stat3%2520Inhibitor%2520for%2520Triple-Negative%2520Breast%2520Cancer%2520Therapy%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2018%26volume%3D9%26spage%3D1098%26doi%3D10.1038%2Fs41419-018-1139-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of Fluorescent Coumarin-Benzo B Thiophene 1, 1-Dioxide Conjugates as Mitochondria-Targeting Antitumor Stat3 Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">236</span>– <span class="NLM_lpage">251</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.04.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1016%2Fj.ejmech.2019.04.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=31048139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC1MXovVOju7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2019&pages=236-251&author=G.+Caiauthor=W.+Yuauthor=D.+Songauthor=W.+Zhangauthor=J.+Guoauthor=J.+Zhuauthor=Y.+Renauthor=L.+Kong&title=Discovery+of+Fluorescent+Coumarin-Benzo+B+Thiophene+1%2C+1-Dioxide+Conjugates+as+Mitochondria-Targeting+Antitumor+Stat3+Inhibitors&doi=10.1016%2Fj.ejmech.2019.04.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of fluorescent coumarin-benzo[b]thiophene 1, 1-dioxide conjugates as mitochondria-targeting antitumor STAT3 inhibitors</span></div><div class="casAuthors">Cai, Guiping; Yu, Wenying; Song, Dongmei; Zhang, Wenda; Guo, Jianpeng; Zhu, Jiawen; Ren, Yuhao; Kong, Lingyi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">236-251</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">STAT3 has been extensively studied as a potential antitumor target.  Though studies on regulating STAT3 mainly focus on the inhibition of STAT3 phosphorylation at Tyr705 residue, the phosphorylation at Ser727 residue of STAT3 protein is also closely assocd. with the mitochondrial import of STAT3 protein.  N, N-diethyl-7-aminocoumarin is a fluorescent mitochondria-targeting probe.  In this study, a series of STAT3 inhibitors were developed by connecting N, N-diethyl-7-aminocoumarin fluorophore with benzo [b]thiophene 1, 1-dioxide moiety.  All designed compds. displayed potent anti-proliferative activity against cancer cells.  The representative compd. 7a(I) was mainly accumulated in mitochondria visualized by its fluorescence.  STAT3 phosphorylation was inhibited by I at both Tyr705 and Ser727 residues.  I inhibited STAT3 phosphorylation whereas had no influence on the phosphorylation levels of STAT1, JAK2, Src and Erk1/2, indicating good selectivity of I.  Moreover, I down-regulated the expression of STAT3 target genes Bcl-2 and Cyclin D1, increased ROS prodn. and remarkably reduced the mitochondrial membrane potential to induce mitochondrial apoptotic pathway.  Furthermore, I in vivo suppressed breast cancer 4T1 implanted tumor growth.  Taken together, these results highlighted that I might be a promising mitochondria-targeting STAT3 inhibitor for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqliPyZjY43-rVg90H21EOLACvtfcHk0lhRbXRIrBeWiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXovVOju7o%253D&md5=5c1e2def16a6656c2d56cfe59168053c</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.04.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.04.024%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DG.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DSong%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DKong%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520Fluorescent%2520Coumarin-Benzo%2520B%2520Thiophene%25201%252C%25201-Dioxide%2520Conjugates%2520as%2520Mitochondria-Targeting%2520Antitumor%2520Stat3%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D174%26spage%3D236%26epage%3D251%26doi%3D10.1016%2Fj.ejmech.2019.04.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glackin, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dellinger, T. H.</span></span> <span> </span><span class="NLM_article-title">Pterostilbene Suppresses Ovarian Cancer Growth Via Induction of Apoptosis and Blockade of Cell Cycle Progression Involving Inhibition of the Stat3 Pathway</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1983</span>, <span class="refDoi"> DOI: 10.3390/ijms19071983</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.3390%2Fijms19071983" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFKlsb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=1983&author=W.+Wenauthor=G.+Loweauthor=C.+M.+Robertsauthor=J.+Finlayauthor=E.+S.+Hanauthor=C.+A.+Glackinauthor=T.+H.+Dellinger&title=Pterostilbene+Suppresses+Ovarian+Cancer+Growth+Via+Induction+of+Apoptosis+and+Blockade+of+Cell+Cycle+Progression+Involving+Inhibition+of+the+Stat3+Pathway&doi=10.3390%2Fijms19071983"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Pterostilbene suppresses ovarian cancer growth via induction of apoptosis and blockade of cell cycle progression involving inhibition of the STAT3 pathway</span></div><div class="casAuthors">Wen, Wei; Lowe, Gina; Roberts, Cai M.; Finlay, James; Han, Ernest S.; Glackin, Carlotta A.; Dellinger, Thanh Hue</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1983/1-1983/12</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A growing body of evidence has demonstrated the promising anti-tumor effects of resveratrol in ovarian cancer cells, including its inhibitory effects on STAT3 activation.  Nonetheless, the low bioavailability of resveratrol has reduced its attractiveness as a potential anti-cancer treatment.  In contrast, pterostilbene, a stilbenoid and resveratrol analog, has demonstrated superior bioavailability, while possessing significant antitumor activity in multiple solid tumors.  In this study, the therapeutic potential of pterostilbene was evaluated in ovarian cancer cells.  Further mol. study has shown that pterostilbene effectively suppressed phosphorylation of STAT3, as well as STAT3 downstream genes that regulate cell cycle and apoptosis, indicating that inhibition of STAT3 pathway may be involved in its anti-tumor activity.  The addn. of pterostilbene to the commonly used chemotherapy cisplatin demonstrated synergistic antiproliferative activity in several ovarian cancer cell lines.  Pterostilbene addnl. inhibited cell migration in multiple ovarian cancer cell lines.  The above results suggest that pterostilbene facilitates significant anti-tumor activity in ovarian cancer via anti-proliferative and pro-apoptotic mechanisms, possibly via downregulation of JAK/STAT3 pathway.  Pterostilbene thus presents as an attractive non-toxic alternative for potential adjuvant or maintenance chemotherapy in ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJSeyyDGs9IrVg90H21EOLACvtfcHk0lhRbXRIrBeWiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFKlsb3O&md5=4134fbeb7185678e2da0bdcbd6cee181</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.3390%2Fijms19071983&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms19071983%26sid%3Dliteratum%253Aachs%26aulast%3DWen%26aufirst%3DW.%26aulast%3DLowe%26aufirst%3DG.%26aulast%3DRoberts%26aufirst%3DC.%2BM.%26aulast%3DFinlay%26aufirst%3DJ.%26aulast%3DHan%26aufirst%3DE.%2BS.%26aulast%3DGlackin%26aufirst%3DC.%2BA.%26aulast%3DDellinger%26aufirst%3DT.%2BH.%26atitle%3DPterostilbene%2520Suppresses%2520Ovarian%2520Cancer%2520Growth%2520Via%2520Induction%2520of%2520Apoptosis%2520and%2520Blockade%2520of%2520Cell%2520Cycle%2520Progression%2520Involving%2520Inhibition%2520of%2520the%2520Stat3%2520Pathway%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2018%26volume%3D19%26spage%3D1983%26doi%3D10.3390%2Fijms19071983" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, P.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagabhushanam, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, M.-H.</span></span> <span> </span><span class="NLM_article-title">3 ’-Hydroxypterostilbene Suppresses Colitis-Associated Tumorigenesis by Inhibition of Il-6/Stat3 Signaling in Mice</span>. <i>J. Agric. Food Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">9655</span>– <span class="NLM_lpage">9664</span>, <span class="refDoi"> DOI: 10.1021/acs.jafc.7b03712</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jafc.7b03712" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1CqtL3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2017&pages=9655-9664&author=C.-S.+Laiauthor=G.+Yangauthor=S.+Liauthor=P.-S.+Leeauthor=B.+N.+Wangauthor=M.-C.+Chungauthor=K.+Nagabhushanamauthor=C.-T.+Hoauthor=M.-H.+Pan&title=3+%E2%80%99-Hydroxypterostilbene+Suppresses+Colitis-Associated+Tumorigenesis+by+Inhibition+of+Il-6%2FStat3+Signaling+in+Mice&doi=10.1021%2Facs.jafc.7b03712"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">3'-Hydroxypterostilbene Suppresses Colitis-Associated Tumorigenesis by Inhibition of IL-6/STAT3 Signaling in Mice</span></div><div class="casAuthors">Lai, Ching-Shu; Yang, Guliang; Li, Shiming; Lee, Pei-Sheng; Wang, Bi-Ni; Chung, Min-Ching; Nagabhushanam, Kalyanam; Ho, Chi-Tang; Pan, Min-Hsiung</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Agricultural and Food Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">9655-9664</span>CODEN:
                <span class="NLM_cas:coden">JAFCAU</span>;
        ISSN:<span class="NLM_cas:issn">0021-8561</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">3'-Hydroxypterostilbene (trans-3,5-dimethoxy-3',4'-hydroxystilbene) presents in Sphaerophysa salsula, Pterocarpus marsupium, and honey bee propolis and has been reported to exhibit several biol. activities.  Herein, the authors aimed to explore the chemopreventive effects of dietary 3'-hydroxypterostilbene and underlying mol. mechanisms on colitis-assocd. cancer using the azoxymethane (AOM)/dextran sodium sulfate (DSS) model.  3'-Hydroxypterostilbene administration effectively ameliorated the colon shortening and no. of tumors in AOM/DSS-treated mice (3.2±1.2 of the high-dose treatment vs. 13.8±5.3 of the AOM/DSS group, p < 0.05).  Mol. anal. exhibited the anti-inflammatory activity of 3'-hydroxypterostilbene by a significant decrease in the levels of inducible nitric oxide synthase, cyclooxygenase-2, and interleukin-6 (IL-6) (p < 0.05).  Moreover, dietary 3'-hydroxypterostilbene also significantly diminished IL-6/signal transducer and activator of transcription signaling and restored colonic suppressor of cytokine signaling 3 levels in the colonic tissue of mice (p < 0.05).  Collectively, these results demonstrated for the first time the in vivo chemopreventive efficacy and mol. mechanisms of dietary 3'-hydroxypterostilbene against colitis-assocd. colonic tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBzhnqQkC-QbVg90H21EOLACvtfcHk0ljy98rCwcG8dQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1CqtL3P&md5=613efde5fbdcd6d2d5e56829bb5479c4</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Facs.jafc.7b03712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jafc.7b03712%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DC.-S.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DP.-S.%26aulast%3DWang%26aufirst%3DB.%2BN.%26aulast%3DChung%26aufirst%3DM.-C.%26aulast%3DNagabhushanam%26aufirst%3DK.%26aulast%3DHo%26aufirst%3DC.-T.%26aulast%3DPan%26aufirst%3DM.-H.%26atitle%3D3%2520%25E2%2580%2599-Hydroxypterostilbene%2520Suppresses%2520Colitis-Associated%2520Tumorigenesis%2520by%2520Inhibition%2520of%2520Il-6%252FStat3%2520Signaling%2520in%2520Mice%26jtitle%3DJ.%2520Agric.%2520Food%2520Chem.%26date%3D2017%26volume%3D65%26spage%3D9655%26epage%3D9664%26doi%3D10.1021%2Facs.jafc.7b03712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riche, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEwen, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riche, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wofford, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschamp, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griswold, M.</span></span> <span> </span><span class="NLM_article-title">Analysis of Safety from a Human Clinical Trial with Pterostilbene</span>. <i>J. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2013</i></span>,  <span class="NLM_fpage">463595</span>, <span class="refDoi"> DOI: 10.1155/2013/463595</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1155%2F2013%2F463595" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=23431291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A280%3ADC%252BC3svgsVKhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2013&publication_year=2013&pages=463595&author=D.+M.+Richeauthor=C.+L.+McEwenauthor=K.+D.+Richeauthor=J.+J.+Shermanauthor=M.+R.+Woffordauthor=D.+Deschampauthor=M.+Griswold&title=Analysis+of+Safety+from+a+Human+Clinical+Trial+with+Pterostilbene&doi=10.1155%2F2013%2F463595"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of safety from a human clinical trial with pterostilbene</span></div><div class="casAuthors">Riche Daniel M; McEwen Corey L; Riche Krista D; Sherman Justin J; Wofford Marion R; Deschamp David; Griswold Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of toxicology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">2013</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">463595</span>
        ISSN:<span class="NLM_cas:issn">1687-8191</span>.
    </div><div class="casAbstract">Objectives.  The purpose of this trial was to evaluate the safety of long-term pterostilbene administration in humans.  Methodology.  The trial was a prospective, randomized, double-blind placebo-controlled intervention trial enrolling patients with hypercholesterolemia (defined as a baseline total cholesterol ≥200 mg/dL and/or baseline low-density lipoprotein cholesterol ≥100 mg/dL).  Eighty subjects were divided equally into one of four groups: (1) pterostilbene 125 mg twice daily, (2) pterostilbene 50 mg twice daily, (3) pterostilbene 50 mg + grape extract (GE) 100 mg twice daily, and (4) matching placebo twice daily for 6-8 weeks.  Safety markers included biochemical and subjective measures.  Linear mixed models were used to estimate primary safety measure treatment effects.  Results.  The majority of patients completed the trial (91.3%).  The average age was 54 years.  The majority of patients were females (71%) and Caucasians (70%).  There were no adverse drug reactions (ADRs) on hepatic, renal, or glucose markers based on biochemical analysis.  There were no statistically significant self-reported or major ADRs.  Conclusion.  Pterostilbene is generally safe for use in humans up to 250 mg/day.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTZJGbrCaVVVRJ5E29YNGvQfW6udTcc2ebmN9h2yXXR7Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3svgsVKhsw%253D%253D&md5=5e3c5ede66637fddb8c637cdc0757b47</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1155%2F2013%2F463595&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2013%252F463595%26sid%3Dliteratum%253Aachs%26aulast%3DRiche%26aufirst%3DD.%2BM.%26aulast%3DMcEwen%26aufirst%3DC.%2BL.%26aulast%3DRiche%26aufirst%3DK.%2BD.%26aulast%3DSherman%26aufirst%3DJ.%2BJ.%26aulast%3DWofford%26aufirst%3DM.%2BR.%26aulast%3DDeschamp%26aufirst%3DD.%26aulast%3DGriswold%26aufirst%3DM.%26atitle%3DAnalysis%2520of%2520Safety%2520from%2520a%2520Human%2520Clinical%2520Trial%2520with%2520Pterostilbene%26jtitle%3DJ.%2520Toxicol.%26date%3D2013%26volume%3D2013%26spage%3D463595%26doi%3D10.1155%2F2013%2F463595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picó, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mañes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asensi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asensio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrela, J. M.</span></span> <span> </span><span class="NLM_article-title">Dietary Administration of High Doses of Pterostilbene and Quercetin to Mice Is Not Toxic</span>. <i>J. Agric. Food Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3180</span>– <span class="NLM_lpage">3186</span>, <span class="refDoi"> DOI: 10.1021/jf803579e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jf803579e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjt1Gqurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2009&pages=3180-3186&author=M.+J.+Ruizauthor=M.+Fern%C3%A1ndezauthor=Y.+Pic%C3%B3author=J.+Ma%C3%B1esauthor=M.+Asensiauthor=C.+Cardaauthor=G.+Asensioauthor=J.+M.+Estrela&title=Dietary+Administration+of+High+Doses+of+Pterostilbene+and+Quercetin+to+Mice+Is+Not+Toxic&doi=10.1021%2Fjf803579e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Dietary Administration of High Doses of Pterostilbene and Quercetin to Mice Is Not Toxic</span></div><div class="casAuthors">Ruiz, M. J.; Fernandez, M.; Pico, Y.; Manes, J.; Asensi, M.; Carda, C.; Asensio, G.; Estrela, J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Agricultural and Food Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3180-3186</span>CODEN:
                <span class="NLM_cas:coden">JAFCAU</span>;
        ISSN:<span class="NLM_cas:issn">0021-8561</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The aim of this study is to evaluate possible harmful effects of high doses of t-pterostilbene (t-PTER) and quercetin (QUER) in Swiss mice.  Mice were fed during 28 days at doses of 0, 30, 300, and 3000 mg/kg body wt./day of t-PTER, QUER, or a mixt. of both, t-PTER + QUER, which are equiv. to 5, 50, and 500 times, resp., the estd. mean human intake of these polyphenols (25 mg/day).  Daily oral administration of QUER, t-PTER, or a mixt. of both of them did not cause mortality during the exptl. period.  There were no differences in food and water consumption on sex.  No significant body wt. gain in the male or female groups was obsd.  Red blood cell no. and the hematocrit increased after polyphenols administration compared to control groups.  Biochem. parameters were not affected.  Histopathol. examn. revealed no alterations in clin. signs or organ wt. at any dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxJmJPNnBaSLVg90H21EOLACvtfcHk0ljy98rCwcG8dQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjt1Gqurg%253D&md5=1f673f6cdb23f96431f0a43517e7d526</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fjf803579e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjf803579e%26sid%3Dliteratum%253Aachs%26aulast%3DRuiz%26aufirst%3DM.%2BJ.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DM.%26aulast%3DPic%25C3%25B3%26aufirst%3DY.%26aulast%3DMa%25C3%25B1es%26aufirst%3DJ.%26aulast%3DAsensi%26aufirst%3DM.%26aulast%3DCarda%26aufirst%3DC.%26aulast%3DAsensio%26aufirst%3DG.%26aulast%3DEstrela%26aufirst%3DJ.%2BM.%26atitle%3DDietary%2520Administration%2520of%2520High%2520Doses%2520of%2520Pterostilbene%2520and%2520Quercetin%2520to%2520Mice%2520Is%2520Not%2520Toxic%26jtitle%3DJ.%2520Agric.%2520Food%2520Chem.%26date%3D2009%26volume%3D57%26spage%3D3180%26epage%3D3186%26doi%3D10.1021%2Fjf803579e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leland, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, M.-H.</span></span> <span> </span><span class="NLM_article-title">Occurrence, Bioavailability, Anti-Inflammatory, and Anticancer Effects of Pterostilbene</span>. <i>J. Agric. Food Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">12788</span>– <span class="NLM_lpage">12799</span>, <span class="refDoi"> DOI: 10.1021/acs.jafc.9b07860</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jafc.9b07860" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjt1ynsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2020&pages=12788-12799&author=W.-S.+Linauthor=J.+V.+Lelandauthor=C.-T.+Hoauthor=M.-H.+Pan&title=Occurrence%2C+Bioavailability%2C+Anti-Inflammatory%2C+and+Anticancer+Effects+of+Pterostilbene&doi=10.1021%2Facs.jafc.9b07860"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Occurrence, Bioavailability, Anti-inflammatory, and Anticancer Effects of Pterostilbene</span></div><div class="casAuthors">Lin, Wei-Sheng; Leland, Jane Valorie; Ho, Chi-Tang; Pan, Min-Hsiung</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Agricultural and Food Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">12788-12799</span>CODEN:
                <span class="NLM_cas:coden">JAFCAU</span>;
        ISSN:<span class="NLM_cas:issn">0021-8561</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Supplementation with natural compds. found in fruits and vegetables has long been assocd. with a reduced risk of several types of cancer.  Pterostilbene is a natural stilbenoid and a dimethylated analog of resveratrol which is found primarily in blueberries.  Pterostilbene exhibits a range of pharmacol. properties, particularly anti-inflammatory and anticancer effects.  Due to two methoxy groups in its skeleton, pterostilbene is more lipophilic than resveratrol and thus possesses higher intestinal permeability and cellular uptake and enhanced stability.  Moreover, pterostilbene exhibits less toxicity and fewer adverse effects, providing it with superior potential in cancer chemoprevention and chemotherapy applications.  Numerous research studies have demonstrated that pterostilbene possesses detoxification activities, mediating the anti-inflammation response, regulating the cell cycle, augmenting apoptosis, enhancing autophagy, and inhibiting tumor angiogenesis, invasion, and metastasis by modulating signal transduction pathways which block multiple stages of carcinogenesis.  In this review, we illustrate that pterostilbene is a natural compd. having bioavailability.  The extensive metab. of pterostilbene will be discussed.  We also summarize recent research on pterostilbene's anti-inflammatory and anticancer properties in the multistage carcinogenesis process and related mol. mechanism and conclude that it should contribute to improved cancer management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiDslD0pbUK7Vg90H21EOLACvtfcHk0liSIQccIrQRDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjt1ynsbs%253D&md5=6d036321a2e4e8cca57073a6e925bc7c</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facs.jafc.9b07860&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jafc.9b07860%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DW.-S.%26aulast%3DLeland%26aufirst%3DJ.%2BV.%26aulast%3DHo%26aufirst%3DC.-T.%26aulast%3DPan%26aufirst%3DM.-H.%26atitle%3DOccurrence%252C%2520Bioavailability%252C%2520Anti-Inflammatory%252C%2520and%2520Anticancer%2520Effects%2520of%2520Pterostilbene%26jtitle%3DJ.%2520Agric.%2520Food%2520Chem.%26date%3D2020%26volume%3D68%26spage%3D12788%26epage%3D12799%26doi%3D10.1021%2Facs.jafc.9b07860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of Bazedoxifene Analogues Targeting Glycoprotein 130</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>199</i></span>,  <span class="NLM_fpage">112375</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112375</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1016%2Fj.ejmech.2020.112375" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=32388278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BB3cXptVemtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=199&publication_year=2020&pages=112375&author=D.+Songauthor=W.+Yuauthor=Y.+Renauthor=J.+Zhuauthor=C.+Wanauthor=G.+Caiauthor=J.+Guoauthor=W.+Zhangauthor=L.+Kong&title=Discovery+of+Bazedoxifene+Analogues+Targeting+Glycoprotein+130&doi=10.1016%2Fj.ejmech.2020.112375"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of bazedoxifene analogues targeting glycoprotein 130</span></div><div class="casAuthors">Song, Dongmei; Yu, Wenying; Ren, Yuhao; Zhu, Jiawen; Wan, Chengying; Cai, Guiping; Guo, Jianpeng; Zhang, Wenda; Kong, Lingyi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">199</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112375</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Deregulation of GP130 in signal transduction is involved in multiple types of human diseases, esp. in cancers, indicating that GP130 is an attractive target for cancer therapy.  However, GP130 was conventionally considered as an undruggable target thus the discovery of GP130 PPI inhibitors is extremely challenging.  By the aid of structure-based drug design, in this study, two series of bazedoxifene based analogs were designed to target GP130 D1 domain and block the IL-6/GP130/STAT3 signaling pathway for antitumor treatment.  Most of these designed compds. displayed potent anti-proliferative activity against cancer cells.  The representative compd. 10a was demonstrated to directly bind to GP130 protein with an affinity (KD) value of 3.8μM via both SPR and DARTS methods.  Subsequently, mol. docking study predicted that 10a targeted D1 domain of GP130 and co-IP assay demonstrated that 10a did not inhibit IL-6R/GP130 interaction, which meant 10a did not bind to the D2 and D3 domains of GP130.  Moreover, 10a selectively inhibited JAK2 and STAT3 phosphorylation as well as IL-6 induced STAT3 phosphorylation. 10a effectively inhibited tumor cell viability, migration and promoted apoptosis.  Furthermore, 10a effectively suppressed xenograft model tumor growth in vivo.  Taken together, this study described a new class of bazedoxifene derived GP130 inhibitors as antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriRN9ycYJhvrVg90H21EOLACvtfcHk0liSIQccIrQRDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXptVemtrc%253D&md5=ba0799bd77a5af1fea9283f3a595f29a</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112375&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112375%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DC.%26aulast%3DCai%26aufirst%3DG.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DKong%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520Bazedoxifene%2520Analogues%2520Targeting%2520Glycoprotein%2520130%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D199%26spage%3D112375%26doi%3D10.1016%2Fj.ejmech.2020.112375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simic, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela Parada, X. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dellinger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guarente, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhee, E. P.</span></span> <span> </span><span class="NLM_article-title">Nicotinamide Riboside with Pterostilbene (Nrpt) Increases Nad(+) in Patients with Acute Kidney Injury (Aki): A Randomized, Double-Blind, Placebo-Controlled, Stepwise Safety Study of Escalating Doses of Nrpt in Patients with Aki</span>. <i>BMC Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">342</span>, <span class="refDoi"> DOI: 10.1186/s12882-020-02006-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1186%2Fs12882-020-02006-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=32791973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1WisbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=342&author=P.+Simicauthor=X.+F.+Vela+Paradaauthor=S.+M.+Parikhauthor=R.+Dellingerauthor=L.+P.+Guarenteauthor=E.+P.+Rhee&title=Nicotinamide+Riboside+with+Pterostilbene+%28Nrpt%29+Increases+Nad%28%2B%29+in+Patients+with+Acute+Kidney+Injury+%28Aki%29%3A+A+Randomized%2C+Double-Blind%2C+Placebo-Controlled%2C+Stepwise+Safety+Study+of+Escalating+Doses+of+Nrpt+in+Patients+with+Aki&doi=10.1186%2Fs12882-020-02006-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Nicotinamide riboside with pterostilbene (NRPT) increases NAD positive in patients with acute kidney injury (AKI): a randomized, double-blind, placebo-controlled, stepwise safety study of escalating doses of NRPT in patients with AKI</span></div><div class="casAuthors">Simic, Petra; Vela Parada, Xavier Fernando; Parikh, Samir M.; Dellinger, Ryan; Guarente, Leonard P.; Rhee, Eugene P.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Nephrology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">342</span>CODEN:
                <span class="NLM_cas:coden">BNMEB7</span>;
        ISSN:<span class="NLM_cas:issn">1471-2369</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Preclin. studies have identified both NAD+ and sirtuin augmentation as potential strategies for the prevention and treatment of AKI.  Nicotinamide riboside (NR) is a NAD+ precursor vitamin and pterostilbene (PT) is potent sirtuin activator found in blueberries.  Here, we tested the effect of combined NR and PT (NRPT) on whole blood NAD+ levels and safety parameters in patients with AKI.  We conducted a randomized, double-blind, placebo-controlled study of escalating doses of NRPT in 24 hospitalized patients with AKI.  The study was comprised of four Steps during which NRPT (5 subjects) or placebo (1 subject) was given twice a day for 2 days.  NRPT dosing was increased in each Step: Step 1250/50 mg, Step 2500/100 mg, Step 3750/150 mg and Step 41,000/200 mg.  Blood NAD+ levels were measured by liq. chromatog.-mass spectrometry and safety was assessed by history, phys. exam, and clin. lab. testing.  AKI resulted in a 50% redn. in whole blood NAD+ levels at 48 h compared to 0 h in patients receiving placebo (p = 0.05).  There was a trend for increase in NAD+ levels in all NRPT Steps individually at 48 h compared to 0 h, but only the change in Step 2 reached statistical significance (47%, p = 0.04), and there was considerable interindividual variability in the NAD+ response to treatment.  Considering all Steps together, NRPT treatment increased NAD+ levels by 37% at 48 h compared to 0 h (p = 0.002).  All safety lab. tests were unchanged by NRPT treatment, including creatinine, estd. glomerular filtration rate (eGFR), electrolytes, liver function tests, and blood counts.  Three of 20 patients receiving NRPT reported minor gastrointestinal side effects.  NRPT increases whole blood NAD+ levels in hospitalized patients with AKI.  In addn., NRPT up to a dose of 1000 mg/200 mg twice a day for 2 days is safe and well tolerated in these patients.  Further studies to assess the potential therapeutic benefit of NRPT in AKI are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY8QV7wPdaurVg90H21EOLACvtfcHk0liSIQccIrQRDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1WisbjK&md5=3b0b32fd33d451a1dd77f8a513c8d801</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1186%2Fs12882-020-02006-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12882-020-02006-1%26sid%3Dliteratum%253Aachs%26aulast%3DSimic%26aufirst%3DP.%26aulast%3DVela%2BParada%26aufirst%3DX.%2BF.%26aulast%3DParikh%26aufirst%3DS.%2BM.%26aulast%3DDellinger%26aufirst%3DR.%26aulast%3DGuarente%26aufirst%3DL.%2BP.%26aulast%3DRhee%26aufirst%3DE.%2BP.%26atitle%3DNicotinamide%2520Riboside%2520with%2520Pterostilbene%2520%2528Nrpt%2529%2520Increases%2520Nad%2528%252B%2529%2520in%2520Patients%2520with%2520Acute%2520Kidney%2520Injury%2520%2528Aki%2529%253A%2520A%2520Randomized%252C%2520Double-Blind%252C%2520Placebo-Controlled%252C%2520Stepwise%2520Safety%2520Study%2520of%2520Escalating%2520Doses%2520of%2520Nrpt%2520in%2520Patients%2520with%2520Aki%26jtitle%3DBMC%2520Nephrol.%26date%3D2020%26volume%3D21%26spage%3D342%26doi%3D10.1186%2Fs12882-020-02006-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galloway, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagrutta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richon, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, P. A.</span></span> <span> </span><span class="NLM_article-title">Nonclinical Safety Assessment of the Histone Deacetylase Inhibitor Vorinostat</span>. <i>Int. J. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1177/1091581809352111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=10.1177%2F1091581809352111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=19903873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktVSgt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2010&pages=3-19&author=J.+S.+Kerrauthor=S.+Gallowayauthor=A.+Lagruttaauthor=M.+Armstrongauthor=T.+Millerauthor=V.+M.+Richonauthor=P.+A.+Andrews&title=Nonclinical+Safety+Assessment+of+the+Histone+Deacetylase+Inhibitor+Vorinostat&doi=10.1177%2F1091581809352111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Nonclinical safety assessment of the histone deacetylase inhibitor vorinostat</span></div><div class="casAuthors">Kerr, Janet S.; Galloway, Sheila; Lagrutta, Armando; Armstrong, Michael; Miller, Thomas; Richon, Victoria M.; Andrews, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Toxicology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-19</span>CODEN:
                <span class="NLM_cas:coden">IJTOFN</span>;
        ISSN:<span class="NLM_cas:issn">1091-5818</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Vorinostat (SAHA, Zolinza), a histone deacetylase inhibitor, is assessed in nonclin. studies to support its approval for cutaneous T-cell lymphoma.  Vorinostat is weakly mutagenic in the Ames assay; is clastogenic in rodent (ie, CHO) cells but not in normal human lymphocytes; and is weakly pos. in an in vivo mouse micronucleus assay.  No effects are obsd. on potassium ion currents in the hERG assay up to 300 μM (safety margin ∼ 300-fold the ∼ 1 μM serum concn. assocd. with the 400 mg/d max. recommended human dose).  No rat respiratory or central nervous system effects are found at 150 mg/kg (>2-fold max. recommended human dose).  No cardiovascular effects, including effects on QTc interval, are obsd. after a single oral dose (150 mg/kg) in dogs.  Vorinostat is orally dosed daily in rats (controls, 20, 50, or 150 mg/kg/d) and dogs (controls, 60, 80, or 100/125/160 mg/kg/d) for 26 wk with a 4-wk recovery.  Rat vorinostat-related adverse findings are decreased food consumption, wt. loss, and hematol. changes; a no obsd. adverse effects level is not established.  In dogs, adverse effects are primarily gastrointestinal; the no obsd. adverse effects level is 60 mg/kg/d (∼6-fold max. recommended human dose).  Toxicities are reversible and can be monitored in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr38wojohFu_LVg90H21EOLACvtfcHk0liKpk9XD6dQtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktVSgt7c%253D&md5=23defc0d0b8e84cc3b8ff021eb4a429f</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1177%2F1091581809352111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1091581809352111%26sid%3Dliteratum%253Aachs%26aulast%3DKerr%26aufirst%3DJ.%2BS.%26aulast%3DGalloway%26aufirst%3DS.%26aulast%3DLagrutta%26aufirst%3DA.%26aulast%3DArmstrong%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DT.%26aulast%3DRichon%26aufirst%3DV.%2BM.%26aulast%3DAndrews%26aufirst%3DP.%2BA.%26atitle%3DNonclinical%2520Safety%2520Assessment%2520of%2520the%2520Histone%2520Deacetylase%2520Inhibitor%2520Vorinostat%26jtitle%3DInt.%2520J.%2520Toxicol.%26date%3D2010%26volume%3D29%26spage%3D3%26epage%3D19%26doi%3D10.1177%2F1091581809352111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chai, Y.</span></span> <span> </span><span class="NLM_article-title">Biosensor-Based Active Ingredients Recognition System for Screening Stat3 Ligands from Medical Herbs</span>. <i>Anal. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">8936</span>– <span class="NLM_lpage">8945</span>, <span class="refDoi"> DOI: 10.1021/acs.analchem.8b01103</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.analchem.8b01103" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1ektr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2018&pages=8936-8945&author=L.+Chenauthor=D.+Lvauthor=X.+Chenauthor=M.+Liuauthor=D.+Wangauthor=Y.+Liuauthor=Z.+Hongauthor=Z.+Zhuauthor=X.+Huauthor=Y.+Caoauthor=J.+Yangauthor=Y.+Chai&title=Biosensor-Based+Active+Ingredients+Recognition+System+for+Screening+Stat3+Ligands+from+Medical+Herbs&doi=10.1021%2Facs.analchem.8b01103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Biosensor-based active ingredients recognition system for screening STAT3 ligands from medical herbs</span></div><div class="casAuthors">Chen, Langdong; Lv, Diya; Chen, Xiaofei; Liu, Mingdong; Wang, Dongyao; Liu, Yue; Hong, Zhanying; Zhu, Zhenyu; Hu, Xiaoxia; Cao, Yan; Yang, Jianmin; Chai, Yifeng</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Chemistry (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">8936-8945</span>CODEN:
                <span class="NLM_cas:coden">ANCHAM</span>;
        ISSN:<span class="NLM_cas:issn">0003-2700</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A surface plasmon resonance (SPR) biosensor-based active ingredients recognition system (SPR-AIRS) was developed, validated, and applied to screen signal transducer and activator of transcription 3 (STAT3) ligands.  First, features of the screening system were investigated in four aspects: (1) specificity of the STAT3-immobilized chip, it shows that the chip could be applied to screen STAT3 ligands from complex mixt.; (2) linearity and limit of detection (LOD) of the system, the min. recovery cycle no. was detd. as 5 cycles; (3) saturability of the chip, the results indicate that it is necessary to select a proper concn. based on the compd.'s Kd value; (4) robustness of the system, it indicates that inactive compds. in the matrix could not interfere with active compds. in the process of screening.  Next, SPR-AIRS was applied to screen STAT3 ligands from medicinal herbs.  Nine candidate compds. were fished out.  Then SPR assay and mol. docking were performed to verify the interplay between STAT3 and candidate compds.  Apoptosis assay and luciferase report assay were performed to investigate the drug effect of candidate compds. on STAT3 activity.  Western blot results indicated that neobaicalein and polydatin could inhibit the phosphorylation of STAT3.  As far as we know, this is the first time that neobaicalein and polydatin are reported as effective STAT3 ligands.  In a conclusion, we have systemically demonstrated the feasibility of SPR biosensor-based screening method applying to complex drug systems, and our findings suggest that SPR-AIRS could be a sensitive and effective soln. for the discovery of active compds. from a complex matrix.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0ePmALYqkl7Vg90H21EOLACvtfcHk0liKpk9XD6dQtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1ektr%252FM&md5=03d3eec683fffbd06e792e594efd0a1a</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Facs.analchem.8b01103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.analchem.8b01103%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26aulast%3DLv%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DHong%26aufirst%3DZ.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DChai%26aufirst%3DY.%26atitle%3DBiosensor-Based%2520Active%2520Ingredients%2520Recognition%2520System%2520for%2520Screening%2520Stat3%2520Ligands%2520from%2520Medical%2520Herbs%26jtitle%3DAnal.%2520Chem.%26date%3D2018%26volume%3D90%26spage%3D8936%26epage%3D8945%26doi%3D10.1021%2Facs.analchem.8b01103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1BG1" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1BG1','PDB','1BG1'); return false;">PDB: 1BG1</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i61"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00136">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_24100"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00136?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00136</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Atomic coordinates of the STAT3/compound <b>14</b> complex (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00136/suppl_file/jm1c00136_si_001.pdb">PDB</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00136/suppl_file/jm1c00136_si_002.csv">CSV</a>)</p></li><li><p class="inline">Representative <sup>1</sup>H NMR, <sup>13</sup>C NMR, HPLC, IR, and HRMS (ESI) spectra of compounds; Pharmacokinetics of <b>14</b> in SD rats (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00136/suppl_file/jm1c00136_si_003.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00136/suppl_file/jm1c00136_si_001.pdb">jm1c00136_si_001.pdb (2.5 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00136/suppl_file/jm1c00136_si_002.csv">jm1c00136_si_002.csv (0.83 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00136/suppl_file/jm1c00136_si_003.pdf">jm1c00136_si_003.pdf (2.43 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00136%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-11%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00136" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66e0a8de19df3291","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
